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SCOLIOSIS: COMPARATIVE ANALYSIS OF SURGERY 
VS. BRACE TREATMENT 
Jerry Frenkel 
INTRODUCTION 
The spine, or spinal column, as it is also called, is a complex structure made up of 
33 vertebrae (bone segments) arranged vertically in succession from just below the skull 
to the tailbone. The entire column is broken up into various classes of vertebrae named, 
from superior to inferior, as cervical, thoracic, lumbar, sacral, and coccygeal. Different 
forms of spinal deformities that can occur include kyphosis, lordosis and scoliosis 
(Neuwirth and Osborn 2001). 
Scoliosis is defined simply in medical terms as a lateral 
three-dimensional irregular curvature of the spine. The 
curvature as seen from the back of the person can be described 
as an “s” shaped bend or a “c” shaped bend. The spinal curves 
are measured by degrees of curvature and depending on the 
severity of the degree of curvature, an appropriate treatment 
method will be determined. Scoliosis curvatures do not retain a 
status quo over time. If not treated properly, the curves tend to 
progressively worsen, causing pain and discomfort to the 
diseased party. In this paper, different methods that are used in 
treating scoliosis are discussed including the different types of 
braces that are used and the various forms of surgeries that are 
performed in such cases.   
CAUSES OF SCOLIOSIS  
Although the causes of scoliosis aren’t fully understood, 
most scientists believe that its causes are multifactorial and 
dependent on the form of scoliosis. Contributing factors may be genetic inheritance or the 
laxity of ligaments and the deformation of the vertebral bones. The factor contributing to 
the disease would place it into one of two categories, either structural or functional 
scoliosis (Wikipedia.org 2010).  
If the cause of the disorder is not genetic, it will fall under the grouping called 
functional scoliosis. This form of scoliosis, which usually appears in people with weak 
vertebral muscles, may be caused by the patient sitting for long periods of time in a 
slouched position or from carrying a heavy backpack on the same shoulder too often. 
Fortunately, functional scoliosis can more often than not be easily treated by toning the 
back muscles or by making a conscious effort to sit and stand erect with proper posture 
(Lyons et al. 1999). 
Although there may be many factors contributing to functional scoliosis, structural 
scoliosis is unanimously agreed upon to be caused by direct genetic inheritance. Structural 
scoliosis, the more common form of the disorder, is the natural progression of the spine 
adapting a curved position and is the more severe form of the ailment. This mode of 
scoliosis cannot be treated through good posture and toning the back; rather, a proactive 
step must be taken to stop the progression and straighten the spinal column (Lyons et al. 
1999).  While certain types of scoliosis have different ratios of men to women (and some 
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2 Jerry Frenkel 
forms may even be more prevalent in males than females) due to the genetic factors 
involved, scoliosis is more commonly found in females than in males. In fact, the more 
severe the vertebral curve is, the larger the female to male ratio gets.  
SCOLIOSIS DIAGNOSIS 
There are various ways in which scoliosis can be diagnosed. To a physician, there 
are certain bodily indications that are easily seen that signify that the patient may have 
scoliosis. Some examples are asymmetric hips, an elevation of a shoulder, a protrusion of 
one shoulder blade or a visibly curved spine. These are all indications of a spinal deformity 
that to any person (not only doctors) are visible to the naked eye. There are a couple of 
more specific tests that a physician will use to diagnose the patient. The Adams forward 
bend test is the simplest and most common scoliosis test used by physicians. The patient 
bends forward with their arms pointed straight down to their toes and the physician 
examines the spine for any curvatures. If the curve is not clearly visible, using a device 
called a scoliometer, the physician can look for elevated muscles or a spinal curvature by 
placing the scoliometer on the back of the patient and measuring the discrepancy between 
different elevations of the back.  
Today, technology has advanced and a more accurate method of diagnosis is used. 
A combination of X-rays and/or radiographs is used in conjunction with the Cobb angle, 
which is the angle two right angles make with the curved spine, to diagnose an exact 
degree of curvature. There are four different types of X-rays that physicians will use along 
with the Cobb angle to determine the severity the bend. The various X-ray forms range 
from the classic and simple front/back X-ray to the complicated bending X-ray. Bending 
X-rays are often used to determine the flexibility of the spine, which could affect the style 
of treatment that is utilized. Visits and X-rays are taken every couple of months to watch 
for progression of the curve so that the proper form of treatment can be determined. 
TYPES OF SCOLIOSIS  
Scoliosis is more much more common in our society than most people imagine. 
Statistics show that an astounding 1/ 40th of the population have a scoliosis curvature of at 
least ten degrees. As the severity of the curve increases the ratio decreases but still 
maintains a high percentage of people, with five people out of every thousand having 
vertebral curves of over 20 degrees (Dotsky and Lipp 2002). The reason scoliosis is so 
common is because there is such a wide variety of different types of scoliosis that people 
can have. No single description of scoliosis can encompass the wide range of curvatures 
that exist. Origin, time of onset and location of curvature are all variables in classifying 
what type of scoliosis affects the patient. Categorization, i.e. the shape of the curve and 
severity, are important because that will determine the form of treatment that a doctor will 
advise. Some curves exhibit considerable lateral curvature and little rotation while others 
have extreme rotation and insignificant lateral curvature.  
All structural scoliosis deformities can fit into one of two more specific categories, 
the idiopathic cases and those cases that have an identifiable cause.  Non-idiopathic cases 
can be further subdivided into congenital and neuromuscular scoliosis. 
IDIOPATHIC  
 Idiopathic scoliosis is loosely defined as scoliosis that progressed for apparently no 
cause. This means that although extensive research has been done, the cause for the onset 
and progression of the scoliosis still evades scientists and it appears that the deformity is 
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unrelated to anything else. Approximately 75-85% of people with scoliosis have idiopathic 
scoliosis in a ratio of 1:8, men to women (Lonstein 2002).  
Idiopathic scoliosis is different than congenital scoliosis in that its onset can occur 
at any point during person’s lifetime. In order to discern between the numerous types of 
situations, specific names are given to each case based on when the onset occurred. 
Infantile idiopathic scoliosis has its onset between infancy and age 3. While scoliosis in 
general is more common in women than men, infantile idiopathic scoliosis is more common 
in boys than girls. Most often, this type of scoliosis will manifest itself as a thoracic curve 
with left convexity (Lyons et al.1999). If the condition appears between age 4 and 10, it is 
labeled as juvenile idiopathic scoliosis, while if it occurs from age 11 till the end of the teen 
years, it is called adolescent idiopathic scoliosis (AIS).  
The majority of idiopathic scoliosis cases are considered adolescent idiopathic 
scoliosis. This may be because even though the onset of the condition began when the 
person was a juvenile patient, since it only became noticeable at adolescence, it will still be 
considered adolescent idiopathic scoliosis (Dotsky and Lipp 2002). Logically, it’s 
understandable that AIS is the most common form of scoliosis, because the adolescent 
growth spurt is the most opportune time for the spine to curve or increase the degree of a 
curve dramatically. Interestingly, AIS tends to follow a series of specific patterns in 
forming scoliosis curves; a) thoracic curves which show a right convexity b) 
thoracolumbar curves which also show right convexity c) lumbar curves which show a left 
convexity and d) double major curves which show a and c together forming an “S” shaped 
deformity of the vertebral column (Lyons et al. 1999).  
Adult idiopathic scoliosis (onset over 20 years of age), although uncommon, is a 
possibility. In fact most adult scoliosis cases are idiopathic and structural as opposed to a 
logical functional cause (due to weaker muscles etc.). This structural deformity is usually a 
consequence of osteoporosis, degenerative arthritis or another condition that causes 
deterioration of vertebrae (Arthritis-Symptom.com). 
CONGENITAL  
Non-idiopathic scoliosis is usually the result of a neuromuscular disease or a 
congenital abnormality (Lonstein 2002).  Congenital scoliosis normally forms when there 
is an abnormal or warped formation in the spinal cord during embryonic development. “A 
key feature of congenital scoliosis is the presence of one or more abnormally formed 
vertebrae. When these anomalies are identified the curve should be classified as 
congenital, even if the deformity is not apparent until adolescence” (Erol et al. 2002). 
There are two main causes of congenital scoliosis; cases are classified based on failure of 
formation, failure of segmentation or a combination of the two (Erol et al. 2002). 
Segmentation defects refer to an abnormal separation of the embryo’s different 
spinal segments, called somites, formed during development of the spine in a process 
called somitogenesis. In this process, segments of tissue called somites are formed in pairs 
surrounding what will eventually become the spinal cord. When somitogenesis is 
disrupted even slightly, congenital vertebral defects result.   
The second classification of congenital vertebral anomalies are those that occur due 
to a failure of formation.  The most common type of formation anomaly is a hemi vertebra. 
This is where a portion of the vertebra is missing resulting in a small, triangular shaped 
“half vertebra” or hemi vertebra. Hemi vertebrae can be sub-classified based on their 
relationship to the adjacent spine, segmented, semi-segmented and non-segmented. When 
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several vertebral segments fail to separate bilaterally, a block vertebra results producing 
fused vertebral bones. Simple hemi vertebrae cause a progression of spinal column 
curvature of 1-3.5° per year (Harms 2010). These forms of abnormalities in the spine are 
usually associated with deformities in other organs and organ systems including the heart, 
kidney and lungs. In fact, a study showed that more than half the congenital scoliosis cases 
are related to associate health problems (Harms 2010). Congenital scoliosis is rare, but it 
may require early surgery due to the severity of the spinal deformity involved. 
NEUROMUSCULAR 
Neuromuscular scoliosis is the other form of the deformity with an identifiable 
cause. Neuromuscular scoliosis is classified based on two possible origins; neuropathic and 
myopathic. Neuropathic diseases involve either the upper or lower motor neurons. Both 
upper motor neuron diseases, such as cerebral palsy, spinal-cord trauma and tumors, and 
spinal muscular atrophy, and lower motor neuron diseases, such as polio, can lead to 
scoliosis. Myopathic diseases include arthrogryposis (joint contractures) and muscular 
dystrophy. Despite the differences, the common factor in these conditions is an inability to 
provide muscular support to the spinal column or an imbalance of the muscular control of 
the spine. Realistically, patients who contracted neuromuscular disease before age 10, 
have a 100% chance of developing neuromuscular scoliosis (Lonstein 2002). Treating 
neuromuscular scoliosis is more challenging due to all the additional problems in the other 
systems that come along with the specific disease of the patient. Bracing is a possible 
approach, but it will only slow the progression, not stop it, while surgery can be 
complicated due to numerous factors (e.g. most of these individuals have to be on 
medications which can affect blood clotting). Sometimes, in wheelchair bound patients, 
surgeons for neuromuscular scoliosis patients will form a base-like structure unlike the 
regular rods and wire system that are put in for normal standing patients (Lonstein 2002). 
TREATMENT OF SCOLIOSIS 
The question arises, what is the best method in treating scoliosis? Unfortunately, 
there is no one correct answer. When the doctor examines a patient for scoliosis, he 
performs a comprehensive physical examination to get a perception of the patient’s health, 
preferred activities and lifestyle. Only by knowing all these things can a doctor 
recommend a treatment that is beneficial for the patient. Of course, the specific type of 
scoliosis that the patient has been diagnosed as having will also affect the form of 
treatment.  
The first step in the treatment process is diagnosing whether there is a need for a 
remedy at all. There are two routes of activity that a scoliosis curve can take; it could be a 
resolving curve or a progressive curve. A resolving curve is a form of scoliosis that like its 
name will probably resolve on its own. These curves that straighten themselves without 
any action done upon them are commonly found in infantile idiopathic scoliosis. 
Progressive scoliosis, obviously the more dangerous of the two varieties, is a curve that 
progressively gets worse unless treated effectively. Treatment of progressive scoliosis can 
take the form of a brace progression (or body casting in very young patients) for lesser 
degree curve or surgical stabilization for those curves that bracing alone won’t be an 
adequate solution. Determining the specific treatment for a patient is based on the 
patient’s age, curve flexibility or curve magnitude.  
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BRACES 
TYPES OF BRACES  
There are many different types of braces which all serve their own designated 
functions. Regardless of their categorization they all are meant to achieve the same 
purpose: to improve scoliosis related deformities, to prevent curvature from progressing 
and to provide postural comfort and stability. Although braces cannot correct scoliosis 
curvatures, they can slow or stop the progression, eliminating or at least delaying the need 
for a surgical remedy. There are four general categories of rigid scoliosis braces known to 
physicians by their acronyms cervical thoracolumbar sacral orthosis (CTLSO), 
thoracolumbar sacral orthosis (TLSO), lumbosacral orthosis (LSO), and the bending 
brace. These braces are more commonly known to the patients by the name of their city of 
origin (e.g. Milwaukee brace and Boston brace). In each general category of bracing, over 
the years, technology has advanced and many new braces have come out. All these newer 
scoliosis braces follow the direction of one of the four general categories but each has their 
own little nuances that make them different from each other. For example, under the 
category of the Boston brace we have other braces that follow the Boston brace prototype 
but are known by other names (i.e. the Wilmington brace and the Miami brace). 
Regarding treatment, there is no brace that is considered better than the others; all the 
different forms of braces cater to different people with different curvatures. Each model 
has a distinct style that will benefit some patients and not others. Sometimes, two brace 
models may be recommended for the treatment of a specific patient and the only reason to 
choose one over the other would be personal preference. 
The Milwaukee brace (Figure 3) was introduced in 1946 and first designed by 
Blount and Schmidt to be worn by patients to “provide comfortable and efficient passive 
correction and fixation following patients post-surgery”. They discovered soon after that 
this brace was very effective in patients who had not yet gone for surgical procedures. 
This became the first form of non-operative treatment for scoliosis patients. This brace is a 
CTLSO brace that is usually given to patients who have high thoracic curves with apexes 
above T7 vertebrae or patients who have double major curves. It is normally used with 
Figure 2: Posterior Views in order from Left to Right: The Milwaukee 
Brace, The Boston Brace, and The Charleston Bending Brace.  
Source: http://www.iscoliosis.com/articles-brace_types.html 
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growing adolescents to hold a 25° to 40° advancing curve (Chow 1997). The brace is 
intended to minimize the progression to an acceptable level, not to correct the curvature.  
The Milwaukee brace is 
commonly worn 23 hours a day 
and is a full torso brace that is 
made to custom fit the patient’s 
torso. It extends from the neck to 
the pelvis and consists of a 
specially contoured plastic pelvic 
girdle and a neck ring connected 
by metal bars in the front and the 
back of the brace. The metal bars 
help extend the length of the torso 
and the neck ring keeps the head centered over the pelvis. Pressure pads, strategically 
placed according to the patient's curve pattern, are attached to the metal bars with straps. 
The Milwaukee brace is often characterized by a chin piece that the patient can rest 
his/her head on. Although the extension of the brace up to the neck is uncomfortable and 
unfavorable, it is the distinguishing feature that makes this brace useful and effective 
(Chow 1997). While wearing the Milwaukee brace, patients found it difficult to perform 
the simple activities of daily living such as putting on socks, tying shoe laces, brushing 
their teeth and eating spaghetti from a plate, due to the immobility of the spine. Although 
the brace is difficult to deal with on a daily basis, studies found that the Milwaukee brace 
is very effective when the patient complies with the proper treatment.  
 The Boston brace and its sub types are the most commonly used braces in 
the United States. This brace is usually used by patients with lumbar or thoracolumbar 
curvatures (apexes lower than T7). Like the Milwaukee brace, the Boston brace has 
various pads that are placed around the brace to provide specific forces to effectively 
maintain the curve in the corrected position. The Boston Brace extends from below the 
breast to the beginning of the pelvic area in front and just below the scapulae to the middle 
of the buttocks in the back. It is designed to keep the lumbar area of the body in a flexed 
position by pushing the abdomen in and flattening the posterior lumbar contour.  
There are two main varieties of the Boston brace, TLSO and LSO. The difference 
between the two types and the reason why a patient would wear one over the other is 
determined by the location of the scoliosis curvature. Curves in the upper lumbar and/or 
accompanied by minor thoracic curves will wear the TLSO version of the Boston brace. 
This version extends up to one or both underarms, while the LSO extends only to the 
lower region of the patient’s back. Therefore, patients with curves strictly in the lower 
lumbar region that show little or no thoracic component will use the LSO version of the 
Boston brace. Cosmetically, the Boston brace is usually preferred over the Milwaukee 
brace because it is easily concealed under normal clothes. Like the Milwaukee brace, the 
Boston is generally worn 20-23 hours a day. 
The Charleston bending brace is different from both the Milwaukee (CTLSO) and 
the (TLSO/LSO) Boston braces in many of its aspects. While the Boston and Milwaukee 
braces are worn most of the day, the Charleston bending braces are only worn at night. 
The Charleston brace is meant to be worn at night as it was originally designed for the 
purpose of increasing compliance in kids and young adults (Hooper et al. 2003). The 
design of the Charleston brace is similar to the Boston brace but its redeeming 
Figure 3: Milwaukee Brace  
Source: http://www.ncbi.nlm.nih.gov/books/NBK27217 
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characteristic is that its shape is molded around the patient’s body. The brace is bent in the 
opposite direction of the curve, thereby “over correcting” the spinal deformity, so while 
the patient is wearing the brace his/her torso is physically being pushed to bend in the 
opposite direction of the natural curve of the spine. Another reason why the brace is only 
used at night is because it forces the patient into a bent over position, which would be 
awkward and prohibitive in daily life. There are many benefits to the Charleston bending 
brace over the other two, nearly all of which are related to the nightwear component.   It 
allows full, unrestricted musculoskeletal development and opportunity for athletic 
participation, if desired. Also, it causes fewer and less severe complications. Results can be 
assessed without the customary long-term follow-up, and decision-making regarding 
success or failure of the program can be made earlier (Hooper et al. 2003).  Patients with 
single lumbar or thoracolumbar curves are the best candidates for the Charleston bending 
brace and have the greatest chance of a positive outcome because inadvertently increasing 
a secondary curve through bracing is not a concern. 
The previous three braces discussed were all forms of rigid bracing. Recently, 
technology has advanced and there is a new system of flexible bracing that is now being 
used to treat scoliosis patients. Researchers at the St. Justine Children's hospital in 
Montreal Canada have developed corrective movements for all types of idiopathic scoliosis 
to "open up" or correct the curves.  The patient is braced in that corrective movement and 
held there 20 hours per day by the elastic bands that make up the brace.  The real action in 
the brace is in the elastic bands.  As the patient goes through the movements of the day, 
they stretch the elastic bands and the bands then resist and pull them back into the 
corrective movement.  This stretch and resist system stimulates the growth centers in the 
deformed vertebrae and in the neuromuscular system and over time the gentle resistance 
of the brace and the reprogramming of the body’s neuromuscular pattern results in a 
relatively permanent stabilization or correction of the scoliosis in almost all patients. 
Unlike rigid braces where patients walk around like a robot, SpineCor allows patients to 
do virtually any physical activity they want.  In fact, exercise and activity are absolutely 
essential for the SpineCor brace to work.  
The brace has a pelvic unit from which strong elastic bands wrap around the body, 
including the thigh and pelvis, pulling against curves, rotations, and imbalances. The 
Bolero is the component that wraps around the torso and provides an anchoring point 
above the pelvis.  Attached between the Pelvic Base and the Bolero, the corrective bands, 
the most important part of the SpineCor, cause the body to be held in the corrective 
movement. Some of the bands will have high tension on them and others will have 
virtually no tension but together they work synergistically to bring about the slow but 
steady stabilization or correction of the scoliosis (Coillard et al. 2010). The SpineCor 
system is very effective; in fact, a study performed by Coillard et al. (2010) concluded that 
“the SpineCor orthosis is a very effective method of treatment of juvenile idiopathic 
scoliosis. Most encouraging perhaps is the fact that the positive outcome appears to be 
maintained in the long term, and that surgery can be avoided or at least postponed.” The 
SpineCor system was actually the 2010 SOSORT winner and in a study done for the 
award, 75% of SpineCor users had their curves stabilized and straightened by at least 5 
degrees. 
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SIDE EFFECTS 
In comparison to surgery, bracing causes fewer complications and poses little risk 
from its treatment but may have an effect on the patient’s daily activities and lifestyle. 
Some side effects include affected pulmonary function, skin complaints, and general 
impact on daily activities. Studies show that back bracing can affect the pulmonary 
function and breathing patterns. Shortness of breath is commonly experienced by patients 
with a brace when climbing stairs or going for a walk or run. This may be caused by the 
brace being so tight around the body that the lungs have little room to expand and take in 
air. Obviously, if the patient finds it difficult to breathe, the patient should remove the 
brace immediately until normal breathing returns. Braced scoliosis patients are usually 
taught breathing techniques to prevent a decline in lung function. Ironically, some people 
have found that bracing actually increases their ability to breathe. Scoliosis curvatures 
may cause the rotation of the spine that will push the ribs to press on the lungs. Bracing, 
which straightens the rotated spine, will actually decrease the pressure of the ribs on the 
lungs and make it easier for the patient to breathe (Lyons et al. 1999).  
Another common side effect of bracing is that the patient can break out with 
different skin rashes, sores, blisters or other skin infections. This can be caused by the 
brace’s constant rubbing against the skin during regular daily activities 
(Scoliosisadvice.com 2010).  
Braces may interfere significantly with daily activities, as wearing a brace is often a 
full-day affair.  Although doctors  do give patients specific directions on when and how 
long to wear the brace, generally most physicians instruct the patient  to wear it between 
18-23 hours a day (depending also on the type of brace).  The brace needs to be worn for 
the full number of hours prescribed by the doctor until the patient finishes growing, 
although it may be removed for activities such as showering, swimming, and sports. Some 
braces are only worn at night and do not affect the patient’s day at all. Young children 
with braces often have an intense physical exercise program they go through to improve 
compliance with treatment and keep the muscles in tone so that the transition period after 
brace removal is easier (Blackman 2009). Ignoring all the physical effects that bracing can 
have on a person, there is still an enormous amount of emotional stress that a person can 
go through in brace treatment. 
SURGICAL TREATMENT 
Some curves are too severe for bracing to be effective and surgery is the only 
remaining option. In most cases surgery is an elective procedure and very rarely is the 
surgery a matter of urgency, especially in adolescent idiopathic curves. Urgent surgery is 
only called for when the spinal rotation is so severe that it is affecting the lungs and 
breathing capacity or any another organ’s functionality. So what is the goal of surgery? 
“Scoliosis reconstruction is undertaken to improve the curve from a cosmetic standpoint as 
well as to prevent further progression of the curve. The purpose of scoliosis surgery is not 
to fully straighten a curve, but rather to obtain reasonable correction of the curve, and to 
restore balanced posture for the patient” (Walker 2010).  In adults, surgery is often used 
to reduce chronic back pain and discomfort in a progressing curve.   
TYPES OF SURGERY 
Once surgery is agreed upon by the doctor and the patient, there are a couple of 
different surgical approaches that the doctor may take. The first and most common style of 
surgery is spinal fusion surgery. In spinal fusion there are still two subcategories, posterior 
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spinal fusion and anterior spinal fusion. Both use a combination of hooks, screws, wires 
and rods. The hooks are screwed in and attached together by wires that are anchored in 
place along the vertebral column. The rods are placed in the anchors and fixed there, so 
that when tightened or rotated they can straighten the spine. The surgeon then fuses part 
of the spine using bone grafts, in posterior fusion taken from the top of the pelvis or taken 
from a rib in the anterior fusion and spread it out along the vertebrae and joints. The bone 
graft pieces ossify and fuse with the spine creating one solid piece of vertebrae 
permanently corrected in the straightened position. Although the rods are no longer 
needed in the patient, removing them would require an added surgery so they are usually 
left in place (Dotsky and Lipp 2002).  
The posterior form of spinal fusion is done through an incision that approaches the 
spine from the back and runs down the length of the body; a long posterior incision can go 
from the shoulder blades down to the waist. The original posterior fusion surgeries used 
Harrington rods (now outdated) which worked by “distraction and compression” to 
straighten the curve. The issues that arose with the Harrington rods (Figure 4) are that 
they tended to make the entire spine abnormally flat from the side plane known as “flat 
back effect”. It did not allow a posture where the head and pelvis were perfectly aligned 
and it did not account for rotational deformity (Figure 5). The more modern systems 
address these problems of sagittal imbalance and rotational deformities (Modi 2009).  
The anterior spinal fusion method approaches the deformity from the front and in 
recent times has become more common. This method of surgery is a more invasive 
operation because it entails moving around internal organs in order to reach the spinal 
column. The incision runs along one side of the abdomen below the ribcage, as opposed to 
the posterior method, which runs along the length of the back. The anterior method is 
mostly used in the scoliosis cases that have a curvature in the thoracolumbar or lumbar 
vertebrae. The discs between the vertebrae are removed, screws are placed into the 
vertebral bodies, and a rod is attached to the screws like a posterior spinal fusion. The 
advantage of the anterior spinal fusion is that a smaller segment of the vertebrae is fused 
leaving more “freely movable” components of the spine. Some people are actually 
Figure 5: Pre and post-surgery X-Rays.  
Source:http://www.scoliosis.org/forum/showthrea
d.php?4254-Live-Broadcast-of-Scoliosis-Surgery 
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candidates for an extremely complex surgery in a combination procedure involving both 
posterior and anterior surgeries. 
The newest approach to scoliosis surgery is the thoracoscopic method. This new 
technologically advanced method uses cameras attached to the surgical instruments, 
inserted into small “peephole” incisions (replacing the long incision and inevitable scar) 
(Figure 6) on the side of the body by the surgeons. The cameras produce an image that is 
projected onto the screen in the operating room so the doctor can perform the surgery 
without exposing the spine. This procedure is not to be confused with thoracoplasty, 
which is another scoliosis related procedure. Sometimes combined with spinal fusion, this 
process involves the removal of 4-6 adjacent rib segments that protrude in a ‘hump”. This 
is caused by scoliosis related rotation of the rib cage, resulting in a visible protrusion of 
specific rib segments. This removal of rib will many times serve as the rib graft needed in 
posterior fusion surgery (Lyons et al. 1999) 
SURGICAL SIDE EFFECTS 
According to the article "Scoliosis" on the Health Scout web site, for people 
undergoing scoliosis surgery "complication rates are high, nearly 10%, with any surgical 
procedure. In fact, 7% of patients require reoperations within 5 years after surgery” 
(Health Scout 2009). Since the risks of surgery are manifold, people don’t really know 
what to expect post-surgery. Risks and potential complications include the following 
(Lyons et al. 1999): 
• allergic reactions to anesthesia  
• bleeding (patients are encouraged to donate blood before the operation 
for use in possible transfusions) 
• postoperative infection of the wound/incision site 
• nerve damage (neurologic injury can occur in 1% of patients, which can 
lead to motor weakness and, in rare cases, paralysis) 
• pseudoarthrosis (or failure of the fusion to take place) 
• disc degeneration 
• lower back pain 
• loss of trunk mobility, balance, and muscle strength 
• leg and back pain 
• dislodging of hooks or broken or loosened rods 
• fracture of a fused vertebra 
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Surgery, like every other method of treatment, has its pros and cons. Advantages of 
surgery include a stop to the progression, a better cosmetic outcome, and an immediate 
decrease in the curvature. However, there are many cons to surgery: Once fused, the  
“arthritis time clock” begins, recovery period is lengthy and painful, many activities 
become unsafe for the new spinal addition, and like any surgery, it comes with many 
possible post and perioperative complications.  
In comparing the long-term effects of bracing and surgery, we find a landslide of a 
difference between the two. While bracing has little potential of long-term complications, 
surgery has many. In every case of spinal surgery there is an irreversible loss of the normal 
active range of movement in the spinal column. Furthermore, the rigid post-surgical spine 
puts a lot of strain on the un-fused portion of the vertebral column, which often causes 
post-surgical degenerative changes and may be a cause for re-operation. Severe back pain 
after surgery is usually an indicator that a re-operation is needed. Infections and 
inflammations have been known to appear as early as days to as late as eight years after a 
spinal surgery. The causes for these infections range from instruments being left in the 
body (which can be a cause for a second surgery to remove the instruments) to 
transmission during a blood transfusion and many other reasons in between. Although a 
rarity, there have been reports showing that the patients received HIV (or other diseases) 
from blood transfusions because of negligent surgeons. It is possible that rods or anchors 
can break or loosen, initiating the onset of curvature progression. Although the bulk of 
surgeries do not have complications that are severe enough to call for a follow up 
operation, nevertheless, the risks are high. 
 
 CRITERIA FOR TREATMENT 
Determining the specific treatment for a patient is based on the patient’s age, curve 
flexibility or curve magnitude. The first factor mentioned, age, is really a reference as to 
whether or not the patient has reached a level of skeletal maturity. Factually, scoliosis 
increases rapidly during general skeletal growth and most rapidly during the adolescent 
growth spurt (Lyons et al. 1999). Therefore, doctors must determine in younger patients 
how far they are from skeletal maturity. Young children, naturally, are significantly far 
from full skeletal maturity and are therefore almost always braced if their curves call for 
non-operative treatment. Adolescents must be carefully analyzed as to whether they would 
be a candidate for bracing based on their skeletal 
growth. Actual age can also be a factor when it 
becomes a health issue like being too old to 
tolerate surgery; most often, though, it is 
considered for younger patients. 
Skeletal maturity is based on a scale 
called the Risser Sign named after Dr. Joseph 
Risser. In 1958 Dr. Joseph Risser made an 
important observation while looking at X-rays of 
the pelvis of an adolescent with scoliosis. He 
recognized that as the growth plate on top of the 
pelvis completed growing, it changed from 
cartilage to bone. Bone would first appear at the 
outer border of the growth plate and then 
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progress inwards as growth neared completion. After two years the X-ray showed that this 
bone had become like a “cap” on top of the pelvis. This signified that when a bone first 
appears a prediction can be made that an average growth of 2 years remains.  The cap can 
then be followed like the hands of a clock from the outer aspect of the pelvis inward 
(Figure 7). Risser divided the appearance of this bony cap into 4 sections; when 25% of 
the bony cap can be seen on X-ray it is described as Risser 1, 50% is Risser 2, 75% is 
Risser 3and 100% is Risser 4. The final stage, Risser 5, is when the space between the cap 
and the pelvis fills in completely with bone (Skeletal Age 2010).  
Most physicians agree that by the time "Risser 3" has occurred, the patient has 
passed the peak of his/her "growth spurt", a period of rapid spinal growth during which 
scoliosis curves can increase rapidly. To recap, during development, the iliac apophysis 
first appears laterally and grows medially. The stages are Risser 1 through Risser 5, where 
Risser 5 denotes that the apophysis has completely fused with the iliac crest and therefore 
skeletal maturity can be assumed (Skeletal Age 2010).  
Curve magnitude is a factor that is equally, if not more, important than determining 
skeletal maturity. Measured in degrees, the curve magnitude combined with the Risser 
sign aids doctors in determining the proper treatment for patients. For curves of 20-29 
degrees, some doctors will continue observation and if the curve progresses they will then 
recommend a brace. Bracing cannot totally fix a vertebral curve but only slow down the 
progression of one (Lange et al. 2009). Occasionally, bracing is used by adults with 
scoliosis to ward off back pain or just for straightening posture, since surgery may not be 
recommended for these older patients due to osteoporosis, arthritis or other health 
reasons. Additionally, younger patients with scoliosis whose conditions are not severe 
enough to require bracing will sometime turn to back bracing to reduce poor posture or to 
relieve muscle pain (Aulisa et al. 2010). 
When determining whether a patient is a candidate for surgery, the same criteria 
that are used in bracing are examined, namely the age (skeletal maturity), flexibility of 
spine and degree of curvature. Age and skeletal maturity can affect a scoliosis surgery 
done at too young of an age. If a patient goes through a fusion at a young age, the 
vertebrae might “weld,” causing it to no longer grow in length with the rest of the body. 
That is why surgery is reserved for older teens with progressive curvature degrees over 40 
and pre-teens with even more severe curves.  
CONCLUSION 
In conclusion, determining the proper from of treatment for any scoliosis patient is 
a multistep process. First, the specific type of scoliosis must be determined by a physician 
and then the potential treatment options can be discussed based on factors like age and 
health. Next, in making a decision to begin orthotic treatment for any scoliosis case 
(juvenile or adolescent), a family has to consider the psychosocial effects, body image 
concerns and lifestyle changes that may affect the patient. Depending on all these factors, 
the family and physician will together decide on the proper form of brace treatment that 
will benefit the patient best. Not all forms of bracing can be used for any patient (although 
there is overlap) and not all have an equal success rate. If the curvature of the patient is 
too severe for bracing to be an option, there are still many different surgeries that can be 
performed. The family also must be aware of all of the concerns and complications that 
can come with any surgical procedure. Both bracing and surgical procedures in general 
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have positive effects on correcting the scoliosis curvature and complications are not 
commonly found in either. 
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IS THERE A GENETIC BASIS FOR ALCOHOLISM? 
David Aharonoff 
ABSTRACT 
This paper reviews studies done on the correlation of alcoholism and genetics. 
Evidence of this correlation can be seen in high heritability of alcoholism. The main methods 
used in determining genetic risk factors are candidate gene studies and genome wide studies. 
This review focuses mainly on findings related to specific neurotransmitters and receptors in 
relation to alcoholism. Evidence has shown that specific neurotransmitters and receptors can 
play a role in increased susceptibility to alcoholism. The neurotransmitters and receptors 
discussed in this paper include GABA, glutamate, and endogenous opioids. There is also a 
discussion focused on mutations of specific enzymes (ADH and ALDH) used to metabolize 
alcohol and its possible effects on developing alcoholism. When applicable, findings include a 
potential pharmacological treatment targeting the possible causation for alcoholism. Results 
from the studies conducted by the Collaborative Studies on Genetics of Alcoholism (COGA) 
have been discussed as well. COGA findings include specific chromosomes and their 
relationships with alcoholism, namely 1, 4 , 7, 11, and a possible indicator for increased 
susceptibility, or level of response (LR).  
The World Health Organization (WHO) estimates that alcohol results in 2.5 million 
deaths each year and in 9% of all deaths between the ages of 15 and 29.  The WHO further 
concludes that alcohol is the world’s third largest risk factor for disease burden; it is the 
leading risk factor in the Western Pacific and the Americas, and the second largest in Europe 
(World Health Organization 2011). An American survey by Hasin and colleagues (2007) 
concludes that alcoholism affects 4-5 % of the population at any given time. As a result of these 
widespread ramifications, alcoholism has been a subject of much research.  This paper will 
primarily deal with the studies of genetic influences that affect alcoholism risk. Locating a 
genetic link can lead to possible alcoholism prevention of those genetically susceptible and help 
better treat those who have already developed the problem. 
DISCUSSION 
In order for researchers to compare and contrast their findings, they must agree 
on the definition of an alcoholic. Most researchers rely on the definition of the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, [DSM-IV] 
(APA 1994) and the World Health Organization’s International Classification of 
Diseases (ICD-10). The Diagnostic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association, fourth edition (DSM-IV) defines alcohol 
dependence, to be equated with alcoholism, as: 
 A maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifested by three (or more) of the 
following, occurring at any time in the same 12-month period: 
1. Tolerance, as defined by either of the following: 
• A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect. 
• Markedly diminished effect with continued use of the same amount of 
substance. 
2. Withdrawal, as manifested by either of the following: 
• The characteristic withdrawal syndrome for the substance. 
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• The same (or a closely related) substance is taken to relieve or avoid 
withdrawal symptoms. 
3. The substance is often taken in larger amounts or over a longer period 
than was intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or 
control substance use. 
5. A great deal of time is spent in activities to obtain the substance, use 
the substance, or recover from its effects. 
6. Important social, occupational or recreational activities are given up 
or reduced because of substance use. 
7. The substance use is continued despite knowledge of having a 
persistent or recurrent physical or psychological problem that is likely to 
have been caused or exacerbated by the substance (e.g., continued 
drinking despite recognition that an ulcer was made worse by alcohol 
consumption). 
The ICD-10 criteria for alcoholism are similar to that of the DSM-IV (Baber 
1992). A main difference is that ICD-10 doesn’t include a category on alcohol abuse, 
but rather refers to the same diagnosis as “harmful use.” The change is meant to 
prevent an underreporting of alcohol abuse (Baber 1992). “Harmful use” includes 
psychical or mental damage due to alcohol dependence (Baber 1992).  
A possible indication that a genetic predisposition for alcoholism exists is the 
fact that an alcoholic’s biological offspring are approximately three to five times more 
likely to develop alcoholism during their lifetime than the biological offspring of 
nonalcoholics (Cotton 1979).  One can argue, however, that the increased rate of 
alcoholism in alcoholics’ biological offspring is due to environmental influences; a 
positive family history can merely be the result of shared environmental influences. 
Therefore, behavioral geneticists use twin and adoption studies to identify the separate 
contributions of genetics and shared environmental factors. 
 Researchers use analyses of genetically identical monozygotic twins (MZ) and 
fraternal dizygotic (DZ) twins to measure the heritability of alcoholism.  There are 
eight major twin studies of alcoholism in men, and in all but one of these studies the 
concordance (same trait in both members of a pair of twins) rate for alcoholism was 
significantly greater in MZ than DZ twins (McGue1999). For example, in a study by 
Kendler, Prescott, Neale, and Pedersen (1997) on 8,939 Swedish male twins born from 
1902 to 1949, the MZ twin concordance rate is significantly higher than the DZ twin 
concordance rate. Overall, the studies’ concordance rates in monozygotic twins are 
approximately 47.9%, and in dizygotic twins, 32.8%.  
Adoption studies also allow researchers to better separate genetics from 
environmental influences on the development of alcoholism. Seminal research by 
Cloninger and colleagues (1987) uses a large-scale adoption study in Sweden to 
identify genetic and other variables that predict alcohol abuse in adoptees.  This study, 
coined the Stockholm Adoption Study, was done on 862 men and 913 women adopted 
by non-relatives at an early age in Sweden.  The study distinguishes between two 
forms of alcoholism: Type I is characterized as late onset of alcoholism, after age 25, 
and marked by frequent psychological dependence; Type II alcoholism is 
characterized as a relatively early onset of alcoholism, before age 25, and marked by 
spontaneous alcohol seeking and aggressive behavior.  Analysis of data from male 
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adoptees shows that although Type II alcoholism has an approximate heritability of 
90%, Type I alcoholism has a heritability estimate of less than 40%. Many of the key 
results from the original Stockholm Adoption Study were independently replicated in 
a second Swedish city, Gothenburg (Sigvardsson et al. 1996).  The replication study 
was carried out on a slightly smaller group (577 men and 660 women) but concludes 
that the risk of Type 2 alcoholism is increased 6-fold in adopted sons with a Type 2 
genetic background compared with others, while Type I alcoholism has only a 4-fold 
increase in adopted men with Type I genetic backgrounds of alcoholism.  
 Due to the evidence that alcoholism is heritable, the next step is to identify the 
possible genetic factors that lead to the heritability. Two basic strategies are used to 
identify genetic risk factors for alcoholism: candidate gene approach and genome-wide 
studies (Sloan et al. 2008). The candidate gene approach involves assessing the 
association between a particular allele (or set of alleles) of a gene that may be involved 
in the disease (i.e. a candidate gene) and the disease itself (Kwon and Goate 2000).  
This approach often begins with the knowledge of potential physiological mechanisms 
that might be related to the endophenotype and makes educated guesses about which 
of the known genes might be important (Schuckit 2000). The genes most extensively 
examined by candidate gene studies are those involved in alcohol (i.e. ethanol) 
metabolism and in neurological pathways responsible for increased risk taking and 
“reward” stimulation from ethanol (Sloan et al. 2008).  
A genome-wide study scans all genomes of individuals and identifies genetic 
polymorphisms. The two main approaches to genome-wide analysis are association and 
linkage (Sloan et al. 2008). Association studies examine genetic polymorphisms 
associated with case or control status, whereas linkage studies investigate the 
inheritance of specific locations on a chromosome within family lines (Sloan et al. 
2008). In association studies, one tests if a given allele contributes to the risk for 
alcohol dependence. For example, if a researcher hypothesizes that Gene A plays a role 
in alcoholism, he would expect this allele to differ between the case and the control 
subjects.  
Linkage analysis scans the genome using a type of genetic variation called 
microsatellites. Microsatellites are nucleotide pair combinations of DNA which repeat 
themselves and form groupings. Microsatellites can be highly polymorphic, making 
them useful for comparative genetic studies of organisms. Then, the pattern of 
transmission of disease (e.g. alcoholism) in families with multiple affected members is 
compared with the pattern of transmission of certain microsatellites (Foroud et al. 
2010). The principal hypothesis in linkage analysis is that alcoholics within a family 
share many risk alleles; therefore, genes containing alleles that increase the risk for 
alcoholism reside within chromosomal regions that are inherited by most or all 
alcoholic family members (Foroud et al. 2010). 
A prime example of specific genes related to the risk of alcoholism are those 
that control the production of the enzymes that metabolize ethanol (i.e. alcohol). 
Ethanol is metabolized in the liver, where it is converted to acetaldehyde by the 
enzyme alcohol dehydrogenase (ADH). ADH is responsible for 80% of ethanol’s 
metabolism to acetaldehyde (Gemma et al. 2006). About 10% of ethanol is metabolized 
by CYP2E1; the percentage increases when ADH is saturated (Gemma et al. 2006). 
Acetaldehyde is then converted to acetate by the enzyme aldehyde dehydrogenase 
(ALDH).  High levels of acetaldehyde in the blood causes nausea, dizziness, and 
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headaches; therefore, variation in the genes coding for the ADH and ALDH enzymes 
are expected to be associated with alcoholism risk (Edenberg 2007).  
There are at least six isoenzymes of ALDH (Schuckit 2000).  ALDH2*2, an 
isoenzyme of ALDH, involves a point mutation that results in the exchange of the 
amino acid glutamate at position 487 of the ALDH protein for the amino acid lysine 
(Edenberg 2007; Foroud et al. 2010). This mutation acts in a nearly dominant manner 
to render the enzyme almost inactive (Foroud et al. 2010). As a result, homozygous 
carriers of ALDH2-2 exhibit highly elevated levels of acetaldehyde, which produces 
aversive reactions, including flushing, tachycardia and nausea after consuming even a 
small amount of alcohol (Eng et al. 2007).  Studies have shown that ALDH2-2 
influences a person’s drinking levels, and, consequently, the risk of developing alcohol 
abuse or dependence (Edenberg 2007; Hurley et al. 2002). There are almost no 
documented cases of homozygous carries of ALDH2-2 being diagnosed as alcoholics 
(Luczak et al. 2006). Even people who are heterozygous for this mutation produce an 
ALDH enzyme with extremely low enzyme activity (Crabb et al. 1989).  
Approximately 10% of Asian men and women (e.g. Japanese, Chinese, and 
Koreans) are homozygous for the mutation of ALDH2*2, although it is not known to 
be found in any other racial group (Wall and Ehlers 1995). An additional 40% of 
Asians are heterozygotes for the ALDH mutated enzyme (Wall and Ehlers 1995). 
Compared with a Chinese man carrying two active ALDH alleles, the odds ratio of an 
alcoholism risk for a Chinese man carrying one inactive ALDH2-2 allele is 0.33 
(Edenberg 2007). Furthermore, although heterozygote ALDH2-2 carriers represent 
almost half of the general population in their countries, they comprise less than 10% of 
Asian alcoholics, further supporting the conclusion that even heterozygotes have a 
relative protection from alcoholism (Murayama et al. 1998). 
There are also coding variations in the ADH gene, called ADH2-2 and ADH2-
3, which encode highly active enzymes which increase the production rate of 
acetaldehyde (Li 2000). These variations also reduce the risk for alcohol dependence 
(Edenberg 2007; Thomasson et al. 1991). For example, a pilot study by Neumark and 
colleagues (1998) was the first example of association between alcohol consumption 
patterns and a polymorphism at the ADH2 locus in a Jewish population. The study 
compares ADH loci in 92 non-drinkers (control) versus 53 heavy drinkers 
(case).  Neumark furthered the study in 2004 by testing the effect of ADH2-2 on 
alcohol-elimination rates (AER) under experimental conditions. The study is based on 
the above-cited hypothesis that ADH2-2 increases the rate at which alcohol is 
metabolized, thereby increasing the production rate of acetaldehyde and producing 
aversive reactions. The study confirms that the rate of alcohol elimination is 
significantly associated with the ADH2 genotype of Jewish males (Neumark 2004). 
The evidence that an increase of acetaldehyde can be a deterrent to the 
development of alcohol abuse has led researchers to develop pharmacological 
treatments. Disulfiram blocks the enzyme aldehyde dehydrogenase, leading to an 
accumulation of acetaldehyde following an intake of alcohol (Heilig and Egli 2006). 
The accumulation of acetaldehyde then causes flushing, shortness of breath, 
tachycardia and other unpleasant symptoms. The point of disulfiram is not that 
patients actually experience adverse symptoms, but that that the anticipation of these 
symptoms helps patients abstain from consuming alcohol (Heilig and Egli 2006). The 
logic is that an accumulation of acetaldehyde poses a possible medical risk. However, 
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disulfiram has a limited and largely negative documentation for efficacy (Heilig and 
Egli 2006). For example, a controlled multisite study of disulfiram treatment of 
alcoholism in 605 men concludes that although disulfiram may help reduce drinking 
frequency after relapse, it does not reduce the probability of abstinence from alcohol 
(Fuller et al. 1986). 
Researchers have also done candidate gene studies on genes for receptors in the 
neurotransmitter gamma-aminobutyric acid (GABA), opioid receptor and components 
of the pathways for the neurotransmitters serotonin, dopamine, and glutamate (Sloan 
et al. 2008). A full discussion of each neurotransmitter surpasses the scope of this 
paper; therefore, but a few neurotransmitters and receptors and their relation to 
alcoholism will be discussed.    
There is evidence supporting a link between the endogenous opioid system and 
excessive alcohol consumption (Gianoulakis 2001; Herz 1997). This evidence, linking 
the endogenous opioid system to alcoholism, led to several theories regarding the 
possible nature of an opioid abnormality in this disorder (Oswald and Wand 2004). 
The Opioid Deficit Hypothesis postulates that physiological cravings for alcohol may 
be the result of a deficiency of naturally occurring opiate like substances 
(Trachtenberg and Blum 1987). Conversely, the Opioid Surfeit Hypothesis maintains 
that excess (i.e. surfeits), not deficits, in opioidergic activity increases one’s propensity 
to consume alcoholic beverages (Reid et al. 1991).  
The first study to suggest a possible link between endogenous opioid and 
ethanol was conducted by Davis and Walsh (1970), who discovered that morphine-
like alkaloids (tetrahydroisoquinolones) are formed in vivo as a result of the 
interaction between ethanol metabolite, acetaldehyde, and certain metabolites of 
dopamine. Due to Davis and Walsh’s findings, further research sought to demonstrate 
that these alkaloids could bind to opioid receptors and produce opioid-like effects 
(Blum et al. 1978; Fertel et al. 1980). However, the pharmacological relevance of these 
compounds in opioidergic processes remains unclear because their concentrations in 
brain tissues is extremely low (Oswald and Wand 2004). 
The best evidence of the linkage between endogenous opioid systems and 
ethanol consumption is that pharmacological blockades of opioid receptors 
reduce alcohol drinking in a dose-related fashion. Naltrexone is an opioid receptor 
antagonist that reduces alcohol cravings and relapses to heavy drinking, but it does not 
necessarily produce total abstinence. The initial study done by Altshuler and 
colleagues (1980) reports on the dose-related effect of naltrexone on decreasing 
ethanol drinking in 10 of 21 rhesus monkeys who were willing to self-administer 
alcohol. The treatment results were replicated by O’Malley et al. in 1992. In a 12-
week, double-blind, placebo-controlled trial conducted on seventy male alcohol-
dependent patients, Volpicelli and colleagues (1992) found that only 23% of alcoholic 
subjects who were administered naltrexone relapsed to heavy drinking, compared with 
54.3% of subjects taking a placebo. Based, in part, on the findings of these studies, 
naltrexone was approved by the Food and Drug administration (FDA) in 1995 for the 
treatment of ethanol dependence. Since naltrexone's approval for the treatment of 
alcoholism, the opioid antagonist has been tested in 29 controlled clinical trials in 
unselected participants with alcoholism (Pettinati et al. 2006). The study concludes 
that “19 (70%) of 27 clinical trials that measured reductions in ‘heavy or excessive 
drinking’ demonstrated an advantage for prescribing naltrexone over placebo, whereas 
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only 9 (36%) of 25 clinical trials that measured abstinence or ‘any drinking’ found an 
advantage for medication over placebo” (Pettinati et al. 2006). 
The effects of naltrexone have led to candidate gene studies on opioid 
receptors. There are three types of opioid receptors (mu, delta and kappa) that 
represent respective targets of the major opioid peptides (Herz 1997). Naltrexone acts 
as an antagonist at opioid receptors, with a relative selectivity for the µ-opioid receptor 
(Oswald and Wand 2004). There are more than 25 identified allelic variants of the 
gene that codes for the µ-opioid receptor (O’Brien 2008). In a human laboratory study 
(Ray and Hutchison 2004), volunteers with Asp40 allele (OPRM1) reported greater 
subjective euphoria at a given ethanol blood level. In a more recent study of heavy 
drinkers, naltrexone attenuated the increased alcohol stimulation in those carrying the 
Asp40 allele (Ray and Hutchison 2007). 
Additionally, GABAergic mechanisms mediate many of the behavioral effects 
of ethanol, including its anticonvulsant, sedative-hypnotic, cognitive-impairing, and 
fine motor skill damaging effects (Kumar et al. 2009). The two classes of GABA 
receptors are GABA-A and GABA-B. GABA-A receptors are ligand-gated ion 
channels (i.e. ionotropic) that confer fast synaptic inhibition (Enoch 2007). GABA-A 
receptors undergo allosteric modulation by several structurally unrelated drugs, most 
with their own binding sites, including ethanol and benzodiazepines (Enoch 2007). 
Initial evidence that alcoholism is related to GABA-A receptors is because 
benzodiazepines show effectiveness in treating alcohol withdrawal (Enoch 2007).  
GABA-A receptors are composed of five subunits (Sigel et al. 2006). Most 
receptors consist of two ! (alpha), two " (beta), and one # (gamma) subunits (Sigel et 
al. 2006). The GABA-A receptor ion channel is lined by the transmembrane (TM) 
segments from each of the five subunits that form the receptor (Enoch 2007). Specific 
mutations in transmembrane domains 2 and 3 of the alpha subunit can abolish or 
markedly reduce the effects of ethanol on these receptors without necessarily affecting 
receptor function; therefore, alcohols may bind in a cavity located between TM2 and 
TM3 (Mascia et al. 2000). 
 Topiramate, which has a complex effect on GABA-A receptors, is 
hypothesized to decrease alcohol reinforcement and the propensity to drink (Johnson 
et al. 2007). A double-blind, randomized, placebo-controlled, 14-week trial of 371 men 
and women concludes that “topiramate was significantly more efficacious than placebo 
at reducing the percentage of heavy drinking days,” and “topiramate is a safe and 
consistently efficacious medication for treating alcohol dependence”( Johnson et al. 
2007).    
GABA inhibits hypothalamic-pituitary–adrenal axis responses to stress whereas 
glutamate activates the response (Herman et al. 2004). Prime targets of ethanol are the 
N-methyl-D-aspartate (NDMA) receptors in the glutamate system (Spanagel 2009). 
NMDA is an amino acid derivative that acts as a specific agonist at the NMDA 
receptor, mimicking the action of glutamate. Acute alcohol exposure inhibits the 
excitatory action of glutamate at the N-methyl-d-aspartate (NMDA) receptor, 
whereas chronic alcoholism results in increased NMDA receptor expression so that 
abrupt withdrawal produces a hyperexcitable state that leads to seizures 
(Guochuan and Coyle 1998). These finding have led to the formulation of the 
glutamate homeostasis hypothesis of addiction which suggests that enhanced 
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glutamate-mediated neuronal excitability during withdrawal and prolonged abstinence 
contributes to craving and relapse (Kalivas 2009).  
Further, “Metabotropic glutamate (mGlu) receptors, which include mGlu1–8 
receptors, are a heterogeneous family of G-protein-coupled receptors which function 
to modulate brain excitability via presynaptic, postsynaptic and glial mechanisms” 
(Schoepp 2001). In contrast to ionotropic receptors, metabotropic receptors influence 
the activity of a cell indirectly by first initiating a metabolic change in the cell. Studies 
provide evidence that activation of group II mGluRs (predominantly presynaptical) by 
a selective mGlu 2/3 agonist (LY379268) dose dependently blocks the effects of both 
stress and drug related environmental stimuli on the recovery of extinguished ethanol-
seeking behavior (Zhao et al. 2006). A similar study on group I mGluRs 
(predominantly located postsynaptically) in alcohol-preferring P-rats, a well-defined 
genetic model of excessive alcohol consumption, shows that infusion of the mGluR5 
antagonist 2-methyl-6(phenylethynyl) pyridine (MPEP) in the nucleus accumbens 
reduces ethanol-reinforced responding (Besheer et al. 2010). Besheer et al. (2010) 
concludes that the data “confirms the importance of mGluR5 activity in the nucleus 
accumbens in regulating drug reinforcement and emphasizes the potential therapeutic 
utility of targeting this receptor system in individuals with genetic risk for excessive 
drinking.”  
The interaction of ethanol and glutamate led to candidate gene studies on 
glutamate. An association study that tested the candidate gene hypothesis of allelic 
variants of the ionotropic glutamatergic N-methyl-D-aspartate receptor (NMDAR) 
provides evidence that they are associated with vulnerability to alcoholism (Wernicke 
et al. 2003). Wernicke and colleagues studied variants of the ionotropic 
glutamatergic N-methyl-d-aspartate receptor (NMDAR the silent G2108A and 
C2664T polymorphisms of the NMDAR1 and the NMDAR2B genes), in exon 5 of 
the EAAT2 gene in 702 subjects of German descent, comprising 367 alcohol-
dependent subjects and 335 control subjects. Genotype frequencies of the NMDAR1 
polymorphism differed significantly between control and alcoholic subjects and the 
NMDAR2B polymorphism revealed a significantly reduced T allele in Cloninger type 
2 alcoholics and in patients reporting an early onset compared with control subjects.  
In 1989, the National Institute on Alcohol Abuse and Alcoholism initiated the 
Collaborative Study on the Genetics of Alcoholism (COGA), a large, systematic effort 
to identify the genes that predispose to alcoholism. COGA’s goal is to elucidate the 
genetic mechanisms that contribute to a person’s susceptibility to alcohol abuse and 
dependence (Begleiter et al. 1995). COGA generated a dataset of 1,857 families 
consisting of 16,062 individuals as of March 2010 (Foroud et al. 2010).  Due to the 
genetic complexity of alcoholism, COGA researchers chose an unbiased survey of the 
entire genome (i.e. genotyping) (Edenberg 2002). Using microsatellite markers, more 
than 1.2 million genotypes were generated on 2,310 people from families of alcoholics 
and 1,238 people from control families (Edenberg 2002). This information enables 
researches to monitor the inheritance pattern of marker alleles within families with 
alcoholics and therefore helps identify chromosomal regions that show genetic linkage 
with alcoholic related traits (Edenberg 2002). To be categorized as a “family of 
alcoholics” the family must comprise at least three first-degree relatives who met 
lifetime criteria for Diagnostic and Statistical Manual of Mental Disorders, Third Edition, 
Revised (DSM–III–R) (Foroud et al. 2010). 
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COGA data collected from families with alcoholism are used for both linkage 
and association analyses (Sloan et al. 2008). In 1998, COGA researchers published 
their initial linkage findings based on an analysis of 291 markers in 987 individuals 
from 105 families (Reich et al. 1998). Substantial evidence points to a susceptibility loci 
for alcohol dependence on chromosomes 1 and 7.  In addition, there is suggestive 
evidence for a protective locus on chromosome 4 near the ADH gene (Reich et al. 
1998). At the same time as the COGA findings were published, a second large-scale 
linkage study of alcoholism, based on a sample of Native Americans, reported 
suggestive evidence of the existence of a predisposing gene on Chromosome 11p, in 
close proximity to the DRD4 dopamine receptor (Long et al 1998). Evidence also 
suggests a protective gene on Chromosome 4p, near the beta1 GABA receptor gene 
(Long et al. 1998). Although only the Chromosome 4 findings overlapped, the two 
studies sampled different ethnic groups, and the genes that underlie alcoholism risk 
might be expected to vary for groups having distinct evolutionary history (McGue 
1999). A more recent COGA study by Yang and colleagues (2005) found potential 
candidate regions on chromosomes 1, 2, and 7 linked with alcoholism susceptibility. 
Overall, Yang viewed his findings as consistent with Reich’s findings (Yang et al. 
2005).  
 Due to prior evidence for the role of the ADH genes in alcoholism 
susceptibility, the COGA investigators did several studies to determine the specific 
nature of the link (Foroud et al. 2010). In one particular study, COGA researches 
genotyped 110 DNA markers known as single nucleotide polymorphisms (SNPs) 
across the seven ADH genes located on chromosome 4q and analyzed their association 
with alcoholism in a set of families (n= 262) with multiple alcoholic members 
(Edenberg et al. 2006). The analyses show strong evidence that 12 SNPs located in 
and around the ADH4 gene are significantly associated with alcoholism (Edenberg et 
al. 2006).  
Evidence of a molecular interaction between ethanol and GABA receptors led 
COGA researchers to study the link between variation in GABA receptors and 
alcoholism. Edenberg and colleagues (2004) performed a linkage analyses of 69 single-
nucleotide polymorphisms (SNPs) within a cluster of four GABA (A) receptor genes 
located in chromosome 4p: GABRG1, GABRA2, GABRA4, and GABRB1. The 
analyses found thirty-one SNPs in GABRA2 associated with alcohol dependence. 
Edenberg concludes his study by stating, “ the convergence of evidence from different 
analyses and phenotypes, along with the biological data on its function, provides 
strong evidence that GABRA2 is a key gene affecting the risk for alcoholism.” 
Interestingly, the GABRA2 is part of the GABA-A ! subunit that was mentioned 
before as a possible binding spot for alcohol.  
The genome-wide association studies (GWAS), also known as the whole 
genome association studies, are examinations of all or most of the genes (the genome) 
of different individuals of a particular species to see how much the genes vary from 
individual to individual. Different variations are then associated with different traits, 
such as diseases. In humans, hundreds or thousands of individuals are tested for 
single-nucleotide polymorphisms (SNPs). The advantage of GWAS is that it allows a 
comprehensive test for associations across the genome, rather than testing only one 
gene at a time.   
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The genome-wide association studies (GWAS) examine up to a millions SNPs 
through the human genome in a single experiment (Foroud 2010). The different 
variations of SNPs between individuals is then associated with different traits, such as 
diseases. An advantage of GWAS is its hypothesis-free strategy and its suitability for 
the discovery of novel genetic contributors to disease (Bierut et al. 2010). 
This first genome-wide significant association study in alcohol dependence was 
published in 2009 (Treutlein et al. 2009). The GWAS included 487 male inpatients 
with alcohol dependence as defined by the DSM-IV and 1,358 population-based control 
individuals (Treutlein et al. 2009). The GWAS tested 524 396 single-
nucleotide polymorphisms (SNPs) (Treutlein et al. 2009).  The analyses found two 
closely linked SNPs located on chromosome 2 (Treutlein et al. 2009). However, a 
recent GWAS of 1,897 European-American and African-American subjects with 
alcohol dependence compared with 1,932 unrelated, alcohol-exposed, nondependent 
controls did not replicate the finding reported by Treutlein and colleagues (Bierut et 
al. 2010). Interestingly, Bierut’s GWAS found SNPs genotyped in GABRA2 that 
overlap with SNPs reported by Edenberg et al. (2004).  
The level of reaction to alcohol has been a useful tool to indicate a possible 
increase in susceptibility to alcoholism. Studies have found a correlation between level 
of response (LR) to alcohol and the risk of developing alcohol dependency (Schuckit 
1999). Numerous alcoholics have reported an ability to consume large amounts of 
alcohol with relatively little effect from early in their drinking careers (Schuckit 1999). 
A low LR is usually evaluated by giving alcohol to individuals and determining the 
intensity of response at a given blood alcohol concentration (BAC), or by indirectly 
measured through a self-report of a history of a higher number of drinks required to 
produce a specific effect (Schuckit 2000). A study of 453 sons of alcoholics and 
controls as conducted over a period of 15 years demonstrated that a low LR was a 
significant predictor of later alcoholism (Schuckit and Smith 1996).   
There are several indications that LR is genetically influenced. For example, a 
study on 3,810 adult twin pairs reported a higher level of similarity on some aspects of 
LR in identical twins than in fraternal twins, with an estimated heritability between 40 
and 60 percent (Martin 1988).  A pilot study (Mazzanti et al. 1999) evaluated 17 men 
with low LR scores, comparing results to 24 individuals who were clearly higher on 
the LR scale. The high LR and low LR groups were then evaluated for the patterns of 
5 candidate genes relating to serotonin and gamma-aminobutyric acid functions. The 
14 men with the LL genotype of the serotonin transporter (5-HTT) polymorphism and 
the seven with the genotype of the GABAA alpha 6 polymorphism had demonstrated 
lower LR scores at about age 20, and had significantly higher proportions of alcoholics 
than the other genotypes for those loci. These studies show that low LR can be a 
potential indicator to a genetic risk of alcoholism.   
CONCLUSION 
In conclusion, evidence has shown that there exists a genetic susceptibility to 
alcoholism. However, it is clear that there are environmental factors, possible as high 
as 50% (Dick and Beirut 2006), that can attribute to alcoholism.  The main focus of 
this paper is to show that the genetic component of alcoholism exists as well, though it 
is clear that alcoholism is a complex disease that involves various mechanisms and 
pathways. Susceptibility to alcoholism cannot be attributed to one single gene, 
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neurotransmitter, or receptor. Other possible neurotransmitters that haven’t been 
discussed but yet can play a vital role are serotonin and dopamine (DRD2). This 
paper is only a brief overview of possible genetic contributions to alcoholism.  There is 
much more research that has been done and more that will be done in the near future. 
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HEALTH RISKS OF VERY LOW CHOLESTEROL 
Menachem Nagar 
ABSTRACT 
Cholesterol is a molecule central to all human physiological processes at systemic as 
well as cellular levels. Cholesterol, combined with Apolipoprotein B as low-density lipoprotein 
(LDL) has been the focus of scientific research because the molecule has been proven to play a 
role in the development of cardiovascular disease, a disease of pandemic proportions. 
Considerable scientific and medical attention has been devoted to identifying the role and 
management of high levels of total serum cholesterol in order to address this global health 
burden, creating large scale awareness regarding lowering cholesterol concentration in 
circulation. However, the same molecule, combined into various lipoprotein moieties, is also 
involved in ‘normal’ physiological processes. In this review, an attempt has been made to 
elucidate some of the physiological events at the other end of the spectrum, when serum 
cholesterol levels are lower than normal. These health risks may need to be managed by going 
against the grain and actually raising serum cholesterol levels. Hypocholesterolemia is perhaps 
as much of a health risk as is hypercholesterolemia. These phenomena emphasize the fact that 
where cholesterol is concerned, maintenance of optimal systemic levels of cholesterol is more 
crucial than going towards either end of the cholesterol scale.  
INTRODUCTION 
Cholesterol has been in the center of many debates concerning its role in the 
human metabolism. Cholesterol is considered as the main culprit behind modern 
lifestyle diseases like atherosclerosis, which leads to cardiac arrest, obesity and 
metabolic syndrome. Although implicated as a causative agent of all of the above, 
cholesterol is also an important component of cellular membranes and is a mediator of 
several cellular processes. Cellular membranes owe their fluidity to the presence of 
cholesterol and lack of cholesterol is likely to have an impact on several physiological 
processes. Cholesterol is an important precursor for synthesis of steroid sex hormones 
(Payne and Hales 2004) as well as vitamin D (Lehmann et al. 2000). Cholesterol is an 
important constituent of cell membranes and, being an amphipathic molecule, it 
interacts with both lipids in the plane of the membrane bi-layer, as well as with water 
and other electrolytic substances owing to the presence of  an –OH group. Cholesterol 
is thought to play an important role in maintaining membrane fluidity as well as 
participate in transient membrane specializations called membrane microdomains or 
‘rafts’ (Sharma et al. 2004). 
The role of LDL in the development of cardiovascular disease (CVD), when 
present in excess in human circulation, has been discussed at length (Stein 2009). The 
consensus is that very high levels of serum LDL-cholesterol and triglycerides are the 
causative factors of atherosclerotic plaques, which can eventually cause blockage of 
cardiac arteries leading to a heart attack. There have been extensive studies on the 
interrelationships between diet, obesity, serum cholesterol levels and CVD as well as 
other co-morbidities like diabetes mellitus (Daniels et al. 2009), leading to the 
formulation of a general assumption that one must slay the cholesterol beast in order to 
live a disease-free life. However, cholesterol is also an essential component of 
biological tissues and is also specifically required for several cellular processes.  
Therefore, the issue that begs consideration here is “How low can one go with 
cholesterol?” Given the importance of having an optimal amount of cholesterol present 
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in the human system, it is likely that extremely low levels of cholesterol are likely to 
bring in another set of health morbidities and risk. This review attempts to understand 
health risks at the other end of the cholesterol range by looking at cholesterol 
deficiency disorders. Physiological deficits in cholesterol levels can result from a 
variety of causes and the effects of these deficiencies on various health parameters are 
discussed in this review. 
CHOLESTEROL METABOLISM 
Cholesterol can be synthesized by all tissues in the human body, barring 
enucleated erythrocytes. In addition to synthesis of cholesterol from acetate, 
cholesterol is also absorbed from ingested food in the form of chylomicrons. 
Chylomicrons are a class of lipoproteins that are produced by intestinal mucosal cells, 
the principal component of which is a small protein apoB-48, produced by alternative 
splicing of mRNA from the apoB gene. Chylomicrons are generated in the intestinal 
cells after the absorption of free fatty acids and cholesterol and are secreted by the 
intestinal cells into the lacteals and are redistributed to other organs and peripheral 
tissues. Chylomicrons are capable of exchanging apolipoproteins with high-density 
lipoproteins (HDL) to generate mature chylomicrons. Cholesterol from peripheral 
tissues is exported in the form of HDL, which is brought to the liver via the vascular 
system. HDL-associated cholesterol and phospholipids are degraded in the liver. 
Cholesterol breakdown products are excreted in bile as bile salts, which, after storage 
in the gall bladder, are secreted into the digestive system. Bile salts help in 
emulsification of dietary fats until they are absorbed in the small intestine.  
The liver is also the site of cholesterol synthesis and hepatic cholesterol is 
secreted into the vascular system in the form of very low-density lipoproteins (VLDL). 
In the plasma, VLDLs coalesce to form low-density lipoprotein (LDL) particles.  
Cholesterol deficiencies can be classified into 
a) Inborn errors in cholesterol synthesis or apolipoprotein synthesis 
b) Clinically observed hypocholesterolemia of undetermined origin such as 
in HIV-positive patients (Miguez et al. 2010; Shor-Posner et al. 1993) 
c) Cholesterol deficiency induced by surgery and critical illness 
THE ROLE OF HDL IN CARDIOVASCULAR DISEASE  
Cholesterol is present in serum in three forms: very low-density lipoprotein 
(VLDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), with 
each form serving a distinct physiological function. Very low-density lipoprotein is the 
form that is created by processing of HDL and LDL by the liver into smaller particles 
meant for excretion. LDL has been implicated as a causative factor principally in 
atherosclerosis especially when plasma concentrations of LDL are high (Daniels et al. 
2009). HDL, on the other hand, functions to transport cholesterol from peripheral 
tissues to the liver for degradation (Podrez 2010). HDL is chiefly composed of 
apolipoproteins A I and II (apoAI and apoAII) with apolipoproteins C, D, E, M and 
A-IV(apoC, apoD, apoE, apoM, apoA-IV) and other enzymes forming the protein 
components of the particles. Cholesterol is the main lipid component but other 
phospholipids as well as free fatty acids have also been reported to be included in 
HDL. 
A sum total of 75 proteins have been found to be included in HDL in proteomic 
studies. These findings suggest that HDL may exist in several distinct forms engaged 
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in several functions apart from transporting cholesterol to the liver (reviewed in 
Podrez 2010). In fact, HDL plays a prominent role as an anti-oxidant molecule by 
preventing oxidation of LDL and acting as a ‘sink’ for oxidized lipids from LDL 
(Podrez 2010; Terasaka et al. 2007). The role of HDL as an antioxidant is thought to 
help in preventing the formation of dysfunctional LDL molecules that may play a role 
in initiating atherosclerotic plaques (Terasaka et al. 2007). HDL is thought to have a 
cardioprotective role and help prevent cardiovascular disease. Low HDL is considered 
as a positive predictor for cardiovascular disease (Schaefer et al. 2010). Patients with 
mutated apoA-I show normal levels of LDL and serum triglycerides and yet are at 
greater risk of developing coronary heart disease (Schaefer et al. 2010). 
The link between circulating levels of HDL and coronary heart disease has 
been demonstrated by other researchers as well. In a 16-year follow-up study with 
3,026 patients, treatment with bezafibrate reduced the risk of coronary heart disease 
and death by myocardial infarction by 22% as compared with patients who had been 
prescribed a placebo (Goldenberg et al. 2009). In this study, patients who showed a 
greater increase in serum HDL levels in response to bezafibrate were at lesser risk for 
developing coronary heart disease. The study vindicates the role of HDL in preventing 
atherosclerosis as well as coronary heart disease. In a Finnish population study of 148 
people who presented with low HDL levels, a reduction in HDL particle size was 
positively correlated with increased carotid intima-media thickness (Watanabe et al. 
2006). Increase in the thickness of carotid intima and media, as assessed by 
ultrasonography, is considered as a reliable marker for atherosclerosis. In this study, 
people with low serum concentrations of HDL also showed a significant reduction in 
the HDL particle size and were consequently deemed to be at greater risk for 
development of coronary heart disease.  
Given the diversity of proteins and lipids associated with HDL in addition to 
cholesterol (Podrez 2010), heterogeneity in size and diversity of functions of HDL is 
to be expected. In a study that sought to understand the relationship between HDL 
particle size and coronary heart disease, Arsenault and colleagues found that smaller 
HDL particle size (which can possibly be attributed to deficiencies in proteins as well 
as associated cholesterol and other lipids) (Arsenault et al. 2009) was positively 
correlated with increased risk for coronary heart disease. Patients with smaller sized 
HDL particles also had greater co-incidence of other unfavorable cardiometabolic 
factors like elevated waist circumference and higher systolic blood pressure and 
elevated serum triglyceride levels. The study does indicate that predominance of HDL 
and large sized HDL particles are indicators of cardiovascular risk, however; analysis 
of the specific contribution of serum cholesterol was not carried out in this context.  
The predominant question that arises from the previous discussion is whether 
HDL particle size is regulated by cholesterol levels or not. HDL particle size analysis 
was undertaken in a study of people who were heterozygous for Tangier disease (TD) 
(Brousseau et al. 2000). Tangier disease is characterized by the presence of orange 
tonsils, very low levels of HDL and enlarged spleen and liver. The essential mutation 
in Tangier disease is one that causes a dysfunctional ATP-binding cassette transporter 
protein ABC1 on chromosomes 9q31. This transporter protein regulates the efflux of 
cholesterol from peripheral tissues and allows it to complex with apoA-I and apoA-II 
to form HDL. In patients heterozygous for Tangier disease mutation, HDL particle 
size was significantly smaller than that seen in controls. Efflux of cholesterol from TD-
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heterozygote cells was reduced by 50 % to that of control cells and this reduction in 
serum cholesterol correlated positively with serum HDL concentration as well as 
HDL particle size (Brousseau et al. 2000). Cholesterol efflux may also influence the 
HDL-subtype distribution in Tangier disease heterozygotes (Asztalos et al. 2001). 
HDL subpopulations can be characterized on the basis of size as well as the 
predominant apolipoproteins associated with them. In a study of people heterozygous 
for Tangier disease as confirmed by low HDL levels, the prevalence of large alpha1, 
pre-alpha1, alpha 2 and pre-alpha2 particles was significantly lower as compared to 
healthy control subjects. The loss of these specific HDL subpopulations may be the 
result of reduced cholesterol efflux mediated by the Tangier mutation in the ABC-1 
gene (Asztalos et al. 2001). Concurrently, the incidence of coronary heart disease was 
also found to be greater by 60%, in the heterozygote group as compared to unaffected 
healthy subjects. Therefore, cholesterol deficiency is likely to influence the particle size 
as well as the specific nature of HDL particles; it is likely that very low levels of 
cholesterol in the serum may actually contribute to increasing the risk of coronary 
heart disease. Although this sounds contradictory to conventional wisdom that 
cholesterol in the form of LDL IS the ‘seed’ molecule for formation of atherosclerotic 
lesions, the lack of HDL particles of appropriate size and functional properties is a 
serious concern for people with very low levels of serum cholesterol.  
CHOLESTEROL AND NUTRITION 
Lipoproteins are involved in the transport of vitamin E from the digestive 
system as well as from the liver to the peripheral tissues. Vitamin E or alpha-
tocopherol is known to bind to HDL, specifically HDL-3 (Goti et al. 1998). HDL-3 
bound tocopherol can be taken up by hepatocytes (in in vitro studies) and is secreted 
out in the form of LDL by hepatocytes. Thus both metabolic forms of cholesterol in 
the form of lipoproteins are involved in the systemic transport of vitamin E.  
Cholesterol is known to participate in transient membrane specializations 
termed as membrane microdomains, along with sphingolipids (Sharma et al. 2002). 
These microdomains are formed laterally in the plane of the plasma membrane and are 
especially important for the endocytosis of the folate receptor. Depletion of cellular 
cholesterol, in in vitro systems has been shown to alter the endocytic pathway 
(Sabharanjak et al. 2002), recycling time as well as intracellular endosomal destination 
of the folate receptor (Sabharanjak and Mayor 2004). The overall efficiency of 
accumulating folic acid in the cytoplasm is also reduced. Although it is unclear whether 
physiological depletion of cholesterol either by suppression of synthesis or by reduced 
dietary intake results in similar disruption of microdomains, the role of cholesterol in 
uptake of water-soluble vitamins is also important.  
DEFICIENCIES IN CHOLESTEROL BIOSYNTHESIS 
Cholesterol in circulation can be derived from dietary components as well as 
from de novo synthesis. Cholesterol is synthesized from hydroxymethylglutaryl co-A 
(HMGco-A) in a series of steps with intermediates like squalene, lanosterol and 
lathosterol. Cholesterol thus synthesized may also get converted into steroid hormones 
like testosterone. Incidentally, low testosterone levels in men are also correlated with 
increased risk of coronary heart disease and show a positive correlation with low levels 
of HDL as well (Nettleship et al. 2009). 
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In the biosynthesis of cholesterol, lanosterol is converted via seven steps to 
lathosterol, which in turn in converted into 7-dehydrocholesterol by the action of 
lathosterol-5-desaturase. Mutations in this enzyme lead to the accumulation of 
lathosterol instead of cholesterol, a defect known as lathosterolosis. This defect has 
been replicated in a mouse model for lathosterolosis. Likewise, the final step in 
biosynthesis is the conversion of 7-dehydrocholesterol to cholesterol catalyzed by 7-
dehydrocholesterol reductase. A genetic mutation of this enzyme has been described as 
the Smith-Lemli-Opitz syndrome (SLOS), which is characterized by severe 
developmental abnormalities including mental aberrations (Gondre-Lewis et al. 2006). 
Both these defects have been established in mouse models described by Y Peng 
Loh and colleagues (Gondre-Lewis et al. 2006). In order to examine the effect of 
abnormal sterol accumulation in membrane trafficking events, these scientists 
characterized and quantified the occurrence of dense core secretory granules in 
exocrine pancreatic tissue as well as neuroendocrine cells. In Sc5d-/- as well as Dhcr7-/- 
mice, the number of secretory granules in pancreatic tissues was significantly lower 
than that found in wild type or heterozygous mice. (Gondre-Lewis et al. 2006). 
Additionally, the fission of dense core granules from the endoplasmic reticulum was 
seen to be impaired in Dhcr7-/- mice, suggesting that lack of cholesterol had interfered 
with formation of dense core granules at the Golgi. The proportion of immature 
granules lacking the dense core was higher in the mutant homozygous mice as 
compared to wild type mice. The accumulation of sterols other than cholesterol is 
likely to hinder secretory processes. Although alpha-amylase was produced by normal 
as well as homozygous mutant mice with both genetic defects, the enzyme was found 
to be constitutively secreted in Dhcr7-/- mice, indicating that cholesterol in the granule 
membrane as well as plasma membrane of pancreatic acinar cells is essential for 
regulated secretion of digestive enzymes.  
This study highlights the importance of having the right sterol in the right 
cellular membranes. The mutant phenotype can be rescued by culturing cells from 
these mice in normal LDL-containing serum (or by dietary supplementation in the live 
animal), which vindicates the requirements of cholesterol in cellular membranes in 
regulated membrane trafficking events. 
Although the lipoprotein measurements in the mouse models have not been 
reported in this study, HDL deficiency has been shown to be associated with SLOS in 
children (Behulova et al. 2000). In this study, serum lipoprotein levels were recorded 
in children suffering from SLOS, ranging from five days to seven years of age. Total 
cholesterol levels were certainly depressed in these children as compared to normal 
children but the authors note that the severest symptoms of SLOS were exhibited by 
children with significantly depressed levels of HDL and HDL-bound cholesterol 
(Behulova et al. 2000). Developmental abnormalities resulting from cholesterol 
deficiency in this syndrome usually mean that children are not able to attain adulthood. 
Heterozygous individuals show normal development owing to the presence of the 
normal DHCR7 allele. 
HYPERCHOLESTEROLEMIA AND SURGICAL AND CRITICALLY ILL 
PATIENTS 
In order to understand hypocholesterolemia, ‘normal’ levels of cholesterol have 
to be defined. From studies of primates as well as ‘primitive’ humans like tribals, the 
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optimal serum concentrations of total cholesterol was found to be 3.0 to 4.0 mmol/l. 
Plasma total cholesterol levels ranging from 2.6 to 3.5 mmol/l have been considered as 
low cholesterol levels in certain conditions (Vyroubal et al. 2008). However, these 
values show a large overlapping range. In another study, the plasma cholesterol 
concentration of patients undergoing hepatectomy was judged relative to their own 
total cholesterol estimations before and after surgery (Giovannini et al. 1999). This 
study shows that patients whose total plasma cholesterol levels were reduced to 55% of 
the pre-operative values were judged as hypocholesterolemic and tended to develop 
fatal health complications.  
In some papers, patients with cholesterol levels <150 mg/dl have been 
considered as being hypocholesterolemic (Miguez et al. 2010; Shor-Posner et al. 1993). 
Cholesterol levels may become a useful diagnostic tool in the prognosis of 
critically ill or surgical patients in the recovery period. Dunham and colleagues have 
demonstrated an association between the hypocholesterolemic state and likelihood of 
recovery in patients who have suffered severe injuries (Dunham et al. 2003). In their 
study of 28 patients maintained on ventilator support, reduction in plasma cholesterol 
levels was observed in the beginning of the convalescence period. Those patients for 
whom cholesterol levels rose to the normal population average were able to recover 
from the trauma and were at reduced risk for sepsis. In contrast, patients with 
persistent hypocholesterolemia tended to develop secondary infections as well as organ 
failure and metabolic dysfunction (Dunham et al. 2003). The association between 
development of sepsis and reduced levels of cholesterol is attributed to the fact that 
lipoprotein complexes are able to sequester bacterial lipopolysaccharides and prevent 
toxicemia. Reduced levels of serum lipoproteins are therefore a predisposition towards 
developing secondary bacterial infections.  
Although this study is limited by the number of patients included in the study 
as well as lack of differentiation between the kinds of lipoproteins (LDL or HDL) 
involved, it is nonetheless an eye-opener for critical care procedures. A study with 
animal models wherein sepsis had been induced by irradiation showed that HDL is 
persistently lowered (for up to 10 days in the recovery period) in individuals who 
developed sepsis following irradiation (Parra et al. 2007).  
Hypocholesterolemia has been shown to be associated with postoperative 
surgical complications as well. Leardi and colleagues have noted that following 
invasive abdominal surgery, patients whose total cholesterol levels fell below 105 mg/dl 
showed the highest incidence of sepsis (Leardi et al. 2000) in the recovery period. 
Likewise, an association between lowered cholesterol levels and increased incidence of 
sepsis and multiple organ failure has been reported by Giovannini et. al in a 
comparative study of 135 surgical patients (Giovannini et al. 1999).  
Taken together, these studies indicate that cholesterol homeostasis (balance) in 
circulation is important for recovery from accidents as well as planned interventions 
like surgery. Hence, hypocholesterolemia is a risk factor to be considered, perhaps, 
before opting for invasive surgical procedures. This fact is likely to be most relevant 
for people bearing known cholesterol metabolism disorders as well as for people 
undergoing statin-based therapy to reduce cholesterol levels.  
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CHOLESTEROL AND INFECTION 
Cholesterol-sequestering lipoproteins are also likely to play a protective role 
against infection in non-traumatized and non-surgical patients as well. The 
sequestration of bacterial lipopolysaccharides (LPS) by LDL to reduce the 
inflammatory response that is launched to counter LPS has been well characterized. 
Experiments conducted with knock-out mice that lacked the LDL-receptor gene 
showed total susceptibility towards septicemia and eventually died (Lanza-Jacoby et 
al. 2003). This research suggests that LDL bound to bacterial LPS may be 
endocytosed by cells bearing the LDL-receptor in order to inactivate this exotoxin.  
In humans, Staphylococcus aureus is a bacterium that not only colonizes and 
persists in the system in the form of biofilms but can also aggressively invade tissues 
leading to system-wide sepsis. In fact, resistance of Staphylococcus aureus to many 
antibiotics is a major health issue that results in nosocomial (resulting from a hospital 
stay) infections (reviewed in Falcone et al. 2009). In the colonized state, when the 
biofilm reaches a certain bacterial population size, an operon termed as agr is switched 
on, triggering an invasive infectious response. Peterson and others have shown that 
apolipoprotein B is a natural antagonist of the agr-mediated aggressive infection. ApoB 
binds to an auto-inducing cyclic thiolactone peptide (AIP) and prevents the binding of 
this protein to its receptor AgrC (Peterson et al. 2008). ApoB is also capable of 
sequestering other forms AIP2-4 and therefore confers protection against S. aureus 
infections.  It is therefore likely that extremely low levels of LDL-cholesterol may 
actually result in loss of protection from S. aureus infections. This is especially a risk 
factor for people bearing implants such as pacemakers since S. aureus biofilms are often 
associated with such implants.  
LDL is a defensive barrier against other bacterial toxins like the Vibrio vulnificus 
cytolysin (Park et al. 2005). LDL has been shown to bind and inactivate the endotoxin 
by causing oligomerization of the toxin. An important feature of this interaction is that 
this is a dose–dependent inactivation mechanism (Park et al. 2005). Therefore, in 
hypocholesterolemic conditions, the reduced availability of LDL is likely to enhance 
the cytotoxicity of bacterial toxins, a factor that may lead to rapid onset of sepsis. 
Typically, in trauma patients, when total serum cholesterol levels fall to 50% of the 
normal population average levels, the risk of sepsis as well as multiple organ failure is 
high (Vyroubal et al. 2008). These interdependencies highlight the fact that an 
‘optimal’ cholesterol balance is required and low levels of cholesterol are just as 
detrimental to health as elevated levels of cholesterol.  
CHOLESTEROL IN MENTAL HEALTH 
Cholesterol, being a membrane component, plays significant roles in neural 
functions as well. In fact, cholesterol is a major component of the myelin sheath that 
covers axons of brain neurons (reviewed in Fantini and Barrantes 2009) and is 
thought to modulate neurotransmitter release and binding to neurotransmitter 
receptors and therefore downstream events. A major neurotransmitter, serotonin, is 
important for the emotional well-being of humans and serotonin deficiencies are 
responsible for depression as well as aggression and suicide.  
An association between serum cholesterol levels and serotonin has been 
established in several studies. People whose serum cholesterol levels are low also tend 
to have lower levels of serotonin in circulation (Steegmans et al. 1996). In a recent 
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study, it was seen that low serum cholesterol correlated with serotonin turnover in 
men. No such conclusive relationship could be demonstrated for women (Markianos et 
al. 2010). These scientists have postulated that lowered serotonin levels could be 
responsible for aggressive and violent behavior in men as a response to the 
evolutionary need to hunt and acquire food.  
In a retrospective analysis of familial and personal suicide attempts, Bocchetta 
and colleagues have proposed a link between low cholesterol and suicidal behavior. A 
total of 783 patients who were undergoing lithium treatment were analyzed for 
reported personal or familial (first-order relative) suicide attempts. Based on one-time 
cholesterol measurements, the researchers found that lower levels of serum cholesterol 
in men were associated with attempted or completed suicide (Bocchetta et al. 2001), 
suggesting a neuromodulatory role for cholesterol. 
In another study with panic disorder patients, the serum cholesterol levels in 
patients who attempted suicide were found to be lower than panic disorder patients 
who had not attempted suicide as well as normal control subjects. The mean total 
cholesterol levels as well as LDL levels were lower in panic disorder patients who had 
attempted suicide (Ozer et al. 2004). The study is hampered by limited sample size as 
well as a large age range of subjects. Extensive analyses will be required to further 
understand the association between low cholesterol and suicidal behavior. 
In a study of 42 people who attempted suicide, a positive correlation was found 
between low serum cholesterol and low 5-hydroxyindoleacetic acid (5-HIAA) in the 
cerebrospinal fluid (Asellus et al. 2010). These patients were not under the influence of 
any other drug or therapy and had attempted suicide. The link between low serum 
cholesterol and depressed serotonergic responses has been suggested to explain these 
results. Although the cohort size was small with 42 individuals included, it is logically 
and practically difficult to add to these numbers of people who attempted suicide but 
missed the bus. Nonetheless, the work does show a correlation between low serum 
cholesterol and attenuated serotonergic response systems, which, perhaps is 
responsible for reckless suicidal behavior.  
At the cellular level, a drastic reduction in the level of cholesterol is likely to 
affect the physiology of serotonin receptors (Paila et al. 2008). Paila and colleagues 
have used an inhibitor AY9944 in Chinese Hamster ovary fibroblast (CHO) cells to 
create a cellular model of the Smith-Lemli-Opitz syndrome. AY9944 inhibits the 
terminal step in the synthesis of cholesterol. In this model, signaling via the serotonin 
1A (5-HT1A) receptor was found to be reduced (Paila et al. 2008). The attenuation of 
signaling via this receptor was not explained by reduction in receptor expression or 
delivery to the plasma membrane. However, signaling via plasma membrane-resident 
5-HT1A was reduced in the absence of cholesterol. Although these cells have 
abundant 7-dehydrocholesterol and 8-dehydrocholesterol, these sterols were not able 
to interact with 5-HT1A in the same manner as cholesterol and facilitate signaling via 
receptor-associated G-proteins (Paila et al. 2008). The overall membrane organization 
as measured by the fluidity of a non-specific fluorescent probe was unaffected in 
normal as well as SLOS cells used in this study. These results argue for a role of 
cholesterol in modulating serotonin signaling, albeit in a cell system that is non-
neuronal.  
In hippocampal tissue, oxidation of cholesterol reduced the binding of agonist 
as well as antagonist ligands to 5-HT1A receptor (Pucadyil et al. 2005). These results 
34 Menachem Nagar  
 
indicate a physical interaction between cholesterol in the plane of the membrane and 
the neurotransmitter receptor. Taken together, these results suggest a mechanism for 
impairment of serotonin receptor dysfunction in situations of low cholesterol 
availability. Attenuated serotonin metabolism is a hallmark of depression and reduced 
availability of cholesterol may be a contributory factor.  
Cholesterol deficiencies are likely to manifest as changes in behavioral patterns 
as well. In a one-year follow-up of patients with unipolar or bipolar disorder, a positive 
correlation between low serum cholesterol and recurrence of manic episodes was noted 
(Fiedorowicz et al. 2010). The patients were assessed for serum cholesterol along with 
other parameters, as well as development of psychotic episodes. Patients with unipolar 
disorder were not affected but those with bipolar disorder experienced manic episodes 
in the year of follow-up. Depression was not seen in both kinds of patients. Although 
the difference in mean cholesterol levels of both groups of patients was slim, the 
persistent deficiency of cholesterol is likely to be influential in neurological responses 
and behavior. In this study, the prevalence of different fractions of cholesterol 
throughout the follow-up period was not monitored and perhaps better assessment of 
the cholesterol status of the patient at the time of occurrence of psychotic / manic 
events will shed more light on the role of cholesterol (Fiedorowicz et al. 2010). It 
would be interesting to know whether a sudden and transient reduction in serum 
cholesterol levels is a trigger or indicator of manic behavior. Since depressive 
symptoms were not associated with hypocholesterolemia, the study points to other 
neuromodulatory roles of cholesterol which remain to be investigated. 
Dietary intake of cholesterol was shown to reduce dissociative behavior and 
aggression in a primate study (Kaplan et al. 1994). Cynomolgus monkeys were fed 
high-fat diets that were specifically low or high in cholesterol. Monkeys who received a 
low cholesterol diet showed aggressive behavior and tended to be socially alienated. 
Serum cholesterol levels may play an important role in addiction as well as de-
addiction from cocaine. In a study of thirty-eight cocaine abusers in hospital-based 
rehabilitation, it was seen that serum HDL levels were depressed in these patients, 
even in the recovery phase. Serum LDL, HDL cholesterol as well as neuroendocrine 
responses were assessed two weeks after discontinuation of cocaine abuse. Serum 
HDL cholesterol was reduced in all patients. The reduction in HDL also correlated 
with greater experience of a ‘high’ feeling and euphoria when the same patients were 
challenged with m-chlorophenylpiperazine (m-CPP). These responses are known to be 
attributed to altered serotonergic neuronal transmission. In agreement with prior 
studies, reduced HDL cholesterol was also seen in patients who had prior episodes of 
aggression (Buydens-Branchey et al. 2000).  
The co-incidence of low serum cholesterol and occurrence of mixed manic 
episodes has also been reported by Cassidy and Carroll (2002). In a study of 174 
subjects, patients suffering from bipolar disorder and mixed manic episodes were 
observed to have serum total cholesterol levels well below the reported national 
average values. Cholesterol levels were also lower in patients who suffered from pure 
manic disorders but a pronounced difference in levels of cholesterol was seen in 
patients who suffered from bipolar disorder. Although it is unclear from this study 
whether low cholesterol is the trigger for mixed manic episodes or whether the manic 
episode results in lowered cholesterol levels, the study suggests a link between these 
two health parameters (Cassidy and Carroll 2002). 
 Health Risks of Very Low Cholesterol 35 
 
Low levels of serum cholesterol have been seen in patients in whom 
Alzheimer’s disease (AD) has been diagnosed. In a study with 138 patients with a 
confirmed diagnosis of Alzheimer’s disease, serum cholesterol levels were found to be 
lower than normal people of similar average age. Within the AD cohort, the decrease 
in cholesterol levels correlated with increasing levels of dementia (Tully et al. 2003). 
Kim and colleagues, in a South Korean study of 291 individuals from a community as 
well as 79 AD patients, reported that people with AD showed lower levels of serum 
cholesterol. However, these researchers found no association between progressive 
dementia and reduction in level of serum cholesterol (Kim et al. 2002). The authors 
suggest that presence of lower serum cholesterol in AD patients may be a marker of 
the impaired cognitive state rather than a causative agent.  
The molecular mechanisms that result in lowered serum cholesterol, however, 
appear to be different than just simple reduction in the synthesis of cholesterol 
resulting from aging. This is indicated by studies which show that treatment with statin 
drugs (HMGCoA reductase inhibitors) actually reduces the production of the amyloid 
peptide (deposition of this peptide in plaques on neurons is the primary cause of 
pathology in AD) and may actually show a neuroprotective therapeutic effect 
(Buxbaum et al. 2002; Friedhoff et al. 2001). Since a deliberate reduction in the total 
synthesis of cholesterol is not likely to be the triggering factor for the development of 
AD, there must be other transport related phenomena associated with cholesterol 
metabolism and its delivery to neurons.  
CHOLESTEROL AND AIDS 
Hypocholesterolemia has been noted in patients seropositive for human 
immunodeficiency virus (HIV). In a study of 94 patients, serum cholesterol and 
triglyceride levels were assessed along with other parameters in patients who were 
seropositive and seronegative for HIV (Shor-Posner et al. 1993). Shor-Posner and 
colleagues found that patients with low total cholesterol (below 150 mg/dl) were 
seropositive (indicating greater viral load and active virus multiplication in the system) 
as compared to patients with higher total cholesterol levels who were seronegative, 
though they were infected with HIV (Shor-Posner et al. 1993). Cholesterol may 
therefore be required as part of an antiviral mechanism that might possibly slow down 
virus progression, if not prevent infection.  
In a recent study with HIV-positive patients, Miguez and colleagues have 
reported a startling connection between cholesterol levels and HIV virulence (Miguez 
et al. 2010). These researchers compared the cholesterol levels of 165 HIV-positive 
people at the beginning of highly active antiretroviral therapy (HAART) and after 24 
weeks. Patients were classified as hypocholesterolemic if their total serum cholesterol 
levels were below 150 mg/dl. These patients showed detectable viral loads as compared 
to patients who had higher levels of serum cholesterol. The CD4+ cell counts in the 
hypocholesterolemic patients were lower than those with higher cholesterol levels 
implying that the immune response was modulated by hypocholesterolemia. The viral 
load in hypocholesterolemic patients was seen despite HAART, indicating that 
cholesterol may be included as a therapeutic molecule in such patients. Thymic output 
was reduced in patients with low cholesterol levels resulting in very low (<200) CD4+-
cell counts in these patients. 
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CONCLUSION 
Cholesterol is an important molecule in human physiology and plays an 
important role in all processes wherein cellular membrane composition and topography 
are crucial. Cholesterol is both synthesized in the human body and is acquired from 
food sources. Excess intake of dietary cholesterol resulting in excessive accumulation 
of LDL-cholesterol in the vascular system has been identified as the causative factor 
for cardiovascular disease (Daniels et al. 2009; Ferrieres 2009), leading to the 
perception that keeping cholesterol levels low has to be a priority in health and 
wellness management. However, exceedingly low levels of cholesterol also have other 
detrimental effects on human physiology. Cholesterol is an important modulator of 
neurotransmitter receptors like serotonin, which are involved in maintaining a healthy 
neurophysiological state (Paila et al. 2008; Pucadyil et al. 2005). Cholesterol in the 
form of lipoproteins also helps to fight bacterial infections by neutralizing bacterial 
toxins and LPS, a function that may be severely compromised in hypocholesterolemic 
patients suffering from sepsis (Wilson et al. 2003).  
Cholesterol is certainly involved in the etiology of cardiovascular disease. LDL-
bound cholesterol is capable of acting as the seed molecule for the formation of 
atherogenic plaques and can be a significant health hazard, moderate to extreme 
reductions in the levels of total serum cholesterol also represent health hazards.  
Mechanisms that result in reduction of total serum cholesterol also seem to 
have a bearing on the health outcomes. For example patients suffering from SLOS, 
although lacking in inherent cholesterol synthesis, do not always suffer from 
depression resulting from serotonergic neuronal dysfunction. Many physiological 
deficiencies of the SLOS defect can be overcome with dietary intake of cholesterol. 
However, in other situations like sepsis and critical injury or surgical trauma, 
cholesterol synthesis alone may not bring up the serum cholesterol to optimal levels in 
some patients (Vyroubal et al. 2008; Wilson et al. 2003).  
Cholesterol is perhaps a unique membrane component that is involved in 
possibly every membrane turnover event such as exocyotosis and secretion (Gondre-
Lewis et al. 2006), neurotransmitter modulation (Paila et al. 2008; Pucadyil et al. 2005) 
and endocytosis (Sabharanjak and Mayor 2004; Sabharanjak et al. 2002), viral 
metabolism and cardiovascular health (Miguez et al. 2010).  
Research suggests that management of ‘optimal’ cholesterol levels should be the 
choice to make rather than aiming for very low levels of cholesterol in circulation. 
REFERENCES 
Arsenault BJ, Lemieux I, Despres JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJP, Khaw KT, 
Boekholdt SM. 2009. HDL particle size and the risk of coronary heart disease in apparently 
healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 
206(1):276-281. 
Asellus P, Nordstrom P, Jokinen J. 2010. Cholesterol and CSF 5-HIAA in attempted suicide. J Affect 
Disord 125(1-3):388-392. 
Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. 2001. 
Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. 
Atherosclerosis 156(1):217-225. 
Behulova D, Bzduch V, Skodova J, Dello Russo A, Corso G, Ponec J, Kasanicka A. 2000. Serum lipids 
and apolipoproteins in children with the Smith-Lemli-Opitz syndrome. J Inherit Metab Dis 
23(4):413-415. 
 Health Risks of Very Low Cholesterol 37 
 
Bocchetta A, Chillotti C, Carboni G, Oi A, Ponti M, Del Zompo M. 2001. Association of personal and 
familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta 
Psychiatr Scand 104(1):37-41. 
Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman M. 2000. 
Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and 
correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res 
41(7):1125-1135. 
Buxbaum JD, Cullen EI, Friedhoff LT. 2002. Pharmacological concentrations of the HMG-CoA 
reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in 
vitro and in patients. Front Biosci 7:a50-59. 
Buydens-Branchey L, Branchey M, Hudson J, Fergeson P. 2000. Low HDL cholesterol, aggression 
and altered central serotonergic activity. Psychiatry Res 93(2):93-102. 
Cassidy F, Carroll BJ. 2002. Hypocholesterolemia during mixed manic episodes. Eur Arch Psychiatry 
Clin Neurosci 252(3):110-114. 
Daniels TF, Killinger KM, Michal JJ, Wright RW Jr., Jiang Z. 2009. Lipoproteins, cholesterol 
homeostasis and cardiac health. Int J Biol Sci 5(5):474-488. 
Dunham CM, Fealk MH, Sever WE 3rd. 2003. Following severe injury, hypocholesterolemia improves 
with convalescence but persists with organ failure or onset of infection. Crit Care 7(6):R145-
153. 
Falcone M, Serra P, Venditti M. 2009. Serious infections due to methicillin-resistant Staphylococcus 
aureus: an evolving challenge for physicians. Eur J Intern Med 20(4):343-347. 
Fantini J, Barrantes FJ 2009. Sphingolipid/cholesterol regulation of neurotransmitter receptor 
conformation and function. Biochim Biophys Acta 1788(11):2345-2361. 
Ferrieres J. 2009. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol 
with statins. Am J Cardiovasc Drugs 9(2):109-115. 
Fiedorowicz JG, Palagummi NM, Behrendtsen O, Coryell WH. 2010. Cholesterol and affective 
morbidity. Psychiatry Res 175(1-2):78-81. 
Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. 2001. Treatment with controlled-release 
lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J 
Neuropsychopharmacol 4(2):127-130. 
Giovannini I, Boldrini G, Chiarla C, Giuliante F, Vellone M, Nuzzo G. 1999. Pathophysiologic 
correlates of hypocholesterolemia in critically ill surgical patients. Intensive Care Med 
25(7):748-751. 
Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. 2009. Long-term benefit of high-
density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of 
the bezafibrate infarction prevention trial. Arch Intern Med 169(5):508-514. 
Gondre-Lewis MC, Petrache HI, Wassif CA, Harries D, Parsegian A, Porter FD, Peng Loh Y. 2006. 
Abnormal sterols in cholesterol-deficiency diseases cause secretory granule malformation and 
decreased membrane curvature. J Cell Sci 119(Pt 9):1876-1885. 
Goti D, Reicher H, Malle E, Kostner GM, Panzenboeck U, Sattler W. 1998. High-density lipoprotein 
(HDL3)-associated alpha-tocopherol is taken up by HepG2 cells via the selective uptake 
pathway and resecreted with endogenously synthesized apo-lipoprotein B-rich lipoprotein 
particles. Biochem J 332(Pt 1):57-65. 
Kaplan JR, Shively CA, Fontenot MB, Morgan TM, Howell SM, Manuck SB, Muldoon MF, Mann 
JJ. 1994. Demonstration of an association among dietary cholesterol, central serotonergic 
activity, and social behavior in monkeys. Psychosom Med 56(6):479-484. 
Kim JM, Stewart R, Shin IS, Yoon JS. 2002. Low cholesterol, cognitive function and Alzheimer s 
disease in a community population with cognitive impairment. J Nutr Health Aging 6(5):320-
323. 
Lanza-Jacoby S, Miller S, Jacob S, Heumann D, Minchenko AG, Flynn JT. 2003. 
Hyperlipoproteinemic low-density lipoprotein receptor-deficient mice are more susceptible to 
sepsis than corresponding wild-type mice. J Endotoxin Res 9(6):341-347. 
Leardi S, Altilia F, Delmonaco S, Cianca G, Pietroletti R, Simi M. 2000. [Blood levels of cholesterol and 
postoperative septic complications]. Ann Ital Chir 71(2):233-237. 
Lehmann B, Knuschke P, Meurer M. 2000. A novel pathway for hormonally active calcitriol. Horm Res 
54(5-6):312-315. 
38 Menachem Nagar  
 
Markianos M, Koutsis G, Evangelopoulos ME, Sfagos C. 2010. Serum total cholesterol correlates 
positively to central serotonergic turnover in male but not in female subjects. Prog 
Neuropsychopharmacol Biol Psychiatry 34(3):527-531. 
Miguez MJ, Lewis JE, Bryant VE, Rosenberg R, Burbano X, Fishman J, Asthana D, Duan R, 
Madhavan N, Malow R. 2010. Low cholesterol? Don't brag yet ... hypocholesterolemia blunts 
HAART effectiveness: a longitudinal study. J Int AIDS Soc 13:25. 
Nettleship JE, Jones RD, Channer KS, Jones TH. 2009. Testosterone and coronary artery disease. 
Front Horm Res 37:91-107. 
Ozer OA, Kutanis R, Agargun MY, Besiroglu L, Bal AC, Selvi Y, Kara H. 2004. Serum lipid levels, 
suicidality, and panic disorder. Compr Psychiatry 45(2):95-98. 
Paila YD, Murty MR, Vairamani M, Chattopadhyay A. 2008. Signaling by the human serotonin(1A) 
receptor is impaired in cellular model of Smith-Lemli-Opitz Syndrome. Biochim Biophys Acta 
1778(6):1508-1516. 
Park KH, Yang HB, Kim HG, Lee YR, Hur H, Kim JS, Koo BS, Han MK, Kim JH, Jeong YJ, Kim 
JS. 2005. Low density lipoprotein inactivates Vibrio vulnificus cytolysin through the 
oligomerization of toxin monomer. Med Microbiol Immunol 194(3):137-141. 
Parra NC, Ege CA, Ledney GD. 2007. Retrospective analyses of serum lipids and lipoproteins and 
severity of disease in 60Co-irradiated Sus scrofa domestica and Macaca mulatta. Comp Med 
57(3):298-304. 
Payne AH, Hales DB. 2004. Overview of steroidogenic enzymes in the pathway from cholesterol to 
active steroid hormones. Endocr Rev 25(6):947-970. 
Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, Sully EK, Sawires S, Cheung A, Otto M, 
Gresham H. 2008. Apolipoprotein B Is an innate barrier against invasive Staphylococcus 
aureus infection. Cell Host Microbe 4(6):555-566. 
Podrez EA. 2010. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp 
Pharmacol Physiol 37(7):719-725. 
Pucadyil TJ, Shrivastava S, Chattopadhyay A. 2005. Membrane cholesterol oxidation inhibits ligand 
binding function of hippocampal serotonin(1A) receptors. Biochem Biophys Res Commun 
331(2):422-427. 
Sabharanjak S, Mayor S. 2004. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 
56(8):1099-1109. 
Sabharanjak S, Sharma P, Parton RG, Mayor S. 2002. GPI-anchored proteins are delivered to 
recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. 
Dev Cell 2(4):411-423. 
Schaefer EJ, Santos RD, Asztalos BF. 2010. Marked HDL deficiency and premature coronary heart 
disease. Curr Opin Lipidol 21(4):289-297. 
Sharma P, Sabharanjak S, Mayor S. 2002. Endocytosis of lipid rafts: an identity crisis. Semin Cell Dev 
Biol 13(3):205-214. 
Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G, Rao M, Mayor S. 2004. Nanoscale 
organization of multiple GPI-anchored proteins in living cell membranes. Cell 116(4):577-589. 
Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E, Baum M. 1993. 
Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency 
virus-1 infection. Am J Med 94(5):515-519. 
Steegmans PH, Fekkes D, Hoes AW, Bak AA, van der Does E, Grobbee DE. 1996. Low serum 
cholesterol concentration and serotonin metabolism in men. Bmj 312(7025):221. 
Stein EA. 2009. Other therapies for reducing low-density lipoprotein cholesterol: medications in 
development. Endocrinol Metab Clin North Am 38(1):99-119. 
Terasaka N, Wang N, Yvan-Charvet L, Tall AR. 2007. High-density lipoprotein protects macrophages 
from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-
ketocholesterol via ABCG1. Proc Natl Acad Sci U S A 104(38):15093-15098. 
Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. 2003. Low 
serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control 
study. Br J Nutr 89(4):483-489. 
Vyroubal P, Chiarla C, Giovannini I, Hyspler R, Ticha A, Hrnciarikova D, Zadak Z. 2008. 
Hypocholesterolemia in clinically serious conditions--review. Biomed Pap Med Fac Univ 
Palacky Olomouc Czech Repub 152(2):181-189. 
 Health Risks of Very Low Cholesterol 39 
 
Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, Salonen R, 
Tuomainen T, Ehnholm C, Jauhiainen M, Taskinen M. 2006. Decreased high-density 
lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish 
low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 
26(4):897-902. 
Wilson RF, Barletta JF, Tyburski JG. 2003. Hypocholesterolemia in sepsis and critically ill or injured 
patients. Crit Care 7(6):413-414. 
40 Jason Yeshaya Friedman  
Jason Yeshaya Friedman, B.S. ’11, majored in Biology.  He will be 
attending UMDNJ Dental School in Fall 2012.  
THE ROLE OF STREPTOCOCCUS MUTANS IN THE 
FORMATION OF DENTAL CARIES: AN ECOLOGICAL 
PERSPECTIVE 
Jason Yeshaya Friedman 
ABSTRACT 
The teeth are among the most distinctive and productive features of the human species. It is 
the longest lasting surface of the body and can be used in research studies many years after death. Yet, 
in the living individual, the integrity of the teeth is constantly assaulted by a microbial challenge so 
great that dental caries, or decay, ranks as one of the most widespread medical afflictions. According 
to studies, dental caries rank third in medical costs, behind only heart disease and cancer (Loesche 
1996). This review will attempt to describe what is responsible for dental caries, namely a bacterium 
called Streptococcus mutans. More specifically, it will concentrate on theories regarding the precise role 
of S. mutans and what causes it to flourish at times when bacteria associated with a healthy oral cavity 
cannot survive. It will further explain how after performing Pure Culture and Mixed Culture studies, 
the results clearly provided a theory referred to as the “ecological plaque hypothesis.”  In this theory, it 
became clear that it was not the mere presence of S. mutans that caused dental caries, but rather it was 
specific environmental factors that allowed S. mutans to thrive while rendering the non-pathogenic 
bacterium insignificant. Based on these updated theories, scientists have been able to find preventative 
methods to inhibit S. mutans even in the environment that normally favors its growth. 
INTRODUCTION 
Although the oral cavities of most mammalian species contain billions of microbial 
cells, most scientists have concluded that Streptococcus mutans is the bacterium that is 
responsible for dental caries, or decay. Over the years, scientists have been researching the 
precise role of S. mutans and what causes it to flourish at times when non-pathogenic bacteria 
cannot survive. It is this precise question that this review will attempt to answer. Specifically, 
it will concentrate on the ecology of the oral cavity and will attempt to prove, via various 
studies, a theory called the “ecological plaque hypothesis.” This theory will appropriately 
explain the role of S. mutans and will open the door for successful prevention mechanisms.  
DISCUSSION 
A healthy human being has an estimated total of 100 trillion living cells (Savage 1977). 
However, 90% of these cells are merely micro-organisms that live in areas such as the 
intestinal tract, skin, and mouth. In fact, each specific habitat has a particular composition of 
micro-organisms which, in a healthy individual, remains stable once it’s established. This is 
called microbial homeostasis. The stability of the microbial community in each distinct habitat 
is due to key ecological factors that are present. These factors include nutrients, pH levels, 
attachment receptors, and oxygen levels (Marsh 2001). Changes in the environment can 
severely alter the homeostatic balance necessary to sustain the microbial species, and this can 
result in disease. 
From all the areas which contain these massive numbers of microbial cells, the oral 
cavity alone contains almost half of these microorganisms, amounting to about six billion 
microbial organisms (Loesche 1996). There are many properties of the oral cavity that make it 
an ideal habitat for microbial species. One such feature is the continuous flow of saliva. Saliva 
greatly enhances the ecology of the oral cavity. The pH of saliva (about 6.95) is ideal for 
micro-organism growth and its ionic composition provides buffering and reparation of the 
enamel (Scannapieco 1994). In addition, saliva keeps the mouth warm (around 35oC) and 
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moist. Yet, perhaps the most beneficial feature of the saliva in the mouth is its ability to 
promote the adhesion of microbial species by coating surfaces of the oral cavity with a 
selective conditioning film. 
Although all surfaces in the oral cavity benefit from saliva and serve as habitats for 
various microbial species, there is one surface in the mouth that has certain features which 
render it the supreme resting place for the oral microorganisms. This surface is the tooth 
(Figure 1). The teeth are oral surfaces that have a unique feature which is not seen in any 
other surface in the body. The tooth surface rarely sheds once it is formed (Bowden 2000). 
This property facilitates microbial growth, because once biofilm is formed on the tooth, it will 
not be removed as a result of shedding of the tooth surface.  
 
The non-shedding character of the tooth makes its biofilm covering more important 
when studying microbial species. The extensive formation of biofilm on the teeth is called 
dental plaque. In healthy dental plaque formation, there is a sequence of events of microbial 
succession that allow its formation (Busscher and Van der Mei 2000). The first step occurs 
shortly after the teeth erupt. As mentioned, the host’s saliva, along with some bacteria, coats 
the enamel surface with film. The first round of microbial species adheres to the film, using 
nonspecific interactions between charged molecules. These organisms grow and create a 
suitable environment for the colonization of more complex species. The new wave of species 
adheres to the already attached organisms. This process results in the dental plaque becoming 
a complex and multi-species biofilm. 
Over the years, there have been numerous studies done on the composition of this 
dental plaque in order to determine which species cause it to decay and facilitate formations of 
dental caries. Although old hypotheses have been modified and study techniques enhanced, 
close to all researchers would agree the main species responsible is a bacteria called 
Streptococcus mutans (Figure 2).  
Figure 1: The structure of the tooth. 
Source: David Zieve, MD, MHA, Medical Director, A.D.A.M., November 12, 
2010 Inc 
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The real question is not whether S. mutans is responsible for disease. It clearly is. 
Rather, researchers have been studying the exact role of S. mutans in dental caries. The 
questions scientists have been studying are about the specific triggers that allow S. mutans to 
grow and how to successfully prevent it from doing harm.   
The first hypothesis in regards to the role of S.mutans was known as the “specific 
plaque hypothesis.”  In this conclusion, it was believed that although there is a vastly diverse 
collection of microbial species present in the plaque, S. mutans causes the disease and caries 
(Emilson and Krasse 1985). It does so by rapidly metabolizing sugar into acid. This process 
creates an environment with a particularly low pH. Under these conditions, S. mutans can 
continue to grow and eventually wear down the enamel.   
However, the “specific plaque hypothesis” did not succeed in painting the full picture. 
The questions of what triggered S. mutans to grow and what allowed it to flourish when 
bacteria associated with healthy enamel could not do so were still unclear. Further study and 
research upon the habitats and the different factors that alter the microbial homeostasis led to 
the formation of an alternative hypothesis which better explains the role of S. mutans in dental 
caries and disease. 
One such study is called Pure Culture Study. This study compares selected healthy 
and diseased stains in a controlled environment. This method provides accurate details on 
how environment affects the microbial species by independently varying different 
environmental cues and observing the microbial response. Early Pure Culture studies 
compared the response of S. mutans, the bacteria implicated in disease, and the bacteria of 
healthy enamel, by introducing them to different sugar and pH environments. The 
conclusions of these experiments showed that S. mutans had the ability to survive and flourish 
over a wider range of pH and was in fact at its optimal growth at acidic pH (about 5). In 
addition, S. mutans had a higher rate of sugar uptake and underwent glycolysis more rapidly. 
As mentioned, these studies clarified the role of S. mutans in dental caries and disease 
beyond the “specific plaque hypothesis”. It confirmed the role of S. mutans in disease, but 
Figure 2: Streptococcus mutans. 
Source: Encyclopedia Britannica Online. Web. 25 May, 2011. 
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expanded the theory by explaining how ecological changes are the key to allow the S. mutans 
to flourish as opposed to the bacteria associated with healthy enamel. It showed how 
differences seen in the composition of plaque are driven by the microbial species’ response to 
environmental changes, resulting in the ability of previously minor components of the 
microflora to flourish. 
To test this hypothesis, and to further explore the impact of environmental changes on 
the balance of the plaque microbial community, it was necessary to develop a more intricate 
study. This led scientists to begin a Mixed Cultures Study. In the Mixed Culture Study, 
researchers exploited the unique advantages of a chemostat to grow mixed cultures of oral 
bacteria in a range of controlled conditions (Marsh et al. 2006). Due to the fact that a 
chemostat allows individual parameters to be changed independently, a clear presentation is 
provided on how specific environmental conditions affect the physiology of the culture. 
The reactions to two main environmental conditions were studied in the Mixed 
Culture experiment. Researchers wanted to see how oral bacteria associated with healthy 
enamel would react differently to S. mutans when presented with large doses of sugar and an 
environment with low pH. To best study the oral bacteria within these parameters, a 
chemostat was developed with a system for growing nine oral bacteria at constant 
temperature (37°C) and pH (7.0). The mixed culture was pulsed with glucose on ten 
consecutive days, either with or without pH control (Table 1) (Bradshaw et al. 1989). 
 
  
To understand the table let us simply focus on the first three species. The first two 
bacteria, S. gordonii and S. oralis are bacteria associated with a healthy oral cavity. The third 
strain, the S. mutans, is associated with disease. We see in the first column, that before any 
glucose was pulsed, the non-pathogenic bacteria dominated over the S. mutans. This 
represents a healthy oral cavity. In the second column glucose is pulsed, yet there is pH 
Source: Bradshaw et al. 1989 
 
Table 1: Effects of glucose pulses, low pH, and fluoride on the stability of a mixed 
culture of nine oral bacteria.   
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control. We see that the non-pathogenic bacteria still remain dominant. This proved that 
sugar-uptake alone is not the real source for dental decay. In the third column, glucose is 
again pulsed, but now there is no pH control. We see in this case that S. mutans greatly 
increase in number due to decrease in pH. It was concluded that it was the low pH and not 
the availability of the carbohydrates itself that was selecting for the unfavorable disease 
causing bacteria.  
The fourth column shows the effect of NaF on oral bacteria. We see that when fluoride 
is added the pathogenic bacteria are destroyed even under conditions of low pH. This will be 
discussed later. 
This experiment was repeated to find out if there was a “critical pH” in which 
homeostasis of the oral cavity broke down. To do this, the mixed culture was again pulsed 
with glucose in three repeating experiments. However, this time the pH was controlled to fall 
at values at around pH 5.0. Results showed that the microbial community was irreversibly 
disrupted only when the pH fell below 5.0. The results showed that when the pH was lower 
than 5.0, the S. mutans dominated.  
Based on the Pure Culture and Mixed Culture studies, the “specific plaque hypothesis” 
was clearly not the most accurate assessment of the cause of dental caries. It is not the mere 
existence of S. mutans that causes dental caries and disease. Rather the most accurate 
hypothesis, based on the above mixed culture studies, became known as the “ecological plaque 
hypothesis” (Takahashi and Nyvad 2008). This hypothesis suggests that key changes in 
environmental conditions trigger shifts in the balance of resident plaque microflora. It is these 
environmental conditions that allow the sites to become predisposed to disease. It is at this 
time that the S. mutans, which has the ability to survive in these adverse conditions which 
altered the resident microflora (i.e. low pH), contributes to dental caries and disease. 
In other words, the ecological plaque hypothesis can be explained as follows. The 
mouth of a healthy individual always contains some amount of S. mutans. However, under 
normal healthy environmental conditions, there are many more healthy bacteria which can 
survive, rendering the S. mutans as a small percentage, weakly competitive, and clinically 
insignificant.  
Yet, if a person would do something to alter the environment, pathogenic bacteria can 
become more competitive. For example, if an individual would increase the intake frequency 
of fermentable sugars, the plaque environment would become much more acidic (lower pH). 
This low pH environment favors the growth of S. mutans, as shown in the above mixed culture 
experiment. At this time, the S. mutans is strongly competitive now that it can render the 
bacteria associated with healthy enamel as insignificant. This causes the dental caries and 
disease. 
An important aspect of the ecological plaque hypothesis is the idea that disease can be 
prevented in ways that do not directly inhibit pathogenic bacteria. Prevention strategies can 
be formed that serve to interfere with the underlying environmental factors that enabled the 
growth of the pathogenic bacteria in the first place. By finding ways to maintain ecological 
stability in the oral cavity, we can prevent S. mutans from ever attaining the strength necessary 
to cause harm. 
As mentioned, it is the highly acidic (low pH) environment which is favorable to S. 
mutans. Thus, mechanisms that can combat the S. mutans viability by also competing in these 
acidic environments can serve as a beneficial source of prevention (Marsh 2001). Thus, the 
most common strategy to prevent disease via the ecological plaque hypothesis is the ability to 
decrease the growth of S. mutans even in highly acidic enamel. Studies have showed that 
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fluoride has such capabilities. Fluoride has the capability to stabilize the environment of the 
enamel and plaque even during times of low pH, rendering the S.mutans ineffective. Thus, 
Fluoride Therapy became the main prevention strategy that is based on the ecological plaque 
hypothesis. 
Based on a similar experiment to the Mixed Culture Study mentioned above, 
researchers have determined that fluoride can serve to be inhibitory toward pathogenic 
bacteria even in environments without pH control (i.e. low pH). To test this theory 1 mmol/L 
of sodium fluoride was pulsed along with glucose into a mixed culture of three oral bacteria 
(Table 2).  
 
Table 2: 
Effects of fluoride on the stability of a mixed culture of three oral bacteria with 10 glucose pulses on 10 
consecutive days with 28 mmol/L glucose and without pH control (percentage viable count) 
 
Bacterium Pre-Pulsing  
without Sodium Fluoride 
After Pulsing  
without Sodium Fluoride
  
After Pulsing  
with Sodium Fluoride 
S. gordonii 28.3 0.2 .002 
S. oralis 15.2 1.3 4.6 
S. mutans 0.3 18.9 0.2 
Source: Bradshaw et al. 1989 
 
The results clearly show the ability of fluoride to inhibit the competitive capabilities of 
S. mutans. In the first column, at pre-pulsing we see the environment of healthy enamel. The 
two bacteria associated with health (S. gordonii and S. oralis) are at much higher concentration 
than S. mutans. In the second column, we see the S. mutans become more competitive due to 
the glucose pulsing and lack of pH control. This is the pathogenic environment seen in the 
earlier Mixed Culture Experiment. The third column represents the presence of fluoride in 
the acidic environment. As soon as fluoride is introduced, the S. mutans is seen to be inhibited, 
thus restoring the enamel culture to health (Aioba and Fejerskov 2002). Clearly, the great 
strides researchers have taken in defining the specific reason for dental caries, via the 
ecological plaque hypothesis, have allowed scientists to form prevention strategies based on 
these very principles. 
CONCLUSION 
In conclusion, it is evident from the research presented that ecological factors in the 
oral cavity play a large role in the effectiveness of S. mutans to cause dental caries. According 
to the ecological plaque hypothesis, S. mutans is always present. However, it is a specific 
environmental cue, such as low pH, which allows the S.mutans to become more competitive 
and outlive the bacteria associated with healthy enamel. Armed with this knowledge, scientists 
were able to realize fluoride’s capability to prevent dental caries by interacting and inhibiting 
S. mutans even in adverse ecological conditions. 
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THE EFFECT OF MELATONIN ON THE OVARIES 
Jaclyn Starr 
ABSTRACT 
Melatonin is a very small molecule whose effects can be both detrimental and beneficial to the 
ovaries depending on its concentration.  Too much of anything is usually not good and so is the case 
with melatonin.  Very high doses can be damaging, but in the right amount melatonin may be able to 
combat various diseases and increase the chances for fertility in women. 
THE PRODUCTION OF MELATONIN 
Melatonin is an indoleamine which is produced in the pineal gland. It was first isolated 
from bovine pineal gland in 1958 and is currently classified as a hormone. This seemingly 
ambiguous hormone is found in many places in the human body and has many functions.  As 
more research is done on melatonin, more of its importance is being uncovered.  
Melatonin is synthesized and released in accordance with how much light reaches the 
eye.  When light enters the eye, the ganglion cells, which contain the photopigment 
melanopsin, send retinal photic signals to the suprachiasmatic nucleus (SCN) through the 
monosynaptic retinohypothalamic tract. The ganglion cells which contain melanopsin are 
sensitive to light with relatively short wavelengths (484 nm) (Macchi and Bruce 2004). 
There are constant rates of 
production of melatonin at night, 
but during daylight hours 
synthesis is suppressed by light 
(Macchi and Bruce 2004).  The 
mechanism which causes the light 
induced suppression and dark 
induced release of melatonin is 
due to norepinephrine. 
Norepinephrine is the input to the 
pineal gland, and melatonin is the 
output.  During the day, the 
retinal photoreceptors are 
hyperpolarized, inhibiting the 
release of norepinephrine and 
thus inhibiting the release of 
melatonin.  Conversely, the lack 
of light at night causes the 
photoreceptors to release 
norepinephrine, thereby 
activating the enzyme N-
acetyltransferase which regulates 
melatonin synthesis (Brzezinski 
1997). In addition, melatonin 
concentrations are affected by 
exercise and changing posture.  
During night hours, 
concentrations of melatonin in the 
Figure 1: Tryptophan to Melatonin. Source: Macchi and Bruce 2004 
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plasma and saliva decrease when moving from supine to standing position and vice versa 
(Macchi and Bruce 2004). 
Production of melatonin begins when pinealocytes take up the amino acid tryptophan 
from the blood.  Tryptophan is then hydoxylated and decarboxylated, thus converting it into 
serotonin.  The enzyme N-acetyl transferase (NAT) then converts the serotonin into N-acetyl 
serotonin. Hydroxyindole-O-methyl transferase (HIOMT) methylates the N-acetyl serotonin, 
converting it into indoleamine N-acetyl-5-methoxytryptamine, which is melatonin (Figure 1).  
(Macchi and Bruce 2004). Additionally, studies suggest that melatonin may be synthesized 
from serotonin in the ovaries. (Itoh et al 1999).  
After production, melatonin is released into the capillaries where 70% of it is bound to 
albumin.   Melatonin is metabolized primarily in the liver where it undergoes hydroxylation 
and conjugation into sulfate and glucuronide  (Macchi and Bruce 2004). 
A highly diffusible hormone, melatonin is found in the blood, saliva, urine, cerebro-
spinal fluid (CSF), anterior chamber of eye, retina, gut, and bone marrow, as well as in many 
reproductive fluids such as breast milk, preovulatory follicles, semen, and amniotic fluid.  
Three melatonin receptors, MT1, MT2, and MT3, have been identified  (Macchi and Bruce 
2004; Adriaens et al. 2006).  These receptors are localized in lymphocytes, prostate epithelial 
cells, granulosa cells, preovulatory follicles, spermatozoa, blood, platelets, and the mucosa and 
submucosa layers of the colon.  
Melatonin and its receptors are found in many parts of the human body, indicating 
that the hormone may have many functions rather than only one main one.  The fact that 
melatonin and melatonin receptors are found in many reproductive fluids and in preovulatory 
follicles suggests that melatonin plays a role in reproduction.   
THE FUNCTION OF MELATONIN 
Melatonin has various functions which are mediated either through specific membrane 
receptors or nuclear binding sites (Tamura et al. 2009). However, unlike other hormones, 
melatonin is unique in its ability to act as a free radical scavenger.  It is an even better 
antioxidant than glutathione, vitamin E, and mannitol, which are known as effective free 
radical scavengers. It is one of the more effective antioxidants because it permeates and 
disperses through cells easily.  Therefore it can prevent oxidative damage at any site of a cell 
(Pandey et al. 2003).  Since melatonin acts forcefully upon free radicals, it is a very important 
hormone (Macchi and Bruce 2004).    
Besides melatonin’s role as an antioxidant, it plays a part in the immune system as well. 
Maestroni (1993) showed that suppression of melatonin (which is found in lymphocytes) 
caused a decrease in thymus and spleen activity.  It also caused a decrease in the primary 
response of antibodies to T-dependent antigens.  These results were reversed with 
administration of melatonin.  In addition, constant administration of melatonin caused an 
increase in helper T cell activity and in IL-2 production (Macchi and Bruce 2004).  High 
estrogen levels cause suppression of cell mediated immune response. Melatonin acts as an 
anti-estrogen, improving immune response (Sanchez-Barcelo et al. 2005). 
Another important function of melatonin is its role in cardiac activity.  When humans 
sleep at night, heart rate and blood pressure are lowered.  It is also during the night that 
melatonin is produced.  This concurrence seems to demonstrate a link between melatonin and 
a decrease in heart rate and blood pressure.  Studies have shown that pineal extracts lower 
blood pressure in humans and in rats.  But when exogenous melatonin was administered, 
heart rate and blood pressure only went down when given during the day.  When melatonin 
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was administered at the time of endogenous melatonin production, only systolic blood 
pressure was lowered. Since melatonin has a beneficial effect on our cardiac system, it is more 
common for a stroke to occur in the morning when melatonin levels are low.  Coronary 
disease patients have low melatonin levels, making melatonin’s role in cardiac function even 
more plausible (Macchi and Bruce 2004). 
Melatonin is released in a circadian rhythm.  Therefore, it has been used to help 
regulate sleep in people with insomnia by entraining their circadian rhythm (Dubocovich 
1988).   In addition to helping regulate sleep, melatonin also regulates seasonal reproduction 
in photoperiodic animals (Macchi and Bruce 2004). These types of animals only reproduce 
during specific seasons of the year. Melatonin regulates reproduction in photoperiodic animals 
because it has a progonadotropic effect on these animals during certain seasons by increasing 
follicular stimulating hormone (FSH) concentrations and luteinizing hormone (LH) pulses 
(Dair et al. 2008). 
MELATONIN AS AN ANTIOXIDANT 
The cells in our body undergo a process called apoptosis, which is programmed cell 
death.  This occurs in order to renew the cells in our body, eliminate defective cells, and 
maintain homeostasis.  Apoptosis can be induced by growth factor deprivation, radiation 
induced DNA damage, activation of death receptors, and oxidative stress.  Overall, it is a 
beneficial process, but only if it occurs when necessary.  Excessive apoptosis can lead to an 
array of diseases such as Alzheimer’s, Parkinson’s, ischemia, stroke, and AIDS (Pandey et al. 
2003). One of melatonin’s most important features is its ability to act as a free radical 
scavenger, thus protecting against oxidative stress.  Much research has been done on the use 
of melatonin as an antioxidant since it is a safe molecule and is therefore an excellent 
candidate for use in treatments for diseases which are caused by excessive apoptosis, which is 
due to oxidative stress (Pandey et al. 2003). 
Research was done on rat hepatoma cells in order to see if serum deprivation induced 
oxidative stress, leading to apoptosis.  Serum deprivation did induce oxidative stress, but 
treatment with antioxidants such as vitamin E and melatonin prevented apoptosis.  One 
hundred (100) µM of melatonin were added to the medium six hours before serum 
deprivation.  Oxidative stress caused by serum deprivation induced production of radioactive 
oxygen species (ROS), but with melatonin pre-treatment, the level of ROS was lowered 
(Figure 2) as seen by the significant reduction in nuclear condensation and cellular blebbing 
(features of cellular apoptosis).   To ascertain that the pre-treated hepatoma cells not only 
survived but remained functional, they were re-plated in complete media.  Most of the cells 
divided; they doubled three times in seventy two hours. In contrast, serum-deprived cells 
(without melatonin treatment) died within ninety six hours (Pandey et al. 2003). 
Another antioxidant, glutathione, is a tripeptide which acts as a free radical scavenger 
by reducing oxidative stress.  In the latter experiment, glutathione levels were tested in the 
serum deprived cells and in the melatonin treated serum deprived cells.  In the untreated cells, 
glutathione levels were decreased, but in the melatonin pre-treated cells, glutathione levels 
remained the same  (Pandey et al. 2003).  This study demonstrates that melatonin not only has 
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MELATONIN AND WOMEN 
Melatonin affects the 
female reproductive system 
by acting upon the ovaries 
both directly and indirectly. It 
acts indirectly on the ovaries 
by acting on gonadotropin 
releasing hormone (GnRH), 
thereby effecting the release 
of gonadotropins (GnRH is 
responsible for the release of 
LH and FSH from the 
anterior pituitary gland) 
(Romeu et al. 2010).  
Melatonin acts on the ovaries 
directly through its 
antioxidant and anti-apoptotic 
properties, as well as its 
regulation of LH mRNA in 
the ovaries (Tamura et al. 
2009).  
One indication that 
melatonin is involved in 
reproduction is that melatonin 
levels decrease at the start of 
puberty.  This may hint to melatonin’s role in reproduction because high levels of melatonin 
are known to inhibit ovulation (Macchi and Bruce 2004).  Secondly, the concentration of 
melatonin in human preovulatory follicular fluid is three times more than in the plasma and 
melatonin and its precursors are found in human ovary extracts.  For example, NAT and 
HIOMT are found in human ovarian homogenates (Itoh et al. 1999). In addition to melatonin 
itself, MT1 and MT2 receptors are also found in ovarian extracts such as ovarian granulosa, 
luteal cells of humans, and rat ovaries. The binding site for the receptors has been detected in 
the granulosa cell membrane.   
There are two possibilities for the source of the melatonin found in the female 
reproductive system.  It is possible that it is synthesized in the ovary and then released 
directly into the follicular fluid, or it may be derived from the circulation.  The latter seems 
more likely because when infertile women were given a 3 mg tablet of melatonin (taken 
orally), there were higher levels of melatonin in the follicular fluid (Tamura et al. 2009).   
High or low melatonin levels in rats can affect their ovaries. In an experiment done to 
determine the effects of melatonin on rat endometrial morphology and embryo implantation, 
results indicated that melatonin had a positive effect on the endometrium by allowing for 
better implantation of embryos (probably by raising progesterone levels) (Soares et al. 2003).  
Rats are non-photoperiodic, just like humans.  Melatonin was administered to the rats 
in large doses in the afternoon of their proestrus phase (the phase proceeding ovulation).  As a 
result, the surge in LH which normally causes ovulation was prevented, not allowing for 
ovulation. In another experiment, when rats were given exogenous melatonin, ovarian weight 
Figure 2: The effect of ROS on cells treated with melatonin versus 
control cells.  Source: Pandey et al. 2003 
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was decreased. But, when the rats were subjected to prolonged light, decreasing the high 
melatonin levels, an increase in ovarian weight was observed  (Soares et al. 2003).   
This antigonadotropic effect was seen not only when melatonin levels were too high, 
but also when melatonin levels were too low. When melatonin production was suppressed in 
rats, either by pinealectomy or light, precocious puberty, ovarian atrophy, chronic 
anovulatory state, permanent estrous condition, and hyperprolactinemia were observed. 
Pinealectomy induced a prolonged estrous stage in the rats, possibly by raising estrogen levels 
and lowering progesterone levels  (Dair et al. 2008).  Moreover, when rats underwent a 
pinealectomy, there was an increase in atretic follicles in the ovaries (Tamura et al. 2009). 
Atresia is hormone controlled apoptosis; approximately ninety nine percent of ovarian follicles 
undergo this degenerative process; the rest proceed to the preovulatory stage (Manabe et al. 
2008). Pinealectomy  of rats in another experiment resulted in overgrowth of the ovarian 
stroma (Romeu et al. 2010). 
From these experiments on rats, it seems that high levels of melatonin have 
antigonadotropic effects (indirectly affecting the ovaries) resulting in a lack of ovulation, and 
low levels of melatonin cause an increase in atretic follicles and decrease in ovarian weight. 
But it should be noted that high levels appear to improve the endometrium for implantation 
by having an effect on hormones such as estrogen and progesterone.  It is also possible that in 
humans, high melatonin levels are detrimental to fertility because infertility may be a result of 
low estrogen levels and high melatonin levels (Macchi and Bruce 2004).   
In women with stress induced, exercise induced, or functional hypothalamic 
hypogonadism, melatonin levels are higher than normally present.  Additionally, women with 
functional amenorrhea, have high melatonin levels which are inversely related to their 
estrogen levels, suggesting a relationship between high melatonin concentrations and 
hypothathalamic-pituitary-gonadal hypofunction which can cause temporary infertility by 
preventing menstruation in women. In one study, exogenous melatonin and progestagen were 
given to women; as a result LH secretion decreased, not allowing for ovulation.  Although the 
luteal phase increase in progesterone was blocked, FSH and estradiol were not affected  
(Macchi and Bruce 2004). 
The relationship between melatonin and estrogen was also studied in breast cancer 
patients.  High melatonin levels decreased the amount of estrogen, and low melatonin caused 
an increase in estrogen.  In breast cancer patients, tumors are sometimes estrogen-dependent.  
These women were treated with estrogen inhibitors such as tamoxifen, which is a drug that 
acts as an estrogen receptor antagonist and agonist. Melatonin acts as an anti-estrogen as well, 
but in a different manner; it interacts with the estrogen receptor signaling pathway. Melatonin 
binds to its own receptors and causes a decrease in expression of estrogen receptors, thereby 
blocking estradiol from binding to the estrogen receptors (Sanchez-Barcelo et al. 2005).  
Therefore, infertile women may have high levels of estrogen which could possibly be treated 
with administration of melatonin. 
Low levels of melatonin in human ovaries may also be unfavorable by affecting the 
ovaries directly. Many studies provide evidence that follicular cell death during atresia occurs 
through apoptosis. Many women who are having ovarian failure such as premature ovarian 
failure, polycystic ovary syndrome, oophoritis, or unexplained infertility, may have these 
disorders due to a large number of follicular cell deaths via apoptosis.  In order for apoptosis 
to occur, the cell’s mitochondrial membrane must become more permeable, so as to release 
pro-apoptotic factors. Melatonin has been shown to directly inhibit the permeability of 
transition pores (a protein pore), causing anti-apoptotic effects.   
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An experiment was done in which mice were injected with either xenogenic anti-
ovarian antibodies or allogenic anti-ovarian antibodies.  One hour before antibody injection, 
melatonin was administered (5 mg/kg).  In the control mice, exogenous melatonin had no 
effect on the ovaries, but in the mice which had been injected with xenogenic anti-ovarian 
antibodies, melatonin reduced the negative effects caused by the antibodies; it improved 
oocyte quality and caused a decrease in the number of follicular cell deaths by apoptosis. 
Melatonin reversed the antagonistic effects of anti-ovarian antibodies on the mouse ovaries, 
but it did not protect against the larger immune reaction of the xenogenic antibodies on a 
systemic level. On the other hand, melatonin administration in mice injected with allogenic 
anti-ovarian antibodies had no effect (Voznesenskaya et al. 2007).   
 In addition to providing anti-apoptotic factors, melatonin in the follicles can scavenge 
free radicals such as radioactive nitrogen species (RNS) and ROS, as mentioned above.  The 
capability of melatonin to act as a free radical scavenger is especially important because 
ovulation stimulates a local inflamatory response, causing inflammatory cells such as 
macrophages and neutrophils to produce free radicals such as ROS and RNS, which induce 
apoptosis in ovarian cells.  Higher melatonin levels in ovarian follicles offers the ovarian cells a 
greater chance of maturing and developing (Tamura et al. 2009). Therefore, if a woman’s 
melatonin levels are too low, there may be an increase in the percentage of follicular deaths 
which would result in a lower number of follicles that have the potential for ovulation.  
Clearly, melatonin levels must be maintained within a certain range, since very high and very 
low levels can prevent ovulation, leading to infertility. 
Very few follicles mature and become capable of releasing their ovum for fertilization 
purposes. The maturing follicle is filled with follicular fluid which contains water, electrolytes, 
serum proteins, and steroid hormones secreted by granulosa cells.  Melatonin affects sex 
steroid production at different phases of follicular growth by regulating the steroidogenic 
enzyme, which activates gene expression in thecal and granulosa cells.  Melatonin has been 
proven to alter granulosa cell steroidogenesis and follicular function.  As follicles mature, they 
shift from dependency on FSH to LH.  The process by which follicles are selected to continue 
maturing may be linked to the timing of mRNA expression encoding LH receptors in 
granulosa cells.   Melatonin may directly affect the ovaries by regulating LH mRNA 
expression; melatonin treatment (10 pM-100 nM) increased the LH receptor mRNA 
expression in granulosa cells  (Tamura et al. 2009).  This confirms that higher levels of 
melatonin in the ovaries can be beneficial, but what concentrations are too high?  
Research was done in order to find a melatonin concentration that would protect 
female oocytes without being toxic.  This experiment was specifically performed to find a way 
for young women who are undergoing treatments such as chemotherapy and radiation to 
Figure 3: The granulosa cells of the ovaries, which each house an oocyte, go through three major phases: the follicular, 
diffuse, and antral stages. Source: Adriaens et al. 2006 
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retain fertility.  Mouse follicles were cultured in vitro and different concentrations of 
melatonin were added to each. Ovulation was then stimulated.  Two (2) mM of melatonin was 
found to be toxic (this is about four thousand times more than physiological melatonin 
concentrations in the follicular fluid); it affected follicular differentiation leading to a 
decreased amount of antral follicles  (Adriaens et al. 2006). 
One (1) mM negatively influenced oocyte development, and 100 µM influenced 
steroidogenesis. Ten (10) µM was the highest concentrations that had no negative effect on 
the follicular system. This dosage could possibly be used to protect female ovaries.  
Additionally, progesterone levels increased significantly in follicles with 100 µM and 1 mM of 
melatonin.  After ovulation was stimulated, progesterone levels increased in all cases except 
for with 2 mM melatonin.  In the control groups, estradiol increased exponentially, but in 
follicles with 1 or 2 mM of melatonin, estradiol amounts were much lower.  As seen by the 
results in Figure 4, large doses of melatonin caused a reduction in the number of granulosa 
Figure 4 :Morphological changes of follicles over a 12 day period under different melatonin 
concentrations Source: Adriaens et al. 2006 
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cells.  But by day twelve, most of the follicles reached the antral stage, with concentrations of 
up to 1 mM melatonin (Adriaens et al. 2006).   
This experiment only used three mice (six ovaries) for evaluation; this is a very small 
control group making its validity questionable.  Everyone has varying levels of hormones, 
such as estrogen, progesterone and melatonin, in circulation so a larger number of ovaries 
should have been used in this study. On the other hand, this study was done well because they 
used concentrations of melatonin spanning physiological and pharmacological follicular fluid 
concentrations (1nM-2mM).  According to this study, there would be no health hazard (in 
regards to fertility) for women to take 3 mg tablets of melatonin (the normal dosage found 
over-the-counter).   
 In another experiment, three week-old mice were whole-body irradiated with gamma-
radiation.  Gamma radiation causes an increase in atresia of ovarian follicles.  The purpose of 
this experiment was to observe if melatonin provided a protective effect against radiation. One 
group of mice was treated with 10 µg of melatonin before radiation, and another was treated 
with 100 µg.  After radiation, the ovaries were taken out and examined.  The number of 
follicles (including normal and atretic) was about one hundred and twenty five in the largest 
cross sections; in the irradiated mouse ovaries, the number of follicles was reduced to about 
one hundred and three. Primordial follicles were the most sensitive to radiation; melatonin 
treatment seemed to protect these follicles from radiation. Ten (10) µg of melatonin did not 
have a large protective effect on the primary follicles from radiation, but 100 µg did display a 
protective effect on them. But lower melatonin concentration did have a protective effect on 
preantral and antral follicles.  Different concentrations of melatonin have protective effects 
against radiation at different stages of follicular development  (Kim and Lee 2000).   
As opposed to most of the previous studies mentioned, one study found that melatonin 
increased follicular atresia.  Research was done to study the effects of pineal indoles 
(including melatonin) on gonadotropin-induced ovulation in mice.  To stimulate ovulation, 
mice were injected with PMSG (pregnant mare serum gonadotropin) and hCG (human 
chorionic gonadotropin). Then various pineal indoles, at a dose of 0.2 mg/25 g body weight, 
were administered.  After the mice were sacrificed, the ovaries were removed and examined.   
Although ovarian weight and quality remained the same, the number of atretic follicles 
appeared to increase in the mouse ovaries which had been injected with melatonin.  Plasma 
levels of estradiol and progesterone were decreased (Chan and Ng 1995).   
The two latter experiments discussed (on gamma radiation and on pineal indoles) both 
used young mice which were prepubertal.  Puberty in humans causes a decrease in 
endogenous melatonin production, as well as other hormonal changes.  When examining 
whether melatonin has protective effects on follicles for the purpose of helping prepubertal 
females, using prepubertal mice is appropriate.  Otherwise, mature mice should be used for 
experimentation because hormone levels and interactions would be more similar to that in 
mature women.   
FUTURE RESEARCH ON MELATONIN 
As seen by the experiments and research done on melatonin, it is apparent that the 
indoleamine affects the reproductive system.  It appears that melatonin is beneficial in high 
concentrations when it is present in the ovaries because it directly decreases apoptosis and 
acts as a free radical scavenger.  Therefore, low melatonin levels in the ovaries are detrimental 
to fertility.  On the other hand, high melatonin concentrations in the blood can inhibit 
ovulation by inhibiting the surge in LH.  It is necessary to determine the concentrations of 
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melatonin that will be most beneficial in increasing ovulation by protecting and helping oocyte 
maturation, without being too high to be antigonadotropic.  In addition, research should be 
done to see if melatonin can be directly administered into the ovaries (in order to decrease 
apoptosis) without too much of it entering circulation and possibly inhibiting ovulation (by 
inhibiting the release of GnRH).  
Moreover, more research needs to be done on finding a concentration of melatonin 
that has protective properties on oocytes (by acting as free radical scavengers) without having 
detrimental effects.  This would be beneficial to young women undergoing chemotherapy or 
radiation treatments whose fertility in the future might be at risk. Ten micromoles of 
melatonin is a dose that should be experimented with further. 
Additional work should be done on the relationship between melatonin and estrogen.  
A few of the experiments done showed that low levels of melatonin, as a result of 
pinealectomy, raised estrogen levels and caused an increase in atretic follicles.  On the other 
hand, other research indicated that high levels of melatonin and low estrogen levels were 
detrimental to fertility.  
Melatonin could also be used as a supplement for treatments of various disorders since 
it is generally safe (Brzezinski 1997).  As an antioxidant and mitochondrial membrane 
permeability transition pore inhibitor, melatonin may be a good candidate to help in the 
management of cancer, Alzheimer’s disease, diabetes, and viral infections (Tamura et al. 
2009).   Research has shown that melatonin can fight against tumors by reducing vascular 
endothelial growth factor (Romeu, et al. 2010).  It is also permeable enough to disperse 
throughout cells and can even penetrate the nucleus where it can protect DNA from oxidative 
damage, reducing the risk of cancer  (Meki et al. 2001). 
CONCLUSION 
 Melatonin has a relationship with estrogen and other hormones, has an anti-
apoptotic effect, and regulates LH mRNA.   With these properties melatonin can be beneficial 
as it may help increase fertility in women who are infertile, prevent damage in diseases where 
there is too much apoptosis, and possibly protect the ovaries from radiation.  Although more 
research has to be done on melatonin and the doses which work best in each case, it seems 
that the hormone will play a role in various therapies  in the future.  
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DID THE FDA PROPERLY ASSESS THE SAFETY OF 
OLESTRA AS A FOOD ADDITIVE? 
Leah Lebel 
INTRODUCTION 
Olestra, a fat-substitute comprised of sucrose that has been esterified with fatty acids 
(Blume 1995), has been the subject of much controversy ever since its creation. Olestra is not 
absorbed (Mattson and Nolen 1972) because it cannot be hydrolyzed by pancreatic lipases 
(Mattson and Volpenhein 1972) or taken up across the enterocyte microvillus membrane 
(Freston et al. 1997), and thus, cannot be utilized for energy. Olestra has physical and 
organoleptic properties similar to those of traditional triglycerides (Jandacek and Webb 
1978) and is emulsified together with triglyceride (Freston et al. 1997), yet it passes through 
the colon and is excreted unchanged (Fallat et al. 1976). It therefore adds no fat, sugar, or 
calories to the diet (Thomson et al. 1998) 
There is a noteworthy advantage of replacing fat with olestra: olestra is far less energy-
dense than its triglyceride counterpart and can, at least in theory, be a valuable asset to a 
weight-loss regimen. Olestra can serve to satisfy one’s cravings for fatty-foods without 
containing the dense energy that triglycerides provide (Eldridge et al. 2002).  By causing a 
reduction in energy intake for consumers, olestra, when incorporated with other calorie-
saving methods, has the potential to cause weight loss when replaced with more energy-dense 
products (Rolls and Bell 1999). 
After Procter & Gamble, the makers of olestra, obtained their first patent on olestra in 
1971 (Nestle 1998), olestra underwent a more than 20-year struggle until it was finally 
approved in January 1996 (Nightingale 1996). Much of the controversy surrounding this 
food additive stems from its versatility, as olestra can withstand high heating temperatures 
and can be used in virtually any food(Eldridge et al. 2002), and from its potential to be 
consumed in large quantities. Olestra presents a potential danger in that it is a macro-additive; 
a serving of olestra-containing food has several grams of the additive, rather than milligrams 
(as artificial sweeteners and many other additives have). This fact presented an 
unprecedented decision for the FDA—it was now choosing to approve something that would 
be consumed in potentially substantial quantities. Nevertheless, on January 25th 1996, the 
FDA released its ruling that olestra was to be approved for use in savory snacks. The FDA 
did, however, require that vitamin losses typically experienced from consuming olestra 
(particularly fat-soluble vitamins) be added to compensate for these losses. Thus, vitamins A, 
Figure 1: The chemical structure of olestra as compared with traditional triglyceride  
Source: http://extoxnet.orst.edu/faqs/additive/olstru.htm 
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D, E, and K are added to olestra during manufacturing. Initially upon approving olestra, the 
FDA, still unsure about long-term safety at 
approval time, required a warning notice 
for all products (Nestle 1998) stating that 
“This Product Contains Olestra. Olestra 
may cause abdominal cramping and loose 
stools. Olestra inhibits the absorption of 
some vitamins and other nutrients. 
Vitamins A, D, E, and K have been added” 
(Center for Science in the Public Interest).      
Much consumer controversy resulted from olestra’s approval (Miller 2001). From 
olestra’s entry into the market, there have been tens of thousands of adverse anecdotal reports 
from olestra consumers. People claimed they had suffered severe diarrhea, fecal incontinence, 
and/or abdominal cramps hours after eating olestra chips. Procter & Gamble, however, 
claimed that there is no proof that olestra is the cause of these effects (Center for Science in 
the Public Interest).      
The Center for Science in Public Interest (CSPI) in particular was infuriated with 
olestra’s passing into market and constantly collected data in an attempt to convince the FDA 
to withdraw their decision. Many other groups and independent challengers also believe that 
olestra should not have obtained FDA approval. They challenged the studies conducted by 
Procter & Gamble, pointing to the fact that some studies conducted by Unilever, Procter & 
Gamble’s competition, show that olestra, when consumed at high levels, causes 
gastrointestinal problems in up to 30% of subjects, point to the large marketing campaigns 
used to promote the product, and claim that significant losses of fat-soluble vitamins, and 
particularly carotenoids, can increase the risk of chronic diseases. Yet because critics could 
not prove that carotenoid losses were harmful and because the product had a label warning of 
GI distress potential, no action was taken to remove the product from the market (Nestle 
1998).  According to Porterfield, “the PDA [sic] granted approval [of Olestra] acknowledging 
that some patients may experience abdominal cramps and diarrhea if they eat too much” 
(Porterfield 1997). 
In 2003, the FDA chose to eliminate the requirement for a warning label, stating that it 
“was no longer warranted as post-market studies showed that olestra caused only infrequent, 
mild gastrointestinal effects” (FDA removes olestra warning 2003).  
Michael F. Jacobson, the executive director of CSPI, notes, "P&G's own studies prove 
olestra causes diarrhea, cramps and other symptoms. If that weren't enough, the FDA has 
more than 20,000 complaints about olestra in its files--more than it has for all other food 
additives in history combined” (FDA removes olestra warning 2003). In a post marketing 
surveillance study, .4% of consumers were hospitalized, and suspected olestra to be the cause 
for their hospitalization (Allgood et al. 2000). Other consumers pointed to other side effects 
such as headaches and blame olestra as the cause (Blume 1995). Nonetheless, there is no 
direct proof that this is the case. As Procter and Gamble noted in their defense, it is quite 
possible that there was another unrelated cause to all these ailments and that experiencing 
ailments at some time after consuming olestra was a coincidental occurrence. 
Despite this, many people began to question the FDA’s approval of olestra. Many ask: 
how has the FDA been able to responsibly pass into market a product that may not be safe for 
such large segments of the population who may not realize the effects of olestra on their 
overall health? Olestra causes side effects of great magnitude; diarrhea, after all, can cause 
Figure 2: Sample of the warning label originally 
required on all olestra-containing products 
Source: http://www.carboh.com/olestra.phtml 
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complications including weight loss, dehydration and electrolyte imbalances (Tortora and 
Derrikson 2006). Moreover, Procter and Gamble contributed funds to the FDA, just weeks 
before the FDA actually approved olestra (Nestle 1998). Thus, many wonder if olestra is safe 
and if the decision was based solely on fact. 
This study attempts to determine whether the FDA took the necessary scruples to 
avoid prematurely allowing olestra into market. An analysis of the standards utilized by the 
FDA, followed by a comparison of those standards with the research is warranted.   
WHAT ARE THE CRITERIA UPON WHICH THE FDA MAKES ITS “SAFE” OR 
“UNSAFE” RULINGS?  
ADDITIVE REGULATION GUIDELINES WHICH THE FDA ADHERES TO:  
In an article aimed at explaining the requirements and procedures involved in the 
FDA’s additive-approval process, Rulis and Levitt (2009) depict many of the factors that 
would explain what Procter and Gamble, the company that manufactures olestra, would have 
had to undergo to get olestra approved for consumer use.  The article notes the fact that the 
FDA requires that additives undergo a strict approval regimen and employs an “unsafe until 
proven safe” mentality: “New food additives are presumed to be unsafe for their intended use 
unless and until they are proven ‘safe’” (Section 3; 2008). The additive in question must meet 
with the FDA’s standards of “reasonableness to cause no harm.” Clearly, “reasonableness to 
cause no harm” is a subjective term and thus in the article’s appendix, the author elaborates on 
just what “reasonableness” is defined as. Section 409(c)(3) of the FD&C act explains that the 
food additive in question requires a “fair evaluation of the data” and that the concept of safety 
involves the question of whether a substance is “hazardous to the health of man or animal.” 
Primarily, calling a product “safe” requires proof of “a reasonable certainty that no harm will 
result from the proposed use of an additive” (House of Representatives, Report No. 2284, 85th 
Congress, 1958, as qtd. in appendix 10 of Rulis and Levitt 2009).  Thus, in assessing the safety 
of olestra, the FDA would have been expected to determine (1) whether olestra could 
potentially be hazardous to the health of man or animal and if the substance in question has a 
reasonable certainty to cause harm based upon the data available prior to olestra’s approval 
date on January 25th 1996.  
 The authors of the articles also reference the House of Representatives Report 
No 2284, 85th congress, 1958 statute 21CFR 170.3(i)) which elaborated upon the term “safe” 
to mean “a reasonable certainty in the minds of competent scientists that the substance is not 
harmful under the intended conditions of use” (italics added). It is important to note that, in this 
ruling, there must be a reasonable certainty only. In other words, the product in question is 
not guaranteed to be safe, but rather, it must present itself as reasonably harmless to health. 
Rulis and Levitt adeptly point out that this wording does “[result]in decisions inevitably being 
made without absolute certainty” (appendix 10).The burden to provide proof of safety lies 
with the petitioner (Rulis and Levitt 2009), and therefore Procter and Gamble would have 
had to demonstrate to the FDA that there is reasonable certainty that the item causes no harm 
in the minds of competent scientists. Hence, the questions that remain for this research paper 
to address is (2) were the competent scientists company based (and thus possibly biased) or 
were they independent researchers and (3) how credible are the studies upon which the 
scientists were basing their decision? A critical review of the literature available until olestra 
became approved is warranted in order to assess the meticulousness of the scruples taken 
before the FDA’s decision was finalized. At least in theory, the research should have been able 
to persuade the FDA of olestra’s reasonable safety. 
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Another inquiry to the above is what is olestra’s “intended condition of use”? Rulis and 
Levitt’s journal article then goes on to explain that “[there are] a range of technical functions 
in food…as outlined by Food Ingredients, as outlined in a brochure produced jointly by the 
FDA in collaboration with the international Food Information Council.”  The article then goes 
on to list some of these technical functions, and the one that best fits olestra would be the 
second one, or, “to improve or maintain nutritional value,” which includes the point of 
“lowering the calorie or fat content of foods.” Hence, reducing the energy consumed would be 
considered a sufficient benefit of the product’s use. The purpose of reducing the energy 
content of a specific food would, in turn, be to lower the weight-gain by the consumer who 
chose to consume the food with the additive rather than the one without. In an age where 
obesity is reaching epidemic proportions (World Health Organization 1998), this is an 
important task to be accomplished. Over a long period, even modest caloric-reduction benefits 
can translate into significant weight loss. In light of this, olestra’s use serves a very important 
function to lower the skyrocketing obesity rate. Thus, it is probably safe to infer that the 
“purpose” or benefit seen by the FDA for olestra’s use would be to produce a weight-loss 
effect in the obese, thus opening a fourth underlying question that would provide the 
justification, or lack thereof, of ruling for olestra’s approval:(4) whether olestra actually 
causes weight reduction in those who would benefit from weight loss. Section three of the 
article then goes on to state that “once approved, food additives must be safe for everyone—
children and the very young; teenagers and adults; the elderly; pregnant and lactating 
women.” This fact obviously raises a fifth question: how does olestra consumption affect those 
who may experience negative consequences resulting from a lower energy consumption (such 
as pregnant women who require a higher caloric intake to support a growing fetus or children 
reaching puberty who also require a higher energy intake to support growth spurts and 
maturation) and can these subgroups easily meet these increased energy needs while 
consuming lower-calorie versions of fat such as olestra. The FDA would have had to assess 
this (5) and would have had to provide special labeling so special-risk subpopulations can be 
properly informed, if necessary that they must avoid the product. At present, no food labels 
are featured on the package of olestra-containing products.  Also, along with the question of 
whether olestra promotes weight loss, is a further question: does it lower the health risks 
associated with Obesity (6), such as the low-density lipoprotein (LDL)or serum triglyceride 
levels. (7) Does the added vitamin K promote coagulation and hinder the effects of warfarin 
therapy? (8) How does olestra interact with lipophilic drugs?  
HOW MUCH DID THE FDA APPROVE AS SAFE? 
CALCULATED ESTIMATED DAILY INTAKE (EDI): 
In FDA’s assessment of an additive’s safety they consider the probable intake of the 
additive, the cumulative effect of all uses of the additive, and the relevant toxicological data 
needed to establish its safety (Rulis and Levitt2009). The FDA determined that the estimate 
for daily chronic intake was a mean of 3.1 grams per day, with the 90th percentile consumption 
at 6.9 grams per day. Even among the highest consumer levels (teens and men) the estimate 
for daily chronic intake was as low as 11.0 grams per day at the 90th percentile level. 
Primarily, 7 grams per day would be considered, according to the FDA, the average chronic 
consumption level. Because a 2-ounce bag of chips contains about 20g of olestra, the chronic 
consumption level would be in effect from one consuming merely about .75 ounces daily 
(Prince and Welschenbach 1998), or about 8 chips daily.  
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POTENTIAL PROBLEMS AND BENEFITS ASSOCIATED WITH OLESTRA 
CONSUMPTION 
WHAT PROCTER AND GAMBLE SUBMITTED TO THE FDA FOR OLESTRA’S 
APPROVAL:  
According to an article published in the Journal of the American Dietetic Association 
(Prince and Welschenbach 1998), Procter and Gamble provided data in five categories: the 
estimated daily intake (EDI), toxicological effects, olestra’s effect on drug absorption, 
nutritional effect, and gastrointestinal effect. This study will provide both the studies 
submitted to the FDA before olestra’s approval and the numerous studies from independent 
research pursuits that occurred subsequent to olestra’s approval to provide an independent 
and comprehensive evaluation and answer not only if the FDA’s decision was appropriate, but 
what effects of olestra that had not been found that may have been available had the FDA 
waited longer before approving olestra.   
TOXICOLOGICAL EFFECTS: 
From studies performed on several animal species including rats, pigs, rabbits, mice, 
hamsters, and dogs, the FDA decided that the data supported the petitioner’s conclusions for 
olestra’s non-toxic and non-carcinogenic properties and that olestra is neither metabolized nor 
absorbed by the body(Prince and Welschenbach 1998). Many people pinpoint the fact that no 
human studies were conducted before FDA approval. While the reasoning behind this 
remains unanswered, the FDA had obviously believed that testing olestra on animals was 
sufficient for determining the safety for the general population’s consumption.  
OLESTRA’S POTENTIALLY NEGATIVE EFFECTS ON CAROTENOID 
CONCENTRATION, 2,3,7,8 TETRACHLORODIBENZO-P-DIOXIN (TCDD) AND 
DRUG ABSORPTION 
Hof and Weststrate (1995)concluded that, “Even at low doses, SPE[sucrose polyester] 
strongly reduces plasma carotenoid concentrations.” 
“Sucrose Polyester and Plasma Carotenoid Concentrations in Healthy Subjects,” concluded 
that, “Even at low doses, SPE strongly reduces plasma carotenoid concentrations. Studies 
suggest that carotenoids have provitamin A activity as well as antioxidant properties (Faulks 
and Southon 1997) and cause a reduced incidence of hypertension and cataracts (Thomson et 
al.1998). On the surface, therefore, this finding would appear to merit “careful consideration 
in its relevance to assessing the long-term health effects of SPE-containing consumer foods” 
(Hof and Weststrate 1995). A subsequent study, however, posits that although olestra would 
have an effect on potentially beneficial phytosterols, this effect would be miniscule and 
nutritionally insignificant (Cooper et al. 1997). Moreover, there is no scientific proof that 
carotenoids contribute to health and wellbeing. Therefore, the FDA determined that the 
assertion of olestra’s negative impact on dietary carotenoid level did not warrant attention and 
did not deem it appropriate to force the company to add compensatory carotenoids to olestra-
containing snacks (Thomson et al. 1998).     
Another possible issue with olestra is that it increases fecal excretion of 2,3,7,8 
tetrachlorodibenzo-p-dioxin (TCDD) by eight to ten fold. In turn, this reduces the 
elimination half-life of TCDD by about 5 years. The article’s author states that these 
compounds may diffuse across the intestinal wall along the concentration gradient of the 
chemical between lumen fat and blood fat. This, according to the author, “would be expected 
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to increase the capacity of the lumen to take up lipophilic contaminants in the blood” (Geusau 
1999). The results of this could be problematic but more needs to be assessed before 
conclusions can be drawn from this study.   
Olestra is a lipophilic substance and therefore has the potential to affect the 
bioavailability of lipophilic drugs (Prince and Welschenbach 1998).  In a 1990 study 
performed on rats, the researchers found little possibility for severe drug malabsorption due to 
olestra’s presence.  At first, the researchers hypothesized that “any effect that a nonabsorbable 
lipid, such as olestra, might have on the absorption of an oral drug will result primarily from 
interference with incorporation of that drug into the intestinal mixed-micelles by solubilization 
of the drug in the nonabsorbable lipid. The more lipophilic the drug is, the higher the potential 
for it to be solubilized by the lipid. The lipophilicity of a drug can be described by its oil-water 
partition coefficient…” (Miller et al. 1990) In other words, a highly lipophilic drug has far 
more potential to be affected by the presence of olestra simultaneously in the GI tract than a 
drug with modest lipophilicity. While Miller et al. (1990) found that “there is little potential 
for olestra to reduce absorption of oral drugs in general,” it is up to competent doctors to 
recognize this and inform patients when olestra may affect the drugs the patient is taking. In 
theory, a patient’s treatment can be hindered in the rare instance where olestra does inhibit a 
lipophilic drug’s absorption and therefore a drug’s efficacy is reduced. However, this is 
unlikely, particularly when adhering to the acceptable daily intakes established by the FDA. 
Another study performed on humans was also reviewed by the FDA, yet in this study, the 
experimental group’s result data does not differ from the control group’s (Prince and 
Welschenbach 1998), and therefore the FDA concluded, based on this study and the one 
conducted by Miller et al. (1990), that “olestra does not interfere with the absorption or 
bioavailability of lipophilic drugs…when administered at the 18g/day level” (Note that this is 
above the FDA approximated toxicity level). Still, it is important to underscore the fact that 
there is no direct proof that olestra does not hinder drug absorption and more research is 
warranted to assess the correlation (although minute) found by Miller et al. 
GASTROINTESTINAL EFFECTS OF OLESTRA:  
The FDA required two 56-day studies to determine the gastrointestinal effects plus a 
4-week multicenter study on patients with inflammatory bowel disease, ulcerative colitis and 
Crohn’s disease. Tests for those in the 4-week study were used to determine if olestra’s 
presence in the GI tract aggravates already damaged epithelium. There was no statistically 
significant increase in bowel permeability, but the FDA decided that the study was too 
narrowly-ranged to rule out detrimental effects that olestra may have on gastrointestinal 
diseases (Food additive petition 7A3997 volumes 192-194 submitted Feb 1993 and volumes 
183-184 submitted January 5th 1993 as cited in Prince and Welschenbach 1998).     
Clinical trials following olestra’s approval pointed to side effects experienced by some 
and sparked adverse publicity about olestra. This prompted Procter and Gamble to establish a 
panel of experts to independently analyze the studies relating to olestra and digestive system 
function. Procter and Gamble agreed to submit the panel of experts’ findings regardless of 
their conclusions. The panel convened in September 1996 and “analyzed data from preclinical 
and clinical studies pertaining to the chemistry of olestra, its mechanism of action, and its 
potential for gastrointestinal effects” (Freston et al. 1997). An article published in Regulatory 
toxicology and pharmacology reviewed and analyzed olestra’s effects on gastrointestinal functions 
and the symptoms experienced as a result of olestra consumption as determined by this board 
(Freston et al. 1997).  
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From the results of clinical trials, the board found that in a study in which subjects of 
the experimental group were consuming 18g of olestra daily rather than triglyceride, no 
statistically significant difference between the two groups with respect to bloating, belching, 
heartburn, nausea, cramping, or diarrhea was found. However, in two studies that involved 
consumption of 20 grams of olestra or more per day, “there was an increase in the number of 
symptom episodes and the total number of days on which symptoms were reported” (Freston 
et al. 1997). Another striking revelation about these two studies is that symptoms were 
reported several days after olestra ingestion. This allows for possibility that other studies of 
very short durations may not have had enough time elapse after olestra consumption for 
symptoms to appear, and therefore might have under-reported symptoms.  
The group established by Procter and Gamble also reviewed studies of children. In the 
three studies that this board reviewed, no significantly worse incidence of symptoms has 
occurred in studies performed on children than on those performed in adults.  
Obviously, consideration must be taken in realizing that the group of reviewers was 
funded by Procter and Gamble. Although this did not necessarily influence the findings of the 
group, it may have done so.     
Post marketing surveillance for olestra via an established toll-free number reported 85 
reports during the first 9 weeks. There were 65 incidences in diarrhea, 64 of cramping, and 16 
of nausea among others. These are pertinent side effects that warrant attention (Freston et al. 
1997). It is not known how much olestra the reporters of side-effects consumed. Not 
necessarily were these symptoms caused from olestra, and it is likely that at least some of the 
reports may have been misattributed to olestra. Nonetheless, the overwhelming number of 
people who suspected side-effects from olestra should necessitate more research in this area.  
Other studies, including two sponsored by Procter and Gamble, including one which 
fed 20 to 32 grams of olestra, which, granted, is more than the FDA recommends, showed 
significant dose-related increases of diarrhea, loose stools, and an increase the severity and 
frequency of GI symptoms (Jacobson and Brown 1998). A rechallenge study confirmed this 
(at the 20g consumption per day level) and a similar study conducted over the course of 5 
days found a significant increase in adverse GI effects at the 34g/day level.  
In 1998, researchers conducted an experiment in a movie-setting (Cheskin et al. 1998) 
whereby subjects who were randomly selected to consume olestra chips were compared to 
those who were not. Of the more than 1,000 people studied, there was no statistically 
significant difference in gastrointestinal effects of the two groups. This serves to support the 
FDA decision. Note that in this study, the amount of olestra consumed by many subjects 
exceeded four servings. This supports the widened gap between the amount approved by the 
FDA (around 8 chips) and the amount consumers are actually ingesting.  An important 
observation of this study is that consumers were given a 13-ounce bag of chips, but no 
measures were taken to check how much, or if any, olestra-containing (or regular) chips were 
actually consumed. This slightly invalidates the conclusion because the experimental group 
may not have consumed the chips. 
In 2000, the Annals of Internal Medicine published a study that tested for steatorrhea, 
the presence of above-normal amounts of fat present in feces, in individuals who consumed 
olestra (Balasekaran et al. 2000). The purpose of the study was to determine the effect of 
olestra consumption on fecal fat excretion. “If olestra increases the amount of measurable fecal 
fat,” the researchers hypothesized,“ physicians may suspect the malabsorption syndrome in 
patients who consume olestra and may subject them to unnecessary diagnostic tests” 
(Balasekaran et al. 2000). The researchers found that “by all three analytical methods [which 
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they used], apparent concentration of fecal fat was higher when the ten participants were 
consuming olestra chips than when they were consuming conventional chips” (Balasekaran et 
al. 2000).  The mean number of bowel movements per day was significantly higher when 
subjects consumed olestra. “Olestra consumption increased stool frequency, wet stool weight, 
percentage of stool solids (measured by lyophilization), and fecal output of both water and 
solids. The output of fecal solids increased by an average of 36.2 g/d, which almost equals the 
quantity of Olestra ingested.” (Balasekaran et al. 2000) In addition, fecal fat output increased 
as consumption of olestra did, a fact that seems to indicate the possibility that olestra causes 
loose or greasy stool. The article also mentions that “when stool from participants who were 
ingesting olestra was stained…more than 100 orange-red fat droplets were found per high-
power field. Drop diameters ranged from 6 to 120 µm. The size and number of the fat droplets 
were not noticeably different after acidification and heating, which suggests that olestra was 
excreted intact rather than as a fatty acid” (Balasekaran et al. 2000). Nonetheless, steatorrhea, 
although uncomfortable, is not necessarily harmful and this would not have hindered the 
FDA’s approval of the product.  
Overall, there seems to be an increase in olestra-related side-effects in some studies 
where the amounts of olestra that the experimental group’s subjects consumed exceeded the 
amount recommended by the FDA.  
DOES OLESTRA HAVE OTHER BENEFITS SUCH AS LOWERING LOW DENSITY 
LIPOPROTEIN (LDL) CHOLESTEROL LEVELS OR SERUM TRIGLYCERIDE 
LEVELS?  
Studies have shown that olestra does lower LDL levels when olestra replaces 60g of 
saturated fat in the diet (far more than the FDA approved as safe) (Glueck et al. 1982). LDL 
levels were reduced without a significant reduction in High-Density Lipoprotein (HDL) 
levels. It is important to note that this change in cholesterol level may not necessarily be due 
to olestra’s presence in the diet (and the possibility that it inhibits cholesterol absorption), but 
rather may be a mere result of lower saturated fat consumption (Miller et al. 1990). 
Another study in which 50 grams of olestra was substituted for an equal weight of fat 
showed that olestra consumption has no effect on plasma triglyceride levels (Fallat et al. 
1976). Serum triglycerides are also decreased after a meal containing olestra as compared with 
a meal containing triglyceride of equal amounts  (as contrary to above where there was no 
significant relationship). Coronary blood flow was greater after olestra consumption above 
(Cook et al. 2000). 
In general, there are health benefits of consuming olestra; however, these benefits 
appear when consuming olestra in exorbitant amounts. The FDA has not proved such large 
quantities as safe. 
DOES THE ADDED VITAMIN K IN OLESTRA AFFECT PATIENTS RECEIVING 
WARFARIN THERAPY?  
Moderate intake of olestra does not seem to affect patients who are receiving long-term 
warfarin therapy despite the added Vitamin K in olestra (Beckey et al. 1999; Holbrook et al. 
2005). 
ARE THE STUDIES THAT WERE REVIEWED BEFORE FDA APPROVAL 
COMPANY-BASED OR OTHERWISE RESEARCHED?  
Petitioners must show the FDA proof of safety; the FDA does not have its own 
allocated funds for independent evaluation. Thus, the research is provided by the petitioner 
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seeking to get the additive approved (Nestle 1998). This addresses question three above: were 
the “competent scientists” company based?  
IS OLESTRA’S INTENDED FUNCTION OF USE, WEIGHT LOSS, LIKELY? 
There is mixed data regarding whether or not substitution of olestra for fat will result 
in weight loss or gain of weight. In theory, substitution of a higher caloric product with a 
lower caloric product would result in fewer calories consumed, and thus weight loss over the 
long term. Studies have demonstrated that when subjects consume lower-calorie, yet similar-
appearing (portion-wise) meals, they do consume fewer calories from their meals (Bell and 
Rolls 2001). If one can consume the same serving size of a lower-calorie product and thereby 
save oneself over fifty calories per serving, thousands of calories per month, and possibly tens 
of thousands per year duration can theoretically be saved(Rolls and Bell 1999). In practice, 
however, this is may not be the case because consumers may compensate for their caloric 
deficits or consume more because they feel that it is a “diet” product.  
The FDA approved olestra in 1996. Perhaps by examining the studies done prior to 
the approval date, a better analysis of the limited data available to the FDA can be obtained. 
 STUDIES PRIOR TO OR DURING OLESTRA’S APPROVAL 
In a study conducted in 1994, researchers found that when lean males were fed 55 
grams of sucrose polyester (far more than the FDA approved) during meals or throughout the 
day, they did not consume more during subsequent meals or throughout the following day. 
Hence, the males consuming sucrose polyester, as compared with those consuming 
triglyceride consumed a reduced total fat and energy intake over the 2-day study. There were 
no reported increases in hunger ratings (Burley et al.1994).In a subsequent study the same 
group fed their experimental groups of lean males the same 55 grams of sucrose polyester to 
replace triglyceride, but this time replacing it specifically at lunch or evening meals. The 
results were consistent with those from the previous study; energy intake and subjective 
hunger ratings (both following the meal and during the next day) of those consuming sucrose 
polyester were not significantly different from the control group consuming triglyceride. 
Again, this resulted in a decreased energy intake over the 2-day study (Cotton et al. 1996a). 
Other studies, such as the two studies done by Hulshof et al. (1995a and b), one by feeding 
normal weight adults buttered croissant preloads after a duration of food-deprivation which 
ranged from .25-4.75 hours and one by giving subjects high-carbohydrate preloads, seemed to 
agree that, when fat is replaced by a polyester substitute, a caloric deficit (and thus eventually 
potential weight loss) would result. 
A study performed in weanling pigs, an animal with a GI tract similar to small 
children, suggested that olestra is not absorbed in children (like adults) (Dahler et al. 1996). 
Young children, however, do seem to compensate for the caloric deficit created by 
substituting full-fat foods for olestra-containing counterparts. In a 1993 study, 29 small 
children (ages 2-5) were studied to determine the compensatory effects of consuming olestra. 
The children were fed diets of either 10% fat or 10% non-fat triglyceride substitute. Children 
who consumed fat-substitute wound up consuming more on a subsequent day and the total 
energy intake difference was only approximately 100 kJ(kilojoules) over 2 days. Children 
adjusted their energy intake to replace the energy deficit from consuming the fat substitute 
rather than actual fat. Therefore, the use of fat-substitute did not produce a noticeable caloric 
deficiency in these children(Birch et al.1993).Eldridge et al. (2002)propose a rationale for this 
compensation: “Young children may regulate energy intake more precisely because of their 
high energy demands relative to body size. Food consumption in children may also be 
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influenced more by physiological factors than in adults in whom external factors may play a 
greater role.” Nonetheless, the same principle is evident when olestra is fed to another group 
requiring high-energy needs per kg of body weight: lean young men. Apparently, it is not only 
children, but also other groups with higher caloric needs, that compensate calories lost by a 
higher consumption later on. Other authors reported that when olestra was substituted for 
fats in diets of lean men, the subjects completely counteracted the effect of the non-caloric 
replacer they were fed (namely, it created an energy deficit) and consumed more, balancing 
the energy intake to match the subjects who consumed the full-fat energy counterparts over 
course of the study (Rolls et al. 1992). This addresses question five (5) of this paper—the 
FDA would not have had to place targeted group warnings to those who would experience 
adverse effects from caloric reduction because the members of these subgroups compensate 
for the imposed caloric deficits.   
STUDIES FOLLOWING OLESTRA’S APPROVAL THAT MAY HAVE AIDED THE 
FDA HAD THEY BEEN AVAILABLE EARLIER 
In a long-term study (9 months) performed by Bray et al. (2002) on overweight and 
obese men, subjects randomly received either a diet of 33% fat (diet A), a diet of 25% fat (diet 
B), or a diet of 25% fat plus 8% of their diet from a fat substitute (diet C). Diet C contained 
the palatability of enough fat equivalent to Diet A. Essentially, although it appeared to the 
subjects given Diet C that they were consuming the amount of fat present in Diet A, they 
were actually consuming a fat percentage resembling that of diet B, yet due to the presence of 
fat-substitute, made the fat content appear (or taste) larger than it actually was. Diet A serves 
as the control in the study; diet B mimics a traditional low-fat diet whereby fat content is 
reduced by 8% of total daily caloric intake, and diet C resembles the traditional diet but is 
actually reduced fat.  While subjects of all groups were required to consume their diets, all 
groups were entitled to consume more of fixed-composition foods if desired. All groups lost 
weight over the first three months of the study, but over the next six months, members of the 
control (diet A) maintained the weight they reached after the three weeks, members of diet B 
(the low-fat diet without substituted olestra for the missing fat content) regained some weight 
and those consuming Diet C (the low-fat diet plus olestra to substitute for the fat) continued 
to lose weight (Bray et al. 2002). This study, although done after olestra was FDA approved, 
seems to indicate that over the long-term, when olestra replaces a portion of the diet’s fat 
content, weight loss results.  A similar study performed on women displayed that when 
subjects have access to products which are normally restricted on diets (such as olestra-
containing potato chips) they feel less deprived and are more likely to comply with their diets 
(Bolton et al. 1996).    
How would olestra’s possible compensatory mechanism differ when olestra is found in 
liquids? Rolls et al. (1992) conducted a study whereby creamed soup (high-fat and non-fat 
(made with olestra)) was fed to subjects.  This study was done on both normal-weight and 
obese-weight subjects and follow-up intake (the next meal) did not differ. Consequently, those 
consuming olestra-containing soup consumed a lower energy level over the course of the 
study, indicating that olestra consumption in liquid form does not promote compensatory 
overeating.  
In another study, in groups of both normal weight and obese people of both genders, 
researchers substituted a tenth of some of the subjects’ diets’ fat at breakfast and dinner with 
olestra while some consumed traditional triglyceride. These results concur that total energy 
and fat intake was lower for subjects consuming olestra rather than triglyceride because, 
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although subjects did compensate for a percentage of the caloric deficit they assumed when 
consuming olestra, they nevertheless did not compensate for the total caloric reduction (Hill et 
al.1998). 
Some presumed that the availability of a fat-free potato chip product would translate 
into a belief for consumers that they can eat as much as they desired without consequences. 
Because olestra provides no energy, foods made with olestra are considerably less energy 
dense than the full-fat options or other reduced-fat alternatives in which fat energy is 
substituted with carbohydrates.  “There are concerns that consumption of reduced-fat foods, 
such as olestra, can lead to unrestrained eating if consumers believe these foods are calorie 
free. There is some research that consumers do not substitute equal amounts of high-fat with 
reduced fat foods; but rather, they may eat larger portions of reduced fat products.” (Satia-
Abouta et al. 2003)      
Many worried that consumers would use the availability of fat-modified food products 
as a rationale to eat more of the reduced-fat food; they may falsely assume that it won’t 
significantly affect weight-gain (Rolls and Miller 1997).  In 1998, The American Journal of 
Clinical Nutrition published a study designed to test whether the knowledge that a product is 
fat free would result in more chips consumed by subjects. Ninety-five subjects were divided 
into groups of those informed about the fat-free product and those uninformed.  The results 
demonstrated that indeed, along with knowledge that a product is “dietetic,” comes a desire to 
consume more of that product. Unrestrained subjects consumed significantly larger amounts; 
however, because the product was lower in fat and calories, they consumed fewer calories as 
compared with the full-fat chip eaters (Miller 1998). This study seems to indicate that the 
FDA’s approval would be worthwhile. Yet it’s important to note the side effects encountered 
during the study among those consuming fat-free chips. The author states “There were no 
significant differences in the occurrence of illness or malaise related to the consumption of the 
two types of potato chips” (Miller 1998). This may have been the case when referring to 
headaches, cold, and flu symptoms, but there were five complaints of menstrual discomfort 
and eight reports of vertigo and dizziness from those consuming fat-free chips and no 
complaints for those consuming regular chips. Additional studies may be in order to determine 
if olestra is a potential cause for these symptoms.  None of the effects or symptoms hindered 
subjects from continuing to participate in the study. Thus, although they may have been 
present, they were probably not very severe. Also, because the study was only ten days in 
length, it is not known if there are any long-term side effects. The study found: “No significant 
changes in body weight occurred in any group as a result of consuming either type of potato 
chip over the 10-d periods.” This seems odd considering the fact that those consuming fat-free 
chips were ultimately consuming fewer calories from the chips. It is possible that the caloric 
savings were modest, and thus the product was not eaten over a long enough duration for the 
net calorie savings to appear as pounds lost (or not gained as compared to those eating regular 
chips)and that that changes in weight would have become apparent had the study continued 
over a longer period of time. It is also possible that the subjects were compensating the 
calories saved due to a stimulated appetite or subsequent hunger caused by the fat-free chips 
(in a similar mechanism to aspartame and other macronutrient substitutes). In either case, the 
study demonstrated that at least, over the short term, no significant weight loss results from 
the substitution of olestra in chips for fat and that indeed, consumers compensate the amount 
and eat more when aware that the product contains fewer calories (Miller et al. 1998).  
In a study designed to measure the relationship between olestra consumption and 
changes in dietary intake, serum lipids, and body weight, participants were required to fill out 
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a thorough food questionnaire; researchers characterized subjects according to both weight 
and olestra intake. Subjects were “normal weight,” “overweight,” or “obese” and either had no 
olestra intake (0g/d), very low intake (0-.4g/d), low intake (.4-2g/d), or moderate/high intake 
(2 or more grams daily). In one ounce of a snack food containing olestra, there are eight 
grams of olestra, and thus those were classified as “moderate/high intake.”  This group was 
eating only one quarter or more of a serving per day, which essentially translates into only five 
chips per day. Only two percent of the sample fell into the high intake category. The sample 
included fewer than 1200 participants; thus, no more than twenty-four participants were 
considered to consume high intakes of olestra. As compared with a baseline clinic visit (before 
olestra had entered the market), carbohydrate intake increased by 37g/d and total energy 
increased by 209 kcal/day among high olestra consumers. Among non-olestra consumers, 
however, a decrease of 87 kcal/day and a carbohydrate intake decrease of 14 g/d were evident.  
The researchers concluded that there was no statistically significant relationship between the 
amount of olestra consumption and serum lipids or body weight. The article attributes the 
lack of significant findings to “the study sample [which] limited the ability of this study to 
detect significant effects” (Satia-Abouta 2003). 
These findings, however, cannot be taken at face value; BMI, and, correspondingly, 
weight (since BMI is essentially a height-weight ratio),is not the most accurate measure of 
one’s body fat (Burkhauser and Cawley 2008). Indeed, there are a number of factors, 
unrelated to body fat, which may affect a person’s weight, and thereby affect his/her height-
weight ratio, and therefore his/her BMI. For example, salt may cause a person to retain more 
water (Kumar and Berl 1998), making his/her body a heavier weight. Because the researchers 
only measured body weight, and not body fat, it cannot be assumed that excess body fat 
accompanied the excess weight gained from participants who consumed the chips. Yet this 
water-weight is short-lived and will disappear thereafter. Particularly because olestra is used 
for heavily-salty snacks, consumption of olestra would translate into increased sodium 
consumption as well. Thus, water retention may have caused the weight gain experienced by 
people in the study, and not the fat-substitute, olestra.      
There is also concern that olestra may adversely affect those with binge-eating 
disorders: “Clinical experience has shown that persons with bulimia and other binge-eating 
disorders are increasingly using fat-free foods during binge episodes. Because persons with 
bulimia are frequently mortified by their abnormal eating behavior, the use of fat-free foods 
allows them to feel less guilt and provides some self justification [sic] for their behavior 
because they are bingeing on “healthful” foods” (Hampl and Sheeley 1998).  In fact, to some 
bulimic people, the after-effects of consuming olestra may be considered a form of purging, as 
many Americans perceive olestra to have a laxative effect. (Hampl and Sheeley 1998).  
Apparently, this idea is believed, despite the fact that research results from a study have stated 
otherwise (Peters et al. 1997). Regardless of whether or not this concern is an accurate one, 
this prediction only became apparent after the FDA approved olestra, and hence, even if true, 
would not have been available to deter the FDA from allowing it to pass. More research is 
required in order to make definite claims for the possible danger of the binge-eating 
disordered population with olestra on the market.    
Cotton et al. found that, in general, the lower the percentage of fat in the diet 
remaining after the replacement of triglyceride with olestra, the more likely caloric 
compensation will occur(Cotton et al. 1996b). Therefore, modest substitutions of fat in the 
diet would result in lower compensation and greater likelihood for weight loss.  
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In a post marketing surveillance study (Patterson et al. 2000), heavy consumers of 
olestra (consuming more than 2.0g/d) had experienced a minor weight loss effect (.55 
kg/year) as compared with an even smaller weight-loss effect for those who were non-olestra 
consumers (.01 kg/year). In this study, olestra and weight loss seem to be insignificantly 
correlated. In fact, this serves to underscore the fact that, even with a large replacement of fat 
for olestra, large weight loss reduction does not necessarily result. Obviously, because this is 
merely a surveillance study, little is known about the people’s eating habits excluding olestra. 
It is possible that consumers of olestra ate more calorie-dense foods, and thus olestra did not 
cause weight loss despite a significant caloric reduction. Also, it is possible that those who do 
not consume olestra do not eat regular chips either and are generally more health-conscience. 
In sum, data on weight loss of olestra presents conflicting results from other studies. 
There is no reliable conclusion that can be drawn from the plethora of diverging statements 
and conclusions. 
REITERATION OF ANSWERS TO THE EIGHT QUESTIONS ABOVE:   
To recapitulate the answers to the eight questions posited: (1) Olestra can be 
potentially hazardous to the health of man or animal if consumed in amounts higher than 
those established as the toxicity level by the FDA. (2) The scientists whom the FDA used to 
evaluate olestra were company based. (3) A case-by-case analysis of individual studies was 
conducted throughout the research paper.(4) No conclusive statements can be made about 
olestra’s cause of weight loss (or lack thereof). (5)Olestra’s possible weight loss effect does not 
endanger subgroups that would be threatened by caloric deficiency because compensation 
occurs in groups who need the calories to maintain and/or gain weight. (6) Olestra seems to 
cause other benefits of weight loss such as lowering LDL cholesterol level and lowering serum 
triglyceride level when consumed in amounts greater than those stated as safe by the FDA. 
(7) Olestra’s vitamin K addition, when olestra-containing products are consumed within FDA 
allowed amounts, does not interfere with warfarin therapy. (8) When consumed within FDA’s 
proposed limits, olestra does not significantly interfere with lipophilic drugs. 
CONCLUSION AND DISCUSSION 
 In light of the fact that FDA only approved olestra in the amount of approximately 18 
grams or fewer per day, and in acknowledging that no statistically significant harmful data 
resulted from studies testing such small amounts of olestra, it is clear that the FDA did do a 
thorough assessment of the product when calculating the allowed amounts for consumption 
during data review. However, there seems to be a considerable mismatch between the amount 
of olestra the FDA approved for safe consumer use and what’s actually being promoted as a 
safe limit and consumed. The stated serving size on a package of olestra-containing Lay’s 
Light chips contains the amount of olestra that exceeds the amount approved by the FDA as 
safe. Moreover, in many of the studies reviewed (particularly those which resulted in side 
effects), it is clear that some people consume far more than one serving of chips. In order to 
avoid future side-effects experienced from olestra, there should be an emphasis placed on 
clearly informing the public of just how much olestra-containing product is at the safety level.  
Thus, better communication is vital in order to avoid potentially hazardous results.  
Some may argue, due to much inconclusive or hazily concluded research (particularly 
papers stating that more research is necessary before making any claims), that olestra had 
been approved prematurely to obtaining assurance of the product’s safety. While it is true that 
numerous studies have been conducted since olestra’s approval which may have shed more 
light on this controversial product, the FDA may have had to weigh the possibilities of 
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damaging effects that might have emerged from a study conducted later against a glaring 
negative consequence of the delay—a possible increase in obesity that could have been 
lessened if olestra had been approved earlier.  This is especially salient, as research bringing 
clear results may have taken a very long time to conduct; in fact, conclusive data from long-
term studies and determination of effects are still underway. 
While it is true that the FDA perhaps did approve olestra hastily and should have 
waited a bit longer until more published studies indicated the harmfulness (or lack thereof) of 
the product, it is important to remember that it is not the FDA’s job to be assured of consumer 
safety; they merely have to possess a reasonable certainty that a product does not cause harm. 
From the data, indeed there was a reasonable certainty. At a later date, when conclusive data 
can be drawn from the multitudinous conflicting opinions and study outcomes, the FDA can 
reassess and once again determine whether olestra’s market circulation is appropriate for the 
general population and the safety of the American consumer. 
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All living organisms, including humans, require nutrients 
in order to survive. The way our bodies absorb these nutrients is 
through the digestive system. This occurs when the swallowed 
bolus travels through the esophagus to the stomach. From the 
stomach it travels to the small intestine, then to the large 
intestine, and it is then excreted via the rectum.  
The question is: how does the body break down the large 
food particles into the nutrients we need? The answer to this is 
the stomach. Composed of a muscular bag, the stomach breaks 
down large food macromolecules. Food is released into the 
stomach via the lower esophageal sphincter (LES), a round 
muscle that controls the entrance to the stomach. Acid, released 
by the parietal cells of the stomach, breaks down the food into their nutrient components. The 
parietal cells release H+ and Cl- via a protein pump. These ions combine in the lumen of the 
stomach (otherwise they would destruct the parietal cells themselves) and form hydrochloric 
acid (HCl), giving the stomach a pH of ~2. The acid helps break down the food into smaller 
molecules. The stomach lining is protected by a mucus sheath secreted by mucus cells in the 
stomach lining. In addition to this, cell division replaces the stomach lining every three days 
(Campbell and Reece 2008).      
This mixture of acid and food known as acid chyme cannot be excreted, as the acid 
would burn through the lining of the intestinal walls. In order to bring the pH back towards a 
neutral 7, the liver and pancreas come into effect, secreting different molecules into the small 
intestine. The liver makes bile salts that are stored in and secreted from the gallbladder. These 
salts function as buffers that resist the change in pH. The pancreas secretes bicarbonate 
(HCO3
-). Together, these secretions work to bring the pH level back up towards neutral 
(Pepitone 2010).  
There are many well-known disorders associated with the digestion process, the most 
common of which is gastroesophageal reflux disease, more commonly known as GERD. 
There are six major factors that are the primary cause for GERD: impaired      esophageal 
motility, defective mucosal defense, lower esophageal sphincter (LES) dysfunction, reflux of 
gastric contents, delayed gastric emptying, and hiatal hernia (DeVault and Castell 1999). 
Impaired esophageal motility occurs when the esophagus has trouble moving the food down 
and normal peristalsis does not occur. Defective mucosal defense can cause irritation to the 
esophagus, eliciting a burning sensation as the acid makes its way past the mucosal defense. 
Lower esophageal sphincter (LES) dysfunction is when the esophageal sphincter does not 
close properly and allows acid chyme to flow back up the esophagus. Reflux of gastric 
contents is similar to LES dysfunction; however, the movements and convulsions of the 
stomach play a major role. Delayed gastric emptying causes a back up in the stomach, which 
can lead to a greater chance of reflux as well as upper abdominal pain (Lewis et al. 2007).      
“Hiatal hernia occurs when the upper part of the stomach moves up into the chest through a 
small opening in the diaphragm….Some doctors believe a hiatal hernia may weaken the LES 
and increase the risk for gastroesophageal reflux” (Nazario 2009). 
Figure 1: The Digestive 
System. Source: 
www.health.com 
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The symptoms of GERD vary depending on the individual. The most common adult 
symptoms are pyrosis, regurgitation, non-cardiac chest pain, and trouble swallowing 
(dysphagia).  
Pyrosis, commonly referred to as heartburn, is described as a “burning, tight sensation 
that is felt intermittently beneath the sternum and spreads upward to the throat or jaw” 
(Lewis et al. 2007). Pyrosis occurs when any of the six factors that can cause GERD disrupt 
the normal digestive system.  GERD then causes an inflammation in the chest, giving a 
burning sensation.    
Regurgitation, another sign of GERD, usually occurs due to the buildup of undigested 
food near the LES. Due to the inability of digesting these food particles, the body rids itself of 
them by vomiting up the undigested food. 
Dysphagia, or the inability to swallow, is a more complex problem then it may appear. 
“Patients are at a high risk of aspiration due to food or liquids going the wrong way into the 
lungs” (Logemann 1998). Dysphagia can also result in dehydration, malnutrition, and renal 
failure. Some symptoms of dysphagia include the inability to control food or saliva in the 
mouth, difficulty initiating a swallow, coughing, and choking. The most common symptom of 
dysphagia is the inability to swallow food, which the patient will describe as 'becoming stuck' 
or 'held up' before it either passes into the stomach or is regurgitated (Logemann 1998).                             
The symptoms of GERD in children are different than those of adults. Children with 
GERD may have any one or more of the following: colic-like symptoms, excessive vomiting, 
bad breath, refusal to eat, swallowing problems, excessive burping after nursing, nighttime 
coughing.  Although most babies have the GERD symptom of mild vomiting, commonly 
known as ‘spitting up,’ most of them will outgrow it once they get a few months older and are 
able to sit up properly. Pediatric GERD is also a common cause of weight-gaining problems 
in infants (Winter 2008). 
GERD can also cause some lesser common diseases. Among them are diseases such as 
Barrett’s esophagus, esophageal ulcers, esophageal 
adenocarcinoma, erosion of teeth enamel, and esophageal 
strictures.  Although these diseases are less common, their 
severity is not lessened by their rarity (Lewis et al. 2007). 
 Barrett’s esophagus is usually caused by chronic 
reflux but is also sometimes caused by ingesting a corrosive 
substance. The acid in the reflux damages the columnar 
epithelium 




of cells is called 
“premalignant,” 
because, although they are not cancerous 
themselves, they significantly raise the risk 
of esophageal cancer. Barrett’s esophagus 
has other symptoms that evolve from the 
changed tissue, including chronic heartburn, 
trouble swallowing (dysphagia), 
Figure 2: Barrett’s esophagus. 
Source: www.medscape.com 
Figure 3: Change in Epithelial Tissue due to Barrett’s 
Esophagus. Source: www.mayoclinic.com 
Normal Cells 
Low-Grade Dysplasia or 
Pre-Canerous Cells 
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regurgitating blood, noncardiac-related pain, and weight loss (Mayo Clinic 2011). 
 Another complication that GERD causes is 
the formation of ulcers. An ulcer is an erosion of a mucus-
covered membrane and, if in a highly acidic area, can be very 
painful.  An esophageal ulcer is a hole in the lining of the 
esophagus corroded by the acid chyme refluxed back up 
through the LES. Esophageal ulcers are usually located in 
the lower section of the esophagus, which is closer to the 
LES. Esophageal ulcers cause pain that is felt behind or just 
below the sternum, similar to heartburn symptoms. Chronic 
and severe recurrences of esophageal ulcers can cause 
esophageal strictures, a narrowing of the esophagus after the 
thicker scar tissue layer forms. Symptoms of esophageal 
ulcers can include heartburn, inflammation of the esophagus, 
the vomiting of black or bright-red-colored blood, and 
bloody or tarry foul-smelling stool (due to oxidized iron from 
hemoglobin) (Sameul 2008). 
     GERD can also cause esophageal adenocarcinoma, a form 
of esophageal cancer. Most commonly occurring in Caucasian men 
over the age of 60 (Chou and Gress 
2006), adenocarcinoma comes from 
glandular cells at the junction of the 
esophagus and stomach, right above 
the LES. The most dangerous aspect of 
this disease is that most people 
diagnosed with esophageal cancer are 
already in the later stage of the disease. 
This is because significant symptoms 
do not usually appear until half of the 
inside of the esophagus is obstructed, 
by which point the tumor has already grown big. Because of 
this, in some severe cases, parts of the esophagus are removed 
due to the spread of the cancerous cells. Another problem of 
late recognition is that the cancer can spread and infect the rest 
of the body, spreading the disease to the entire digestive 
system, including the liver and pancreas. However, under 
chemotherapy, the tumor may shrink enough for it to be 
removed in a standard operating procedure.  The risk of 
esophageal cancer is much higher for a patient with Barrett’s 
esophagus. This is because Barrett’s esophagus changes the 
tissue in the esophagus to a pre-malignant stage (Mayo Clinic 2011). 
The symptoms of esophageal adenocarcinoma vary greatly depending on the severity 
of the disease. Among the most common symptoms are: dysphagia (difficulty swallowing), 
odynophagia (painful swallowing), substantial weight loss (due to reduced appetite and poor 
nutrition), pain (usually a burning, heartburn-like feeling), husky, raspy, or hoarse sounding 
cough, (as a result of the tumor obstructing the airway).  The presence of the tumor may 
disrupt normal peristalsis of the esophagus, leading to nausea, vomiting, coughing, and a 
 
Figure 5: Esophageal cancer 
(A) with corresponding barium 
swallow x-ray (B) and 
endoscopic view (C). Source: 
disease-picture.com 
 




Figure 4 Esophageal Ulcer. 
Source: stomach-ulcer-
symptoms.com 
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feeling of ‘something stuck’ in the throat. If the ability to swallow becomes too restricted, a 
stent can be surgically placed in the esophagus. The stent widens the esophagus, easing 
swallowing (Lewis et al. 2007).!!!!! 
Another side effect of GERD is the erosion of dental enamel. The main mineral of 
enamel is hydroxylapatite, which is a crystalline calcium phosphate. High acidity levels in the 
mouth allow bacteria to thrive and enter into the crevices of the enamel, causing cavities. 
GERD plays a major role in the pH level of the mouth. Usually the alkalinity of the saliva 
alone is enough to counter and neutralize the ingestion of acidic products. However, when a 
patient suffers from GERD, the acidity level in the mouth becomes much greater and 
overpowers the basic saliva. This usually occurs at night when the patient is sleeping in a 
supine position and the acid chyme is able to make it all the way back up into the oral cavity 
(Fried 2010). 
The erosion of enamel is very serious because as the enamel continues to become less 
mineralized, it is unable to prevent the encroachment of bacteria, and the underlying dentin 
becomes affected as well. When dentin, which normally supports enamel, is destroyed by  
decay, enamel is unable to compensate for its brittleness and breaks away from the tooth 
easily. This leads to the complete destruction of the upper layers of the tooth, requiring either 
a replacement crown or a dental implant (Fried 2010). 
The chronic occurrence of GERD can cause esophageal strictures. Esophageal 
strictures are when the esophagus narrows, 
making it hard to swallow. If a person 
suffers from GERD, the acid reflux 
inflames the esophagus. When the 
esophagus heals, scar tissue grows thick to 
prevent reoccurrence. This causes the tissue 
to pull and tighten, which can lead to 
difficulty swallowing. During healing, a 
change in texture of the esophagus also 
occurs. Instead of consisting of very soft 
tissue, the strictures cause the walls of the 
esophagus to harden. This can cause severe 
pain when swallowing (Logemann 1998). 
Figure 7: Tooth Erosion. Source: www.colgate.com 
Figure 8: Esophageal Stricture. 
Source: www.medscape.com 
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Esophageal strictures may also be cancerous. As 
mentioned above, (see Barrett’s esophagus) the change in 
the tissue of the esophagus can spread and infect other cells 
and cause those cells to become cancerous. Symptoms of 
esophageal strictures include heartburn, choking, coughing, 
shortness of breath, frequent burping and hiccupping, a 
bitter or acidic taste in the mouth, pain or trouble 
swallowing, the vomiting of blood, and unintentional weight 
loss (Drugs.com 2011).   
There are a few major ways in which a doctor can 
diagnose a patient with GERD. Among the most commonly 
used methods are esophageal pH monitoring, X-rays 
(barium swallow), esophagogastroduodenoscopy (EGD), 
and esophageal manometry.  
Esophageal pH monitoring measures the acidity level in the esophagus. The latest 
technological way to test the pH involves the use of a Bravo pH monitor.  The procedure of 
the Bravo capsule is as follows:  
You will be asked to sit or lie back while the physician places the capsule into the 
esophagus. After the capsule is in place, suction is applied, drawing a small amount of tissue 
into the capsule. The capsule is then locked into place. The placement procedure is simple to 
perform and well tolerated by most patients. The capsule begins measuring the pH levels of 
the esophagus immediately, transmitting pH measurements wirelessly to a small receiver worn 
on your waistband or belt. The receiver houses three symptom buttons, and you will be asked 
to press the corresponding button when you experience heartburn, regurgitation, or chest 
pain during the procedure… The disposable capsule will spontaneously detach and pass 
naturally through a bowel movement a few days after the test (Given Imaging). 
Figure 9: Esophageal Stricture. 
Source: www.hopkins-gi.org 
Figure 10: Esophageal pH monitor. 
Source: www.givenimaging.com 
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A physician may also utilize X-rays to determine if the patient has GERD. The patient 
is first given a radio contrasting solution that improves the visibility of internal structures. The 
most commonly used radio contrast for this procedure is 
barium sulfate. Barium sulfate is insoluble when mixed 
with water, and in the X-ray, reveals the internal structures 
in a cloudy white color. The X-ray can reveal the 
movement of acid chyme backing up toward the esophagus. 
Although barium is a heavy metal, and its water-soluble 
compounds can be highly toxic, the low solubility of barium 
sulfate protects the patient from absorbing harmful 
amounts and is secreted out of the body along with regular 
fecal matter (Lerner 2003; Fallon and Shratter 2012) 
Another way a 
doctor may test for 
GERD is with an 
esophagogastroduoden
oscopy (EGD). More 
commonly referred to 
as an endoscopy, it is a 
15-20 minute, 
minimally invasive 
procedure that images 
the esophagus. Endoscopy involves passing an 
endoscope, a long, flexible black tube with a light and 
camera on the end, through the mouth to examine the 
esophagus, stomach, and small intestine. The camera 
sends a live feed to a monitor. In some cases a biopsy may 
be taken together with an endoscopy. The biopsy usually 
takes a small sampling of 1 to 3 mm of tissue from the 
esophagus via a forceps inserted into the endoscope. The 
sample is then sent to a laboratory for further histological testing. There are some possible 
complications with an endoscopy, such as the possibility of tearing the esophagus or stomach. 
However, the procedure has less than a 1 in 1000 chance of a serious complication occurring 
(Barrettsinfo.com). 
Esophageal manometry is another method for 
determining if a patient has GERD. A manometry is used 
to determine if the peristalsis of the esophagus is 
functioning correctly. During an esophageal manometry, 
a thin, pressure-sensitive tube called a catheter is passed 
through the mouth into the stomach. Once in place, the 
tube is pulled slowly back into the esophagus. When the 
tube is in the esophagus, the patient will be asked to 
swallow. The pressure of the muscle contractions are 
measured along several sections of the tube. The data is 
graphed by a computer, and the results show the 
peristalsis of the esophagus. Abnormal peristalsis can be a 
determining factor in diagnosing a patient with GERD 




Figure 12: Endoscopy Procedure. 
Source: www.barrettsinfo.com 
Figure 13: Esophageal Manometry 
Graph. Source: www.ctsnet.org 
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(Longstreth 2011). 
There are various treatments a doctor can use to treat a patient with GERD. There are 
three general categories of treatments: medication, life style changes, and surgery.  There are 
five main classes of drugs a doctor prescribes for GERD: H2 receptor blockers, H
+ pump 
inhibitors, antacids, foaming agents, and prokinetics. 
H2 receptor blockers work by acting as anti-histamines at the H2 receptors. This 
suppresses the acid secretion, which reduces gastric juice volume, decreasing reflux 
reoccurrence. A few common H2 receptor blockers are cimetidine (Tagamet®), famotidine 
(Pepcid®), nizatidine (Axid®), and rantidine (Zantac®) (HealthCentral.com). 
Doctors also prescribe H+ pump inhibitors. H+ pump inhibitors prevent the secretion of 
H+ ions from the parietal cells. This slows the formation of hydrochloric acid in the lumen of 
the stomach, effectively raising the pH in a short period of time. H+ pump inhibitors include 
esomeprazole (Nexium®), lansoprazole (Prevacid®), omeprazole (Prilosec®), pantoprazole 
(Prononix®), and rabeprazole (Aciphex®) (Cohen 2007; Lewis et al. 2007). 
Antacids are another category of treatment used to relieve GERD. Antacids neutralize 
gastric acid by acting as buffers to help raise the pH, reducing acidity in the stomach. 
Although some antacids were found to actually raise the pH level in the stomach, all antacids 
reduced acidity in the lower esophagus, relieving the symptoms of GERD. Antacids also 
promote ulcer healing and reduce reoccurrence. There are two types of antacids: absorbable 
and non-absorbable. Absorbable antacids usually contain sodium bicarbonate (NaHCO3) or 
calcium carbonate (CaCO3) and undergo complete neutralization. The most common 
absorbable antacids are Alka-Seltzer® (NaHCO3), Maalox tablets® (CaCO3), and Tums® 
(CaCO3). Among the most common non-absorbable antacids are Maalox liquid® (Al(OH)3 
and Mg(OH)2), Mylanta® (Al(OH)3), and Milk of Magnesia® (Mg(OH)2). Another 
common antacid is Pepto-Bismol® (C7H5BiO4) (Brown et al. 2006).      
Both classes of antacids share common side effects in addition to their individual side 
effects. A common shared side effect is a problem with reduced acidity, which results in the 
inability to digest and absorb essential nutrients. Low acidity can also lead to infections; high 
acidity usually kills ingested bacteria, so when the pH becomes more basic, bacteria are able 
to survive. Too much absorbable antacid consisting of sodium (Na) can increase blood 
pressure as well as cause kidney disease. High levels of carbonate (CO3) can cause kidney 
stones, and the high level of CO2 output can distend and stretch the intestinal walls. Although 
the side effects of non-absorbable antacids are fewer, high levels of Mg(OH)2 can lead to 
hypermagnesium, causing cardiovascular and neurological complications. An excess amount 
of Al(OH)3 can cause formation of insoluble Al(PO4) complexes, leading to decreased 
phosphate levels in the blood (Decktor et al. 1995).  
A doctor may also suggest the use of foaming agents to relieve GERD. Foaming agents 
coat the stomach and esophagus, preventing the acid chyme from reaching the mucosal layer. 
Common foaming agents include Gaviscon® and sucralfate (Carafate®) (NDDIC 2008). 
Another treatment for GERD involves the use of prokinetics. Prokinetics are drugs 
that increases the frequency of contractions in the small intestine, thereby making them 
stronger. Prokinetics also assist in strengthening the LES, and helps empty the stomach 
faster. Metoclopramide (Reglan®) and bethanechol (Urecholine®) are the two most common 
prokinetics (Lewis et al. 2007). 
Instead of drugs, or in addition to them, doctors also recommend various life style 
changes to prevent reoccurrences of GERD. Doctors suggest changes that lower the chance 
of reflux. These include, but are not limited to, eating smaller meals, sleeping with the head 
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raised, wearing looser clothing to relieve stomach pressure, losing weight to reduce intra-
abdominal pressure, quitting smoking  in order to increase the LES’s competence, and 
avoiding foods known to cause reflux, including fatty foods, chocolate, peppermint, caffeine 
products, alcohol, and acid based products (NDDIC 2008; Eckstein 2012). 
In the most serious of cases, when a hiatal hernia or esophageal stricture is involved, 
and if conservative therapy fails, surgery may be recommended. The surgery is referred to as 
a Nissen fundoplication. During the surgery, the upper section of the stomach is wrapped 
around the LES in order to strengthen it. Nissen fundoplication is a minimally invasive 
surgery known as a laparoscopy, which decreases complications and the overall cost of 
hospitalization (Lewis et al. 2007).      
Endoscopic radiofrequency is another procedure used. “During this procedure a 
balloon-tipped four-needle catheter, called a Stretta device, delivers radiofrequency energy to 
the smooth muscle of the LES. The radiofrequency energy induces collagen contraction, 
which helps form a barrier against reflux” (Lewis et al. 2007).       
GERD is a common illness, affecting about a third of the American population, 
according to the International Foundation for Functional Gastrointestinal Disorders 
(IFFGD). In most cases it is easily manageable and with proper care, reoccurrence can be 
prevented. In the most severe cases, GERD may cause life-threatening illnesses such as 
esophageal adenocarcinoma. Doctors use various methods for diagnosing and treating 
patients.  Treatment may be as simple as life style changes or as complex as surgery. If one 
suspects that he or she is suffering from GERD, a competent medical doctor should be 
consulted.  
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ALTEPLASE: THE CLOT-BUSTER 
Mayer Goldberg 
INTRODUCTION: 
The human body is defined by many complex and inconsistent characteristics. For 
example, the body forms blood clots in traumatic events, but blood clots are likewise 
associated with hazardous or fatal conditions. Platelets are small cells, derived from the 
precursor megakaryocytes, which are responsible for blood clotting to prevent bleeding from 
a ruptured blood vessel. Platelets fasten to each other and release a coagulation factor that 
solidifies around the ruptured area to prevent blood loss. A subordinate quantity of platelets 
can result in excessive bleeding. However, high platelet numbers can progress into blood 
clots, which may potentially be dangerous because they produce a condition known as 
thrombosis. Thrombosis precedes harmful conditions such as stroke, myocardial infarction, 
pulmonary embolism, and other conditions associated with the disruption of circulatory blood 
flow.  
Depending on the severity of the condition, there are different treatments available for 
thrombosis.  Some patients may require surgery for an illness caused by thrombosis.  In other 
instances, there are thrombolytic or fibrinolytic drugs that can be used as medicinal therapy to 
dissolve blood clots. Thrombolytic drugs disintegrate blood clots by converting plasminogen 
into plasmin. The plasmin, a serine protease, actually does the blood clot dissolving. The most 
important thrombolytic drug categories include tissue plasminogen activator and 
streptokinase (Klabunde 2005). While there are two significant families of thrombolytic 
medications that can be utilized in thrombolytic therapy, alteplase, a recombinant tissue 
plasminogen activator, is the preferred medication for treatment of acute ischemic stroke, 
myocardial infarction with ST elevation, and, in some rare cases, pulmonary embolism. 
DISCUSSION: 
THROMBOLYTIC THERAPY FOR STROKE 
For approximately a decade, stroke has been the third leading cause of death in the 
United States following cardiac diseases and cancer. Roughly 137,000 Americans die from 
stroke every year (Center for Disease Control 2009). Since stroke can cause brain cell damage 
or cell death, patients often exhibit sudden numbness or paralysis of the face, legs, or arms. 
Thus, stroke is the primary cause of permanent disabilities. There are two general 
classifications of stroke: ischemic strokes and hemorrhagic strokes. 
ISCHEMIC STROKES 
 Almost 90% of strokes are ischemic strokes, caused by decreased blood flow to the 
brain (Swanson 1998b). Whenever normal blood flow to the brain is interrupted, the neurons 
begin to die within minutes. Since brain cells require oxygen for survival, and they acquire 
oxygen from red blood cells, they begin to decline in function (see figure 1).  There are two 
subcategories of ischemic strokes: thrombotic and embolic. A thrombotic stroke is caused by 
the formation of a blockage, thrombus, in one of the arteries supplying the brain with blood. A 
thrombus forms from arteriosclerosis, which is created by an accumulation of fatty deposits.  
An embolic stroke occurs when the body carries a blood clot from an alternate origination to a 
blood vessel in the brain. For example, atrial fibrillation in one of the two upper chambers in 
the heart can proceed to the formation of a blood clot that will travel elsewhere in the body. 
Thrombolytic drugs are utilized in ischemic strokes to bust open the thrombus or embolus. In 
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the 1980s, the first drug developed for the treatment of stroke was streptokinase, but this 
medication was abandoned after it caused unacceptable incidence of cerebral hemorrhage 
(Saver and Lutsep 1995). Alteplase was developed, and research found it to be a safer and 
more efficient choice for thrombolytic therapy in ischemic stroke patients. An alternate study 
showed the efficacy of alteplase administered to acute ischemic stroke patients up to four 
hours after the onset of symptoms. 
 
Patients were admitted or excluded from the alteplase clinical trial based on various 
elements. Some of the inclusion criteria for the acute ischemic stroke trial were the ability to 
have the study drug administered between 3 and 4.5 hours after the onset of stroke symptoms 
and the presence of stroke symptoms for at least 30 minutes with no significant improvement. 
Some rejection criteria were  intracranial hemorrhage, seizures at the onset of stroke, and 
serious head injury within the previous three months. For a complete list of selective and 
dismissive criteria see table 1(Hacke et al. 2008). 
A total of 821 patients enrolled in the trial and were randomly assigned to either the 
alteplase group or a placebo group.  The alteplase group had 418 patients, and the placebo 
group had 403 patients. Approximately 82 patients were administered the drug or a placebo 
between 3 and 3.5 hours, 384 patients obtained it between 3.5 and 4 hours, and 322 received it 
between 4 and 4.5 hours. Of the remaining patients, treatment time for 12 patients from the 
alteplase group and 15 patients from the placebo group were not obtainable. Additionally, one 
patient from the alteplase group and five patients from the placebo group were administered 
treatment after 4.5 hours. The trial result was a ratio of 41.6% to 36.7% in favor of the 
alteplase group.   Although the results indicated more symptomatic  intracranial hemorrhage 
Figure 1: Ischemic Stroke: The illustration shows how an ischemic stroke can occur in the brain. If a 
blood clot breaks away from plaque buildup in a carotid (neck) artery, it can travel to and lodge in an 
artery in the brain. The clot can block blood flow to part of the brain, causing brain tissue death.         
 Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_ischemic.jpg 
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in the alteplase group than in the placebo group, the overall outcome of the trial showed a 
more favorable result for the alteplase group in the 4.5 hours range.  This indicates that 
supplying alteplase intravenously can clinically better the condition of ischemic stroke patients 
up until 4.5 hours following the incipience of symptoms (Hacke et al. 2008).  
HEMORRHAGIC STROKES 
 Hemorrhagic strokes take place following a rupture or leak from a blood vessel in the 
brain (Figure 2). There are two subdivisions of hemorrhagic strokes: intracerebral 
hemorrhage and subarachnoid hemorrhage (Swanson 1998a). In an intracerebral 
hemorrhagic stroke, a blood vessel bursts causing blood seepage into brain tissue. The sudden 
increase in pressure within the brain can cause cellular damage. Furthermore, the brain cells 
beyond the ruptured blood vessel are damaged due to the interruption of blood flow and 
oxygen delivery. A subarachnoid hemorrhagic stroke is caused by leakage from a blood vessel 
into the space between the surface of the skull and the brain. Hemorrhagic strokes are not 
treated with thrombolytic therapy because of the major risk of further hemorrhaging. 
Source: Hacke et al. 2008 
Table 1: Major exclusion and inclusion criteria. 
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THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION 
 Major heart disease is the leading cause of death in the United States.  According to 
the CDC, nearly 48% of all deaths reported in 2010 were cardiac related. Heart attack, also 
known as acute myocardial infarction, happens when there is an interruption of the blood 
 
Figure 2: Hemorrhagic Stroke: The illustration shows how a hemorrhagic stroke can 
occur in the brain. An aneurysm in a cerebral artery breaks open, which causes bleeding 
in the brain. The pressure of the blood causes brain tissue death. 
 Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_hemorrhagic.jpg 
Figure 3: Heart with Muscle Damage and a Blocked Artery: Figure A shows a heart with dead heart 
muscle caused by a heart attack. Figure B is a cross-section of a coronary artery with plaque buildup and a 
blood clot. 
Source: http://www.nhlbi.nih.gov/health/dci/images/heart_coronary_artery.gif 
86 Mayer Goldberg 
 
flow to the heart, causing the cardiac muscles to die (Pub Med Health 2010a). Many heart 
attacks are caused by blood clots forming an obstruction in one of the coronary arteries, 
which carries blood and oxygen to the heart tissues. The blockage disrupts the oxygen flow to 
heart tissues, causing heart muscle cell death (Figure 3). Atherosclerosis, a principle cause of 
blockages, is the accretion of plaque that adheres to the coronary artery walls and forms an 
occlusion. The plaque may tear, and blood platelets may fasten to it forming a thrombus (Pub 
Med Health 2010a). A myocardial infarction (MI) can be classified as a non-ST elevation MI 
or an ST elevation MI based on electrocardiogram changes (Cleveland Clinic 2009). 
MYOCARDIAL INFARCTION WITH NON-ST SEGMENT ELEVATION 
A non-ST elevation MI does not exhibit changes on an electrocardiogram. 
Additionally, the extent of damage is minimal since the artery is only partially obstructed 
(Cleveland Clinic 2009). According to the American Heart Association, there is a close 
correlation between non-ST elevation MI and unstable angina. Unstable angina is a condition 
caused by a diminished supply of blood flow and oxygen to the heart; as research indicates, it 
can be an introduction to a heart attack (Pub Med Health 2010b). Non-ST elevation MI and 
unstable angina are treated by anti-platelet agents, anti-thrombin agents, or anti-ischemic 
agents (Jevon et al. 2008). Although the treatments for non-ST elevation myocardial 
infarction and unstable angina are similar, there is a different course of action taken for a 
myocardial infarction with ST elevation. 
MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION 
An ST-elevation MI is caused by the prolonged obstruction of blood supply that 
affects a large portion of the heart. Thus, ST segment changes on an electrocardiogram are 
clearly visible and are easily detected (Cleveland Clinic 2009). If ST-elevation MI is detected 
early enough, thrombolytic treatment can be an essential part in its treatment as thrombolytics 
restore blood flow, thus decreasing casualties. Thrombolytic treatment is the preferred 
treatment for ST segment myocardial infarction, because it is the most effective at achieving 
reperfusion. Thrombolytic treatment can effectively restore blood flow when administered 
within 12 hours of symptom onset, but maximum benefit is obtained when administered 
promptly (Hilleman et al. 2007).  
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries, known as the Gusto-I trial, was conducted to compare the 
efficacy of streptokinase and alteplase in ST segment myocardial infarction. Additionally, the 
study determined whether earlier and sustained reperfusion with alteplase improves the 
survival rate in people with acute myocardial infarction. A total of 41,021 patients within six 
hours of the onset of acute myocardial infarction with ST segmentation were randomly 
assigned to one of four thrombolytic treatments: streptokinase, streptokinase with intravenous 
heparin, accelerated tissue plasminogen activator, or tissue plasminogen activator with 
intravenous heparin. The primary follow-up and end point of the trial was 30 days (Hacke et 
al. 2008).  
After the 30 days, the results indicated that patients receiving accelerated tissue 
plasminogen activator had a more significant reduction in mortality during the 30-day period 
than those administered streptokinase and any other combined strategies. There was, 
however, an increase of hemorrhagic stroke episodes in accelerated tissue plasminogen 
activator patients above the others.  Still, the overall endpoint of death or permanent disability 
was lower in patients administered accelerated tissue plasminogen activator than in patients 
administered any other combination. A Gusto-III trial was soon established to determine if 
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reteplase, a newer recombinant tissue plasminogen activator, was better than alteplase. More 
than 15,000 patients, all within six hours of the onset of symptoms, entered the trial. The 30-
day mortality rate for reteplase did not exhibit any additional survival benefits in acute 
myocardial infarction (Hacke et al. 2008).     
THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM 
A pulmonary embolism is an occluded artery that disrupts the blood flow to the lungs. 
Deep vein thrombosis, the most common cause of pulmonary embolism, occurs when an 
embolus that originated in a deep thigh vein travels up to the lungs and blocks the blood flow 
(Fischbein 1981). Pulmonary embolism is an extremely dangerous condition, since it may 
cause damage to lung tissue due to a diminished oxygen supply. Additionally, it can damage 
other organs due to a lack of oxygen and, in some severe cases, may even cause death. 
Pulmonary embolism affects men as well as women. If the pulmonary embolism is caused by 
deep vein thrombosis, patients may exhibit symptoms such as 
swelling of the leg, pain or tenderness in the leg, or a 
discoloration of the skin on the affected area. Pulmonary 
embolism is responsible for 10% of all deaths, and an initial 
diagnosis is not straightforward.  In fact, in 70% of all 
pulmonary embolism patients, it was not clinically suspected 
but confirmed after an autopsy (Davidson 1999) (Figure 4). 
A majority of patients with pulmonary embolism are 
treated with anticoagulation medication. Anticoagulation 
therapy is beneficial in the treatment of pulmonary embolism, 
because it provides prophylaxis against further 
thromboembolic events while the body's own fibrinolytic 
system gradually lyses the embolus. Since dissolving the clot 
is the treatment for pulmonary embolism, many have 
wondered if thrombolytic therapy would be even more 
efficient as thrombolytic drugs dissolve clots more rapidly 
than endogeneous fibrinolytic activity can. There was a study 
comparing the efficacy of recombinant tissue plasminogen 
activator and anticoagulants in pulmonary embolism. As part 
of the study, 790 stable patients with pulmonary embolism 
were randomly assigned to either the heparin (anticoagulant) 
group or the alteplase (recombinant tPA) group. While 169 
patients received recombinant tissue plasminogen activator, 
550 patients received heparin alone. The overall 30-day 
mortality rate for patients administered tissue plasminogen 
activator compared to those receiving heparin was 4.7% to 
11.1% respectively. Additionally, during the in-hospital 
phase, recurrence of pulmonary embolism was more frequent 
in patients taking heparin. In fact, the ratio of recurrence was 7.7% to 18.7% in favor of 
alteplase (Arcasoy and Kreit 1999). 
SYNTHESIS OF THROMBOLYTIC DRUGS 
ALTEPLASE 
Alteplase is beneficial in thrombolytic treatment because it is easily synthesized using 
recombinant DNA technology. The composition of alteplase consists of a purified 
Figure 4: Deep vein thrombosis 
can cause pulmonary embolism  
Source: Fischbein 1981 
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glycoprotein consisting of 527 amino acids.  It is synthesized using a complementary DNA 
from a human melanoma cell line. Alteplase is manufactured by secretion of an alteplase 
enzyme into a culture medium. After secretion of the enzyme, the antibiotic gentamicin is 
added to the culture causing fermentation. Gentamicin, however, is not present in the 
recombinant tissue plasminogen product. The product also undergoes lyophilization, which is 
the process of rapidly freezing and dehydrating in a vacuum (Genetech 2005). 
STREPTOKINASE  
  On the other hand, streptokinase is a drug easily synthesized from a "-hemolytic 
streptococcus culture. However, there is a major drawback to using streptokinase. Most 
people have had a streptococcal infection at some point in their lives, so they are likely to have 
built up antibodies against streptococcal bacteria. Streptokinase is produced from 
streptococcal bacteria, so the circulating antibodies are likely to neutralize its effect on the 
clots (Finkel et al. 2009). Furthermore, once administered to a patient, streptokinase cannot 
be used again for some time due to its antigenic property.  Thus, the antigenic property of 
streptokinase is one of the most significant detriments to the drug.   
MECHANISM OF ACTION 
ALTEPLASE 
Alteplase has a mechanism of action that makes it fibrin specific and thus favorable for 
thrombolytic therapy (Figure 5).  First, alteplase attaches to fibrin on the surface of a clot and 
initiates fibrin bound plasminogen. Then plasmin is cleaved from the plasminogen associated 
with the fibrin, fibrin molecules are broken apart by the plasmin, and the clot dissolves. 
Although alteplase has a low attraction for plasminogen in the plasma, it activates 
plasminogen attached to fibrin in a blood clot (Klabunde 2005). Alteplase’s fibrin selectivity is 
what makes it therapeutically useful. Thus, administering alteplase in low doses lyses only the 
wanted clot without degrading other proteins. 
 
STREPTOKINASE 
Streptokinase is a protein cultured from the broth of streptococci bacteria. Since 
streptokinase is not a protease, it contains no enzymatic activity and has a different 
mechanism of action than alteplase. Streptokinase forms an active complex with the 
plasminogen (Figure 6).  The active complex activates and releases the plasmin to dissolve the 
clots (Klabunde 2005). However, streptokinase is not fibrin specific and, therefore, its 
Figure 5: (1) Recombinant t-PA (alteplase) binds to fibrin in thrombus 
(2) converts entrapped plasminogen to plasmin (3) that initiates local 
fibrinolysis.  
Source: http://www.cathflo.com/images/moa.gif 
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associated plasmin lyses circulating and non-circulating plasminogen. Streptokinase decays 




PHARMACOKINETICS OF THE THROMBOLYTIC DRUGS 
Pharmacokinetics is the pharmacological research of drug movement within the body. 
Moreover, it studies the mechanism of absorption, span of drug impact, and chemical 
modifications the body experiences. On certain occasions, a drug will be administered 
intravenously to ensure that the distribution of medication is instantaneous and efficacious. 
The half-life of a medication is the moment it takes a medication to decrease to half its original 
potency. Consequently, half-life forecasts the length of time it will take for a drug to leave the 
blood plasma. Therefore, if a drug contains a relatively brief half-life, the body disposes and 
eliminates that drug quickly. In contrast, when a medication has a prolonged half-life it lingers 
in the blood plasma for an extended period of time.  Thus, half-life is a good indicator for drug 
dosage, because it measures the length of time it takes for the body to dispose of a medication. 
While sometimes a short half-life is beneficial for patients, other times a long half-life is 
advantageous for a patient. 
HALF-LIFE OF THROMBOLYTIC DRUGS     
Alteplase has an extremely brief half-life of approximately five minutes. There is an 
advantage and a disadvantage to the short half-life in alteplase. An advantage is that alteplase 
is a powerful clot busting medication that lyses only a specific clot and is eliminated from the 
body in a very brief time. A disadvantage of alteplase’s short half-life is the increased 
possibility of reocclusion (Greer 2007). In contrast, streptokinase has a much longer half-life 
than that of alteplase. However, the longer half-life of streptokinase also has disadvantages, 
since streptokinase has antigenic properties and poses the risk of other allergic reactions. 
Additionally, it is usually unsafe to administer streptokinase a second time within 6 months 
due to its highly antigenic property (Rivera-Bou and Brown 2010).  
CONCLUSION 
The Food and Drug Administration approved alteplase as a treatment for acute 
ischemic stroke on June 8, 1996. Astonishingly, to this very day, alteplase is the sole approved 
medication for patients suffering from ischemic stroke. Additionally, it has bumped stroke 
from the third leading cause of death to the fourth leading cause of death in the United States 
Figure 6: Streptokinase and its effect on the fibrinolytic system. 
Source: http://www.anzcp.org/CCP/Pharmacology/streptokinase_files/image002.gif 
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(Center for Disease Control 2010). The Gusto-I and Gusto-III trials indicate that alteplase is 
a more practical and powerful drug than streptokinase in patients suffering from myocardial 
infarction with ST segmentation. In fact, according to the American Heart Association, the 
ideal time to administer thrombolytic drugs is within 90 minutes after the heart attack. 
However, if administered up to 12 hours after the onset of symptoms, the chances of surviving 
and recovering are still enhanced (Health Guide 2010). 
Pulmonary embolism is not an easily detected condition, but deep vein thrombosis, an 
equally serious condition, is detectable.  The use of alteplase in acute massive pulmonary 
embolism has shown more efficient and steadfast results than that of anticoagulation therapy. 
Due to an extremely brief half-life, possibly resulting in reocclusion, alteplase has come under 
fire.  However, with the use of recombinant technology, more generations of alteplase are 
being synthesized and produced to enhance the already proficient drug.     
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ABSTRACT 
Recently, research has been conducted to determine if thrombolytic therapy works to dissolve 
clots and if it is a safe treatment option.  The specific purpose of this study is to determine if 
thrombolytic therapy is safe for use in the elderly.  This study was conducted by reviewing the relevant 
literature that has been published from the time that research began to test the usefulness of 
thrombolytic therapy.  Numerous journals were examined to ensure impartiality and emerge with an 
unbiased conclusion.  The journals were discovered using PubMed article finder, using Google as a 
search engine, and by scrutinizing relevant references found within articles citing previous studies. It 
was discovered during the course of the study that thrombolytic therapy has been proven to be a 
useful treatment.  The main danger of the therapy comes not from the drug itself but from the 
possibility of causing an intracranial hemorrhage due to reperfusion to the ischemic tissue.  
Thrombolytic therapy should not be withheld from the elderly based solely upon age; rather, each 
patient’s full history should be considered, and the decision should be based on the patient’s blood 
pressure, glucose level, age, and history of recent surgery or trauma.  The issue of microbleeds has 
been examined, and there is no conclusive evidence to suggest that they cause or do not cause 
intracranial hemorrhage in patients treated with thrombolytic agents.  
DISCUSSION 
There are two types of strokes: embolic and hemorrhagic.  Hemorrhagic strokes are 
caused by ruptured blood vessels in the brain. Embolic strokes are caused by a blood clot that 
forms in the brain and prevents blood from reaching the neurons or from a blood clot that 
forms in the extremities and subsequently travels to the brain with the same deleterious effect.  
The axiom doctors refer to when treating embolus strokes is, “Time lost is brain lost.”  The 
longer the brain fails to receive fresh, oxygenated blood the more damage there is likely to be. 
In a typical middle cerebral artery ischemic stroke, two million nerve cells are lost each 
minute reperfusion has not been achieved (Saver et al. 2010). One of the newest, most 
innovative, and controversial treatments for both strokes and heart attacks is thrombolytic 
therapy.  This therapy involves using drugs that break down clots to restore blood flow.  
These drugs have been proven to be effective in treating both strokes and heart attacks. 
However, there is an inherent risk in using thrombolytic therapy. Drugs commonly used for 
clot lysis are not specific to brain clots; they break apart all clots formed anywhere around the 
body. The irony of thrombolytic therapy is that, while attempting to curtail damage caused by 
a stroke, it may end up causing an intracranial hemorrhage.   
In general, any therapeutic approach must conform to the sequence of events of a 
stroke:  after interruption of the blood supply, while some tissue probably suffers irreparable 
damage within minutes, a variable amount remains deactivated but in a viable state for several 
hours.  Restoration of the blood supply, therefore, may save the ischemic tissue and improve 
the patient’s overall outcome. Although research suggests that the blocked artery will open by 
itself sometime between twenty-four hours and a week, information on this is scanty at best; 
many factors including composition, age, and location (e.g. middle cerebral vs. superior 
cerebellar) contribute to overall recovery. There is clear evidence, however, that spontaneous 
lysis of a thrombus does occur. Current research is aimed at studying if the spontaneous 
process can be accelerated in time to restore the useful brain function without unacceptable 
risk (Wardlaw and Warlow 1992).  
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Research on thrombolytic therapy has increased in response to strokes being the third 
most common cause of death in the developed world.   In addition, strokes leave many people 
disabled and dependent on family and social or health services.   Stroke has defied the 
considerable efforts of medical science to find an effective treatment (Wardlaw and Warlow 
1992). Considerable interest in the use of thrombolytics also stems from the fact that they 
have been proven to work in patients suffering acute myocardial infarctions. The general 
thought is that if thrombolytic agents have been proven useful in heart attacks, they should 
also be a viable alternative to stroke treatment (Hommel et al. 1996). 
To fully appreciate the benefits and risks of thrombolytic therapy, it is necessary to 
first understand the biochemistry and molecular biology of thrombolytic drugs.  The assumed 
culprit of strokes is fibrinogen; the goal of the clot-busting drug is to dissolve the fibrin clot, a 
process known as fibrinolysis.  Plasminogen is an inactive proteolytic enzyme, which upon 
activation becomes plasmin.  Plasmin is able to hydrolyze many types of coagulation proteins, 
most notably fibrinogen. Plasminogen is activated by plasminogen activators released from 
endothelial cells, normally.  Plasminogen activators include streptokinase (SK), urokinase 
(UK), and tissue plasminogen activator (TPA).  In the case of an acute heart attack or stroke, 
these activators can be given to the patient.   In cellular biology, where one finds activators, 
one also finds inhibitors.  All the different plasminogen activators are inhibited by 
plasminogen activator inhibitor-1 (PAI-1). Plasmin, which breaks down fibrin to fibrin 
degradation product (FDP), is inhibited by numerous inhibitors including alpha-2-
antiplasmin (Figure 1) (Kunamneni et al. 2007).    
A thorough understanding of the biochemical mechanisms of thrombolytic drugs is 
important in understanding how they work. If the activators are being used as a cure for heart 
attacks and strokes, then perhaps, in the event of an intracranial hemorrhage, use can be made 
Figure 1: Schematic representation of the fibrinolytic system 
Source: Kunamneni et al. 2007 
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of the inhibitors to prevent fibrinogen breakdown and induce clotting. Perhaps these 
inhibitors can even be used to assist in treating hemophiliacs1.    
If clot-busting drugs carry such a high risk of intracranial hemorrhage, why would 
doctors use these drugs as opposed to another safer method?  The answer is that no other 
medications seem to work. Antiplatelet agents such as aspirin and anticoagulant agents such 
as heparin reduce platelet aggregation and thrombin formation; however, they have no effect 
on fibrinogen and blood viscosity.  In fact, in two different studies, aspirin and heparin were 
given to patients having acute strokes, and they both showed very little effect. Thrombolytic 
agents, on the other hand, fill all three functions in one therapy: they lower the viscosity of the 
blood by fibrinogen reduction, potentially allowing blood flow back into the blocked region of 
the brain; they act as anticoagulants, and they may act as antiplatelet agents (Lowe 1998). 
Antiplatelet agents, anticoagulant agents, and thrombolytic agents pose nearly the 
same risk of interfering with hemostatic plug formation (the forming of a clot to maintain 
hemostasis).  It can be inferred that the risks of intracranial hemorrhage are not necessarily 
reduced using alternative drugs. Indeed, based on trial evidence, alternative drugs do lower 
the chances of recovery.   Aspirin was tested as a preventive drug against strokes, and it was 
noted during the 4.6-year long trial that, not only did aspirin not prevent stroke (in men with 
a mean age of 57), it also increased the risk of intracranial hemorrhage.  Although some 
studies found aspirin to be helpful to middle aged women predispositioned to certain types of 
stroke, women who took it in excess (> 15 tablets/week) had a higher rate of hemorrhage 
(Cornett et al. 2008.  In a later study, patients treated with thrombolytic therapy also received 
both a platelet aggregation inhibitor (aspirin) and an anticoagulant (heparin), and neither the 
heparin nor the aspirin were associated with intracranial hemorrhage. It can be suggested that 
the seeming disassociation between aspirin, heparin, and intracranial hemorrhage was because 
the aspirin and heparin were given several hours after the thrombolytics were administered.  
In fact, if signs of intracranial hemorrhage became apparent, the heparin and aspirin  would 
not have been given (Simoons and Maggioni 1993).  
This information would seem to suggest that there is a connection between fibrinogen 
levels, blood viscosity, and instance of stroke.   A study proving the connection appears in the 
New England Journal of Medicine as early as 1984.  The study shows that fibrinogen is as 
important a predictor of stroke as high blood pressure; consequently, patients with both high 
blood pressure and high fibrinogen levels have the highest risk of stroke (reviewed in Lowe 
1998).   Another study, appearing in 1996, shows that fibrinogen levels predict atrial 
fibrillation and congestive heart failure, which are both risk factors for strokes.  This study, 
though, shows that high fibrinogen is a secondary cause of stroke, not a direct cause.  A study 
comparing incidence of stroke and fibrinogen levels in Americans vs. Japanese shows that 
Japanese have a lower level of fibrinogen and, correspondingly, a lower incidence of stroke 
(reviewed in Lowe 1998).  In another early study, showing a more direct relationship, the 
fibrate drug clofibrate (used to lower cholesterol levels in blood) lowered the plasma 
fibrinogen and blood viscosity, resulting in a significant increase in the cerebral blood flow  
(reviewed in Lowe 1998). 
                                                
 
 
1 In the event of an intracranial bleed it would seem to be too late to try using deactivators; however, this 
knowledge could present a possible entry point into looking for a treatment.  
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Once scientists realized the potential for thrombolytic therapy, they had to ask 
themselves: Is this treatment option really going to work?  And, even if this potential 
treatment does work, is it safe?  In 1992, research was conducted to assess whether or not 
thrombolytic therapy is effective.  The results of 10 different trials were combined and 
examined, and it was noted that there was a reduction in the risk of death and deterioration to 
stroke patients treated with thrombolytic therapy. This provides some evidence that 
thrombolysis is beneficial in acute ischemic stroke.   The study concludes that although this 
was not enough evidence to recommend widespread usage of the thrombolytic drugs, there 
was enough improvement in patient outcome to encourage larger randomized trials (Wardlaw 
and Warlow 1992). 
The main problem with this retrospective study is that the administration of 
thrombolytic drugs, which should have begun within 24 hours from the time of symptom 
onset, ranges anywhere from 24 hours up to five days later (the median being 72 hours).  
Additionally, the severity of the stroke was not taken into account. 
Hommel et al. (1996) record the results of a trial done to determine if thrombolytic 
therapy is indeed safe.   The trial included 154 patients in a placebo group and 156 patients in 
a streptokinase group.  Six months after treatment, 124 patients from the streptokinase group 
and 126 patients from the placebo group had either died or were severely disabled.   At ten 
days after treatment, more patients who received the thrombolytics had died than placebo 
patients.  Researchers noted that most of the deaths came about because of cerebral 
hemorrhage.   Hommel et al. conclude, “Treatment with streptokinase resulted in an increase 
in mortality.  The routine use of streptokinase cannot be recommended in acute ischemic 
stroke.”  However, they did note at the end of the article that those patients who had been 
treated with the thrombolytic agent and survived the treatment without subsequent disability 
had significant improvement in their level of function.  Fewer patients in the streptokinase 
group were disabled as compared to the placebo group.   Hommel et al. cautiously speculate 
that one possible explanation of this can be that thrombolytic agents do actually work to 
improve function.   
It is important to note that when trial participants were treated with these drugs, the 
doctors did not know about the various contraindications.  The criteria for exclusion during 
this trial were previous hemorrhagic stroke, recent surgery or trauma, pregnancy, or other 
illness known to compromise the prognosis.  Nowadays researchers know more about the 
contraindications, e.g., hypertension, diabetes, gender, use of oral anticoagulants, and, 
possibly, age.  Furthermore, only 25% of the patients treated with the thrombolytic agents 
received the therapy within 3.75 hours of symptom onset.  The median delay from symptom 
onset was 4.6 hours.  Presently, the drug companies are trying to have the FDA approve the 
drugs to be given after 4.5 hours; less than 25% of patients in this trial received the drug in 
that time slot.    
In May 2009, the American Heart Association guidelines for the administration of 
recombinant tissue-Plasminogen Activator (rt-PA) following acute stroke were revised to 
expand the window of treatment from 3 hours to 4.5 hours to provide more patients with an 
opportunity to receive benefit from this therapy. Eligibility criteria for treatment in the 3 to 
4.5 hours after acute stroke are similar to those for treatment at earlier time periods; however, 
there are additional exclusion criteria: patients older than 80 years, patients taking oral 
anticoagulants, and patients with a history of stroke and diabetes. Patients falling into any of 
these categories are excluded (Saver et al. 2010). 
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In 2004, a research group pooled together all the data of six randomized placebo-
controlled trials of intravenous rt-PA to study whether or not thrombolytics are helpful after 3 
hours of symptom onset.  They retrospectively analyzed 2775 patients from more than 18 
countries, thus ensuring a large sample population and randomization in the test subjects.  
The problem was that every research group that did a trial used their own eligibilty criteria, 
and they grouped the patients differently based on time of treatment.   The group did, 
however, feel it safe to confirm on the basis of the collective data that rapid treatment is 
associated with better outcomes at 3 months.  The group also stated that the possible benefit 
of rt-PA treatment may extend beyond 3 hours, but it definitely does not extend to 6 hours, 
because, as time goes on with the stroke untreated, progressive disappearance of the ischemic 
penumbra (ischemic but still viable cerebral tissue) occurs.  Accordingly, patients  who have 
potentially viable ischemic brain tissue at later time might have substantial treatment benefits  
(Hacke et al. 2004). 
During the course of the research, the team noticed a striking phenomena.  Patients 
with more severe strokes arrived at the hospital earlier than those with less severe strokes, 
thereby receiving rt-PA earlier. The mortality and disability rates are high for those patients 
in early treatment intervals due to the severity of the stroke, but, at the same time, the effect of 
the rt-PA is greatest in those treated early despite the greater stroke severity  (Hacke et al. 
2004) . This proves the effectiveness of rt-PA when given early. 
One of the big concerns that doctors have is the presence of microbleeds. A microbleed 
is a tiny focal collection of blood breakdown products adjacent to histologically abnormal 
small vessels, resulting from blood leakage through the fragile vessel wall (Figure 2).  The 
actual size of a microbleed is likely to be less than a millimeter.  It is suggested that 
microbleeds result from small vessel damage. Recent research suggests that there may be a 
genetic component as well (Werring 2007). 
One of researchers’ concerns regarding microbleeds is whether there is a connection 
between cerebral microbleeds and treatment with a thrombolytic agent during an ischemic 
stroke.  The basis for this well placed assumption is that cerebral microbleeds are found in 
54% to 71% of all primary intracerebral hemorrhage occurrences (Werring 2007).  Ho Sung 
Kim et al. (2006) retrospectively evaluated 279 patients and selected 65 patients (37 men, 28 
women, mean age being 67 years old) who fit their extremely selective criteria. The criteria 
Figure 2: Cerebral microbleeds: A microbleed can be seen in the middle picture 
located near the right thalamus and marked with an arrow. Source: Werring 2007 
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included: symptom onset within 6 hours of receiving the drug, no previous history of 
intracranial hemorrhage, thrombolytic treatment immediately after the initial MRI, and 
another MRI 1-3 days after the thrombolytic treatment. They found that, after being treated 
with thrombolytic agents, 25 patients of those 65 had microbleeds.   Of the 40 patients who 
did not have microbleeds, 9 had signs of hemorrhage.   Of the 25 patients that did have 
microbleeds, 8 had signs of hemorrhage.  From this research it seems clear that there is no 
correlation between presence of microbleed and subsequent intracranial hemorrhage as a 
result of treatment with a thrombolytic agent. 
 A limitation of this experiment is that the test group used is very small. They began 
with 279 patients which is already small, and  the test numbers were further reduced due to 
the very selective criteria.   Further research with more test subjects involved is needed to 
reach a firm conclusion.  The author also mentions that the maximum number of microbleeds 
any patient had was 10, and, in future studies, he would like to see what happens to patients 
with more than 10 microbleeds. 
  Another study comparing location of microbleed and symptomatic hematoma 
(collection of blood outside blood vessels) concluded that there is a correlation between the 
two; however, they were not sure how to interpret the correlation (Roob et al. 2000).They 
note that there was some tendency toward a regional association between microbleed location 
and the site of a symptomatic hematoma, but they could not discern the specific patterns of 
microbleed distribution.  Kim’s study, which mentions that presence of a microbleed is not a 
contraindication to thrombolysis, seems to contradict Roob’s  study, which notes a correlation 
between the two.   
 Also interesting is that in Roob et al.’s study, which was also done retrospectively, the 
population consisted of 109 patients who had an intracranial hemorrhage (as opposed to 65), 
which is still very small for a study, and 54% of those patients had microbleeds.  However, the 
patients in this study had up to 90 lesions, which is a great deal more than anyone else in  Kim 
et al.’s study, but the average number of microbleeds was still 14, which is not that much more 
than  Kim et al.’s study.    In Roob et al.’s study, the researchers grouped the individual with 
90 microbleeds in the same group as the patient with one microbleed. What would be 
interesting is if there was research conducted which would compare number of microbleeds to 
incidence of intercranial hemorrhage, because there  is limited data to suggest that microbleed 
number may actually be a predictor of future bleeding risk after intracranial hemorrhage.  In 
fact, microbleeds are associated with larger volume of intracranial hemorrhage  (Werring 
2007).   
One of the primary concerns of both doctors and researchers is:  is thrombolytic 
therapy safe for use on the elderly?  The problem that researchers had is that most of the 
information about hemorrhage as a result of thrombolytic therapy comes from clinical trials, 
and elderly individuals are either scarcely selected due to the highly selective criteria of the 
trials, or not included in the trial at all.  The reason for this is that elderly patients often have a 
poor prognosis for recovery, high mortality rate, high health care costs, and in the case of a 
heart attack the doctor can always treat the patient with angioplasty.  Therefore, information 
about how the elderly would respond to thrombolytic agents is scarce (Brass et al. 2000).  
Pundik et al. (2008) set out to determine three things:  the rate of intracranial hemorrhage 
associated with thrombolytic therapy for elderly patients suffering an acute heart attack, 
whether there are any independent predictive factors for intracranial hemorrhage, and a way 
of estimating the risk of an intracranial hemorrhage.  
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Stroke is more common in the elderly, and the morbidity and mortality after a stroke 
are higher with increasing age.  The incidence of stroke doubles with each consecutive decade 
above the age of 55, and the mortality for patients over 85 years old is tripled compared with a 
younger group.  In addition, the rates of a favorable outcome after a stroke are significantly 
lower in older patients.  Because stroke rates are so high in the elderly, researchers and 
clinicians need to find a viable treatment, and thrombolytic therapy seems to be the most 
promising.  The problem is that, unlike higher admission blood pressure, treatment delay, and 
hyperglycemia, which have all been proven to be risk factors of intracranial hemorrhage, 
advanced age is not a clear indicator (Pundik et al. 2008).  
 A research team analyzed the charts of 218,663 patients who were eligible and treated 
31,732 of them with thrombolytic therapy.  The mean patient age was 73 years old.   Out of 
31,732 patients, 455 (1.43%) of the patients ended up with intracranial hemorrhage, and 72% 
of the patients that had intracranial hemorrhage died within 6 months compared to 18% of the 
patients who did not receive the therapy and died within 6 months (Brass et al. 2000). 
The goal then was to figure out what some of the risk factors for intracranial bleeding 
are, because if some of the risk factors can be identified,  the individual patient’s risk of 
hemorrhaging can be assessed.  Studies previous to the 1993 study by Simoons and Maggioni 
suggested that age, hypertension, overdose of drugs based on body weight, being female, 
previous central nervous disease, and the use of oral anticoagulants are all associated with 
increased risk of hemorrhage.  It has been suggested that the reason the elderly are at greater 
risk is not because of age per se;  it is actually because elderly patients tend to have more 
contraindications to thrombolytic therapy.  They found that patients over the age of 75 were 
more likely to have a history of hypertension, diabetes, congestive heart failure, previous 
bypass, and stroke among others  (DeGeare and Grines 2000). Poor outcomes after ischemic 
stroke in the elderly could also be caused by other factors that are associated with aging.  It 
has been shown in animal and clinical studies that effects of ischemia and reperfusion on 
brains are hastened in aged organisms (Pundik et al. 2008). 
Researchers theorized that the reason elderly patients with congestive heart failure do 
not respond well to thrombolytics is because poor cardiac pump function results in decreased 
perfusion, making it difficult for the thrombolytic agents to penetrate the occlusive thrombus.  
This theory is hard to accept because, if the thrombolytic agent is not able to penetrate the 
thrombus because the heart is not pumping strong enough, it stands to reason that the 
thrombolytic agent would not be able to cause a hemorrhage either.  If the elderly patients 
would simply not respond to the drug at all then they would have a valid point, but it  does 
not seem to follow that the thrombolytic agent cannot get to the thrombus but can get to the 
brain. 
As stated above, one of the primary predictors of intracranial hemorrhage is 
hypertension.  However, research suggests that the bleeding risk depends not only on the 
state of the intracranial blood vessels but also predominantly on the blood pressure at the time 
of the thrombolytic therapy.  This is based on an observation that patients with intracranial 
stroke often have higher blood pressure than those patients experiencing other types of 
strokes.   Consequently, before beginning any course of thrombolytic treatment, the patient’s 
blood pressure should be assessed and, if necessary, corrected (Simoons and Maggioni 1993). 
In 2002, Tanne et al.  reported that intravenous rt-PA is an effective therapy for acute 
ischemic stroke, but they wanted to identify baseline factors that are  associated with 
thrombolysis related intracranial hemorrhage.  During their retrospective investigation of 
1,205 patients treated with rt-PA within 3 hours of symptom onset, of which 72 patients (6%) 
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developed intracranial hemorrhage, they determined that the main contraindications were 
diabetes melitus, past cardiac disease, increasing stroke severity, advancing age, use of an 
antiplatelet agent before treatment, and elevated pretreatment blood pressure.  They 
determined that advanced age is a risk factor because they noted a particularly low rate of 
intracranial hemorrhage in patients under 60 years old (Tanne et al. 2002).   
In 2004, research was done by Simon et al. to assess whether or not thrombolytic 
agents are safe for the elderly.  As part of an  ongoing monitoring process, a database was 
created that records all the details of patients treated for strokes with rt-PA since 1996.  The 
database gives researchers access to many important details such as demographic data, blood 
pressure and glucose level at time of admission, severity of the stroke, and age of the patient.  
Of the hundreds of patients that received rt-PA during those years, 62 patients were over 80 
years of age.  Six out of those 62 patients experienced a  severe intracranial hemorrhage, only 
slightly higher than the 6.4% of patients under 80 years of age who experienced severe 
intracranial hemorrhage.  Thus, while it is true that patients over the age of 80 suffer from 
higher mortality and morbidity rates than younger patients, the elderly should not be denied 
the chance to benefit from thrombolytic therapy based on age alone (Simon et al. 2004). 
In 2006, a systematic review performed by Engelter, Bonati, and Lyrer analyzed data 
taken from many websites such as PubMed, MEDLINE, and Science Citation Index and 
found many instances where elderly stroke victims were treated with thrombolytic agents.  
They found that stroke patients over 80 years old that receive  rt-PA do have a substantially 
higher mortality rate than patients under 80.  Additionally, older patients, even if they do 
recover, will not have as favorable a recovery (based on various neurological tests such as the 
Rankin scale). However, they also found that the risk of Intracranial hemorrhage was similar 
in both groups.  They believe that age is a predictor of how well an elderly patient will recover 
after a stroke , but, because the likelihood of intracranial hemorrhage did not favor one age 
group, they conclude that  rt-PA is a viable treatment option for the elderly, because the 
potential bleeding risks are unlikely to outweigh the potential benefit of treatment. 
In 2008, researchers collected data from the Brain Attack Database at University 
Hospitals in Cleveland, Ohio.  The database contained all cases of acute stroke dating back to 
1993.  The researchers had 488 cases where the patients suffered an acute stroke and were 
subsequently treated with a thrombolytic agent.   Of the 488 patients, 404 were under age 80 
(mean age 62 years old with a range of 20-79) and 78 patients where above age 80 (mean age 
83 with a range of 80-99).  The rate of intracranial hemorrhage in the elderly was 12.82%, but 
that figure was then adjusted.  The reason is that most of the elderly patients who 
subsequently hemorrhaged did so as a result of treatment with intra-arterial therapy (not 
intra-venual therapy).  The rate of hemorrhage in the younger group was 10%.  Based on this 
research evidence, thrombolytic therapy should not be ruled out as a treament for an elderly 
patient simply because of advanced age, although method of treatment should be considered 
(Pundik et al. 2008). 
There are some interesting trends in the demographic characteristics that deserve 
mentioning.  In the younger group (age under 80), 43% of the patients treated for stroke were 
women, and in the older group, 55% of the patients were women.  Pundik et al. (2008) 
suggest that the reason for this is because there is a prevalence of acute ischemic stroke in 
older women. Also interesting to note is that 61% of the younger patients exhibited 
hypertension compared to 80% that exhibited hypertension in the elderly group.   Another 
significant trend is that in the younger group, 22% of the patients had a history of smoking 
compared to 8% of the older group that has a history of smoking.   
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The problem with their conclusion is that they suggest that thrombolytic therapy is 
safe for patients above 80 with no maximum age.  Perhaps it would be helpful if in the future, 
the research team would, instead of using  ranges of 20-79 and 80-99,  break the ranges down 
into 5 year intervals. By ranging the patients in groups of 80-85, 85-90,  and so on, the 
researchers can perhaps establish a maximum age for thrombolytic therapy.    
Doctors believe in thrombolytic therapy as a treatment for acute stroke, and they want 
this therapy to work. The problem is that a great danger is associated with the therapy.  What 
if doctors could lower the risk of intracranial hemorrhage?  Researchers compared how 
patients treated in a CCSU – a Critical Care Stroke Unit recovered as compared to those 
patients treated in an ASU – Acute Stroke Unit.  They found that patients treated in Acute 
Stroke Units received more treatments with  rt-PA, had a shorter length of stay in the 
hospital, and had a lower 90-day mortality and disability rate.  The researchers suggest that 
the reason for the better outcome is because in the Acute Stroke Unit, patients receive care 
quicker, and they are monitored very closely for fever, hypertension, hypotension, cardiac 
arythmias, and glucose levels.  It is suggested that the continued monitoring and specialized 
nursing of the Acute Stroke Unit permitted the early detection, control, and treatment of 
factors related to hemorrhage  (Roquer et al. 
2008). 
Perhaps the biggest problem with t-PA is 
that the FDA states that after 3 hours it is not 
safe for a physician to administer this potentially 
life saving or life ending drug.  Is there an 
alternative treatment to t-PA for after 3 hours?  
In 2005, research was conducted to see if a 
blood vessel occlussion could be removed by 
mechanical means.  This would be accomplished 
by inserting a catheter into the femoral artery, 
directing it into the cerebral circulation, and 
deploying a corkscrew-like device to ensnare the 
clot which is then withdrawn from the body. 
(Patients who were candidates for treatment 
with t-PA were excluded from this trial.) The Mechanical Embolus Removal trial was 
attempted as long as 8 hours after the onset of symptoms.  The overall mortality was 44% of 
the patients, which is very high although not unexpected, as 8 hours is a long time after 
symptom onset.  However, in 48% of the patients, recanalization was achieved, which means 
that the treatment has potential but just needs some fine tuning to be made safe and more 
effective  (Cornett et al. 2008).   
Another treatment method that is being looked into is angioplasty and stenting.  The 
theory is that if angioplasty has been proven effective in preventing heart attacks, it should 
also be effective in preventing strokes.  Early trials suggest that this could be a viable 
treatment option for patients who can not receive thrombolytics, but more research is needed  
(Saver et al. 2010). 
CONCLUSION 
Thrombolytic agents restore cerebral blood flow in some patients with acute ischemic 
stroke and may lead to improvement or resolution of neurologic deficits. Unfortunately, 
thrombolytics can also cause symptomatic intracranial hemorrhage. Therefore, if a patient is a 
Figure 3: Mechanical Thrombectomy. 
Source: wikipedia.com 
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candidate for thrombolytic therapy, inclusion and exclusion criteria must be reviewed 
thoroughly. The exclusion criteria focus largely on identifying the risk of hemorrhagic 
complications associated with thrombolytic use (Saver et al. 2010).  Based on research done 
within the last 5-10 years, it would seem that if a patient comes into a hospital having a stroke 
(assuming it is a stroke severe enough to warrant treatment with a thrombolytic agent) and 
the patient is in otherwise good health, i.e., no  prior history of heart disease, not a diabetic, 
not hypertensive, and no history of bleeding disorders, and it is within 3 hours of symptom 
onset (perhaps 4.5 hours of symptom onset), then  it would seem to be safe to administer the 
drug.  If any of these contraindications are present the doctor needs to weigh the possible risk 
of hemorrhage vs the severity of the stroke.  Interestingly enough, based on the recent 
research, clinicians should be more concerned about treating an obese 40 year old with a 
history of high blood pressure than an 85 year old who is in otherwise perfect health. 
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